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1.1 The Glutamatergic System

L-Glutamate is the primary excitatory neurotransmitter in the mammalian
central nervous system (CNS). It is capable of participating in standard fast
synaptic communication, as well as in higher order signal processing linked to
development, synaptic plasticity, learning and memory (Balazs, Bridges and
Cotman, 2006). Excessive concentrations of glutamate can overstimulate the
excitatory amino acid (EAA) receptors, leading to cell damage and eventual cell
death (excitotoxicity). Excitotoxicity is believed to play key roles in disorders of
the CNS including: stroke, epilepsy, spinal cord injury, ALS, and Alzheimer’s
disease (for reviews see: Rao and Weiss 2004; Won et al., 2002; Malva et al.,
2003; Hynd et al., 2004). The primary regulators of extracellular glutamate in the
CNS are the excitatory amino acid transporters (EAATs), which are capable of
influencing the amount and/or time course that L-glutamate is in contact with the
excitatory amino acid (EAA) receptors.
The glutamate-glutamine cycle is a crucial component of neuronal
communication (Berl et al., 1968). It begins with the packaging of glutamate into
vesicles via the vesicular glutamate transporter (VGLUT)
Takamori, 2006).

(for a review see:

Action potentials in the presynaptic neuron cause the

concentration of intracellular calcium to increase. The calcium binding protein,
calmodulin (CaM) activates CaM Kinase II which phosphorylates synapsin I.
Phosphorylation of synapsin I decreases the affinity of this protein for the actin
cytoskeleton and/or the vesicles and causes the vesicles to undock.
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Figure 1. The Glutamatergic Synapse; figure by Brent Lyda of the Esslinger
research group.

2

Simultaneously, calcium causes synaptotagmin, a Ca2+ binding protein located
on the synaptic vesicle, to prime the vesicle for fusion with the presynaptic
membrane.

For fusion to occur a trimeric trans-SNARE (soluble N-

ethylmaleimide-sensitive factor attachment protein receptor) complex must form
consisting

of

the

vesicle

associated

membrane

protein

(VAMP2

or

synaptobrevin) on the synaptic vesicle, and syntaxin-1 and synaptosomal
associated protein of 25 KDa (SNAP-25) from the plasma membrane (for a
review see: Martens and McMahon, 2008). Upon fusion, the synaptic vesicle
membrane is incorporated into the presynaptic membrane and glutamate is
released into the synaptic cleft where it can stimulate pre- and postsynaptic
glutamate receptors. This translates the chemical signal into an electrical signal
either directly by opening ion channels (ionotropic) or indirectly through second
messenger systems (metabotropic) (Nakanishi and Masu, 1994).
The EAA receptors are grouped into two categories.

The ionotropic

receptors AMPA, Kainate and NMDA, named after the selective agonists that act
at each receptor: N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-methyl
isoxazole-4-propionate (AMPA) and kainic acid (KA) (Figure 2).

The

metabotropic glutamate receptors mGluR1-5, are G-protein coupled receptors
linked to multiple second messenger systems. These two classes of receptors
mediate and modulate information transfer at the majority of excitatory CNS
synapses (Mayer, 2005; Swanson et al., 2005).
The ionotropic glutamate receptors are a family of heteromeric ligand-gated
ion channels that span the plasma membrane. They are believed to mediate the

3
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Figure 2. Selective agonists of the glutamate ionotropic receptors.

majority of excitatory neurotransmission in the vertebrate CNS. The binding of Lglutamate causes a conformational change which opens the receptor associated
ion channel thereby allowing Na+ and/or Ca2+ to flow into the cell (Armstrong and
Gouaux, 2000).

If the influx of positive ions sufficiently depolarizes the

membrane potential past a critical threshold value of approximately -55mV,
measured at the axon hillock, sodium channels open. This allows sodium ions to
rapidly enter the cell causing an action potential. Potassium channels, which
respond slower than sodium channels restore the membrane potential by
allowing potassium to exit the cell. Sodium channels then close, resulting in a
short period of hyperpolarization during which the cell is less likely to fire an
action potential. The cell then returns to its resting potential of approximately -70
mV.
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AMPA and Kainate receptors (AMPARs and KARs) are responsible for
mediating fast synaptic transmission (Collingridge et al., 1983; Ganong et al.,
1983) and are activated by low frequency stimulation (Davies et al., 1989).
AMPARs are responsible for most fast excitatory responses. In addition, the
recruitment of AMPARs to the cell surface from an intracellular pool may be an
important component of long term potentiation, LTP. LTP is a process whereby
synapses become more robust through the insertion of AMPARs into the
postsynaptic membrane.

This occurs via the calcium/calmodulin dependent

protein kinase (CAMKII) which phosphorylates AMPARs in the synaptic
membrane. Phosphorylation increases sodium conductance and promotes the
migration of AMPARs from intracellular stores to the membrane (Breedlove et al.,
2007). This results in the enhancement of AMPAR activation, thereby increasing
synaptic current (Luscher et al., 1999; Luthi et al., 1999).
Kainate receptors (KARs) are found throughout the CNS and are present
both pre- and post-synaptically. Postsynaptic KARs are believed to carry part of
the charge that contributes to the post synaptic response along with AMPARs
and NMDA receptors (NMDARs).

Presynaptic KARs are hypothesized to

regulate neurotransmitter release at inhibitory and excitatory synapses
(Rodrigues-Moreno et al., 1997).
The NMDA receptors (NMDARs) contain a Mg2+ and a glycine recognition
site in addition to a glutamate site. The Mg2+ site is situated deep within the
channel pore and is removed when the cell is partially depolarized (Flatman et
al., 1983) causing NMDARs to respond only after repetitive synaptic activation

5

(Manabe, 2008). In addition to the removal of the Mg2+ block NMDARs require
the co-agonist glycine in order to be activated (Johnson and Ascher, 1987).
NMDARs are permeable to Ca2+, Na+ and K+.

The increase in postsynaptic

calcium is an important step to activating further processes which may constitute
long term potentiation LTP as well as higher cognitive functions such as learning
and memory (Cavara and Hollman, 2008).
The metabotropic glutamate receptors are G-protein coupled receptors
(GPCRs) of which 8 have been cloned (Nakanishi, 1992; Pin and Duvoisin,
1995). They are subdivided into three groups based on sequence similarity,
intracellular signaling mechanisms and pharmacology. Group I mGluRs consist
of mGluR1 and mGluR5 and are coupled to phospholipase C-β (PLC-β) and
intracellular Ca2+ signaling. Group I mGluRs modulate NMDA receptor-mediated
synaptic transmission and plasticity and mediate mGluR-dependent plasticity
(Cheyne and Montgomery, 2008). Group I mGluRs are primarily expressed at
postsynaptic sites. Group II (mGluR2, mGluR3) and group III (mGluR 4,6,7 & 8)
inhibit adenylyl cyclase (AC) activity, which results in a decrease in cAMP levels
and PKA activity. A decrease in PKA activity is required for the induction of
group II mGluR dependent long term depression. Group II mGluRs are
expressed both pre- and post-synaptically and Group III mGluRs are expressed
primarily at presynaptic sites where they regulate neurotransmitter release
(Reviewed in Kim et al., 2008).
In order to prevent overstimulation of the glutamate receptors, which can
lead to excitotoxicity, glutamate must be quickly cleared from the synaptic cleft.

6

This occurs via diffusion or by EAAT mediated substrate uptake (Auger and
Attwell, 2000; Huang and Bergles, 2004). The EAATs, of which 5 have been
identified to date, are expressed in glial cells (EAAT1 and EAAT2) and in
neurons (EAAT3, EAAT4 and EAAT5).
Once glutamate has been transported into the astrocyte by EAAT1 and/or
EAAT2, it is converted to the neutral amino acid glutamine by glutamine
synthetase. Glutamine can then be transported out of the astrocyte by SNAT3
(SN1), a system N amino acid transporter localized to perisynaptic astrocytes.
Glutamine is thought to be transported into the neuron by (SNAT1 & SNAT2),
system A transporters, though the localization of these transporters is mainly in
the somatodendric domain and rarely axon terminals (Cont and Melone, 2006).
In addition, the inability of system A inhibitors to affect basal transmission
suggest that transporters not yet identified may be responsible for the uptake of
glutamine into the neuron (Kam and Nicoll, 2007).
The glutamatergic system has a central role in excitatory signaling in the
CNS. Glutamate levels must be tightly regulated to maintain excitatory signaling
as well as to prevent the overstimulation of the glutamate recpetors. Regulation
of this system relies on multiple factors, one being the rapid clearance of
glutamate from the synaptic cleft by the glutamate transporters.

7

1.2 Characterization, Localization and Function of the EAATs

Historically, the glutamate transporters have been grouped into three
categories depending upon their substrate specificity: the C-4 dicarboxylate
transporters found in bacteria, the glutamate/aspartate transporters found in
bacteria and eukaryotes and the neutral amino acid transporters also found in
bacteria and eukaryotes (Slotboom et al., 1999).
Recently, the glutamate transporters have begun to be classified
according to the Human Genome Organization (HUGO) nomenclature. The five
glutamate transporters EAAT1-5, which share 50-60% amino acid homology,
along with two neutral amino acid transporters ASCT1 and ASTC2, comprise the
solute carrier family 1 (SLC1). EAAT1 is encoded by the gene SLC1A3, EAAT2
by SLC1A2, EAAT3 by SLC1A1, EAAT4 by SLC1A6 and EAAT5 by SLC1A7,
ASCT1 by SLC1A4 and ASCT2 by SLC1A5 (Kanai and Hediger, 2004).
The five glutamate transporters have been identified by molecular cloning
and functional expression.

EAAT1-5 have been isolated and cloned from

mammalian tissue: GLAST (glutamate and aspartate transporter 1) and GLT1
(glutamate transporter 1) from rat brain (Storck et al., 1992; Pines et al., 1992)
and EAAC1 (excitatory amino acid carrier 1) from rabbit small intestine (Kanai &
Heidger, 1992). The almost simultaneous cloning of these three transporters
was quickly followed by the cloning of the corresponding human homologues by
Arriza, who suggested using a standard naming system, the excitatory amino
acid transporters (EAATs), of which EAAT1 is the human homologue of GLAST1,
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EAAT2 of GLT1 and EAAT3 of EAAC1 (Arriza et al., 1994). Four additional
transporters were quickly isolated using homology screening, EAAT4 from the
retina, EAAT5 from the cerebellum (Fairman et al., 1995; Arriza et al., 1997), and
the two neutral amino acid transporters of the SCL1 family; ASCT1 and ASCT2
(Alanine, Serine and Cysteine Transporters 1 and 2) (Arriza et al., 1994).
The EAATs are found throughout the brain and periphery with enrichment
in certain tissues and brain regions depending on the specific EAAT. EAAT1 is
expressed throughout the brain with high levels in the heart and skeletal muscle
and lower levels in the placenta and lung. EAAT2 expression is largely restricted
to the brain with low levels found in the placenta.

EAAT3 is expressed

throughout the brain with high levels in the kidney and lower levels expressed in
the lung, placenta, liver, muscle and heart (Reviewed in Danbolt, 2001).
In the CNS, EAAT1 and EAAT2 are expressed on glial cells and EAAT 3
and EAAT4 on neurons. The glial transporters, EAAT1 and EAAT2 and the
neuronal transporter EAAT3 are the primary transporters of synaptic glutamate
(Arriza et al., 1994). They are found throughout the brain with enrichment in
differing regions.
EAAT1 is the primary transporter of glutamate in the cerebellum where it
is found in high levels in Bergmann glia. EAAT1 is also found in lower levels
throughout the CNS. Mice deficient in mEAAT1 are susceptible to cerebellar
injury and display reduced motor coordination (Watase et al., 1998).
EAAT2 is the dominant glutamate transporter throughout the CNS except
in the cerebellum where EAAT1 dominates. EAAT2 expression is particularly
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high in the hippocampus, lateral septum, cerebral cortex and the striatum (Lehre
et al., 1995; Chaudhry et al., 1995).

EAAT2 is found on most astrocytes

throughout the CNS, and on all astrocytes in the neocortex, striatum and
thalamus.

Mice deficient in mEAAT2 are susceptible to lethal spontaneous

seizures and acute forebrain injury (Tanaka et al., 1997).
EAAT3 is enriched in the hippocampus, cerebellum and basal ganglia,
though the levels of EAAT3 protein are much lower than the other glutamate
transporters (Haugeto et al., 1996).

EAAT3 has a unique distribution, being

found over neuronal bodies and processes as well as presynaptically at GABA
terminals (For a review see Nielullon et al., 2006). The localization of EAAT3 to
presynaptic GABAergic terminals implicates it as a source of glutamate for GABA
synthesis (Sepkuty et al., 2002).

The perisynaptic localization of EAAT3

suggests that this transporter helps to regulate spillover, in addition EAAT3 may
be the major route for neuronal cysteine uptake (Zerangue and Kavanaugh
1996b; Himi et al., 2003), a necessary precursor for neuronal glutathione
synthesis (Aoyama et al., 2006).

Glutathione is a major antioxidant, directly

linked to the metabolism of nitrosyl oxidants and peroxide (Dringen, 2000).
EAAT3 knock-out mice present significantly reduced spontaneous locomotor
activity at 12 months of age but otherwise the CNS appears normal. A major
dysfunction of EAAT3 knock-out animals is the onset of dicarboxylic
aminoaciduria due to the loss of uptake from the renal tubules by EAAT3
(Peghini et al., 1997).
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The highest expression of EAAT4 is found in cerebellar Purkinje cells with
very low levels expressed in the hippocampus, neocortex, striatum, brain stem
and thalamus (Furuta et al., 1997; Reviewed in Danbolt, 2001).

EAAT4 is

hypothesized to remove extracellular glutamate that is not cleared from the
synapse by EAAT1-3 (Mim et al., 2005). In Purkinje cells EAAT1 seems to be
the major contributor to the uptake of glutamate from the synaptic cleft and
EAAT4 appears to remove low concentrations of glutamate that escape the glial
transporters, thereby preventing glutamate spillover to neighboring synapses
(Takayasu et al., 2005).
EAAT5 is restricted to the retina where it is found in cone and rod
photoreceptor terminals and in axon terminals of rod bipolar cells (Fairman et al.,
1995; Rothstein et al., 1994; Arriza et al., 1997; Localization reviewed in detail in
Danbolt, 2001). Here, EAAT5 has a unique role and is believed to act as a
presynaptic receptor in mouse bipolar cells and may play a major role in
controlling the output from these cells (Wersinger et al., 2006).
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1.3 Transport Mechanisms and Molecular Structure of the EAATs

It is estimated that glutamate transporters can concentrate glutamate
5x106 fold in cells under physiological conditions (Zerangue and Kavanaugh,
1996a). In order to accomplish this, the EAATs couple the transport of glutamate
into the cell to the influx of 3 sodium ions and one proton (for review see;
Danbolt, 2001; Kanai and Hediger, 2004).

The transporter returns to the

extracellular side of the membrane by coupling this movement to the transport of
one potassium ion (Zerangue and Kavanaugh, 1996a).

In this manner the

EAATs harness energy derived from the concentration gradients of sodium and
potassium, to import glutamate into the cell and to return to the extracellular side
of the plasma membrane.
In addition to the transport current, substrate applied to the EAATs creates
a substrate gated anion conductance that is not stochiometrically linked to
glutamate transport (Fairman et al., 1995; Wadiche et al., 1995). The anion
current is a small component of the EAAT1-3 total current associated with the
transporter. In contrast, the current associated with EAAT4 and EAAT5 is almost
entirely made up of the anion current. This suggests that the primary role of
EAAT4 and EAAT5 may be to regulate cellular excitability via glutamate gated
anion channels (Torres-Salazar and Fahlke, 2007).
Advancements in determining the structure of the EAATs has been made
through the crystallization of a glutamate transporter homologue from
Pyrococcus horikoshii (Gltph), a sodium dependent aspartate transporter, which
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shares a 37% amino acid identity with human EAAT2. The transporter
homologue was recently crystallized with bound aspartate (closed state) and the
glutamate transport inhibitor threo-β-benzoylaspartic acid (bound TBOA, open
state). An advantage of having crystal structures of the transporter in these two
states is the mechanistic information it affords (Yernool et al., 2004; Boudker et
al., 2007).
Data suggests that the transporter is a trimer with a bowl shaped basin
facing the extracellular space (Figure 3). Three binding sites lay at the bottom of
the basin, each gated by two loops. Helical hairpin loop 1 (HP1) acts as the
intracellular gate and helical hairpin loop 2 (HP2) acts as the extracellular gate.
The substrate binding site is located about 5 Angstroms below the bottom of the
aqueous basin buried in a polar cavity formed by the tips of HP1 and HP2, the
unwound

region

of

transmembrand

7

(TM7)

and

polar

residues

of

transmembrane 8 (TM8). HP2, which acts as the extracellular gate is initially in
the open position, allowing access of the extracellular solution to the aqueous
basin. The authors predict that two sodium ions bind with aspartate, one sodium
coupled to HP1, below aspartate, and the other coupled to HP2, above
aspartate. The sodium ions are hypothesized to help stabilize the loops. Binding
of two sodium ions and substrate induces the HP2 loop to close, giving the
“occluded” state. Next, the HP1 loop opens to create an aqueous pathway to the
cytoplasm. When HP1 opens, HP2 moves into the space previously occupied by
HP1 in order to prevent an open pore thereby allowing “alternating access” from
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the extracellular to intracellular ssides
ides of the membrane (Yernool et al., 2004;
Boudker et al., 2007).

Figure 3. EAAT3 homology model shown with three bound sodium ions and
aspartate bound in one of the three active sites.

In addition to structural information, the crystal structure lends insight into
the manner in which ligands recognize and bind to the active site. TBOA and
aspartate were observed to bind by the same recognition points, thereby
validating that TBOA works in a competitive manner, as well as giving credence
to the modeling based on the belief that the protein recognizes compounds by at
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least 3 points; the α carboxyl group, C1; the distal carboxyl group, C2 and the
nitrogen, N (Esslinger et al., 2005).

The bulky aromatic group of TBOA is

believed to interfere with the closing of HP2, effectually blocking further
conformational changes (Boudker et al., 2007). This interference may result in
the observed inhibitory acitivity of TBOA.

Figure 4 illustrates this point by

showing TBOA in the active site of the EAAT3 homology model. The homology
model was created by aligning the EAAT3 sequence (Yernool et al., 2004) to the
crystal structure coordinates of Gltph TBOA bound (Boudker et al., 2007).
Valuable information, such as the generation and analysis of EAAT
homology models, can be extracted from the Gltph crystal structures.

This

information can be used to examine the basic structure of the EAATs as well to
determine where changes in amino acids surrounding the binding site may affect
substrate binding across the different EAATs.

In spite of the wealth of

information the EAAT homology models afford, the template from which this
information is based upon, Pyrococcus horikoshii, remains a generic model of the
EAATs. By itself, it is not sufficient to delineate the subtle variations between the
individual EAAT binding sites.
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HP2 loop

HP1 loop

Figure 4. TBOA in the active site of the EAAT3 homology model (threading
done by Holley D. and Mavencamp T.).
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1.4 Molecular Pharmacology of the EAATs

In order to determine the subtle differences between the individual EAAT
subtypes, selective inhibitors can be employed.

By examining the structure

activity data of compounds at the EAATs, hypotheses about individual binding
sites can be formed. These hypotheses can be tested by the synthesis of new
analogues designed from the analysis of structure activity data of previous
inhibitors. This method aids in elucidating the subtleties of the individual EAAT
binding sites and often results in more selective and potent inhibitors with each
round of synthesis.
Molecular

pharmacology

played

an

important

role

in

the

initial

characterization of the EAATs. Radiolabeled glutamate was used early on to
examine the substrate specificity of the EAATs.

It was found that other

neurotransmitters did not affect glutamate transport but that L-glutamate, Daspartate and L-aspartate (Figure 5) are good substrates (Ki = 1-10µM) and that
D-glutatmate is not transported (Ferkany and Coyle, 1986; Rauen et al., 1992;
Arriza et al., 1994).
HO2C
HO2C
H2N

HO2C
CO2H

D-Aspartate

H2N

CO2H

L-Aspartate

H2N

CO2H

L-Glutamate

Figure 5. Natural amino acid substrates
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The first EAAT inhibitors were mostly developed via simple modifications
to known substrates and thus, many showed substrate activity. The downfall of
using substrates to characterize the EAATs is that substrates induce
heteroexchange, a process whereby exogenously applied substrate induces the
efflux of internal substrate.

Heteroexchange may increase the amount of

glutamate in the synaptic cleft making it difficult to study the role of the EAATs
(Shigeri et al., 2004).
One of the first analogues used to characterize glutamate uptake by the
EAATs was β-threo-hydroxyaspartate (THA) shown in Figure 6 (Fletcher and
Johnston, 1991; Bridges and Esslinger, 2005). THA, a competitive substrate of
EAAT1-4 and a non-substrate inhibitor of EAAT5, is one template for EAAT
inhibitors that has been used as a lead molecule in the development of many
potent and selective inhibitors.

TBOA, one of the first β-carbon substituted

analogues of THA, continues to be the most widely used non-substrate inhbitior
of the EAATs. The L-enantiomer of TBOA is the more potent enantiomer with
IC50 values of 23 µM, 3.8 µM and 7 µM for EAAT1-3, respectively (Shimamoto et
al., 1998; Sakaguchi et al., 2004). Modifications to the aryl moiety of TBOA
(Figure 6) generally increase the potency over TBOA while retaining nonsubstrate activity. Replacing the benzyl moiety of TBOA with a naphthyl moiety
(L-TNOA1 and L-TNOA2) yields IC50 values of 15 µM, 1.3 µM and 4.8 µM for LTNOA1 and 16 µM, 2.2 µM and 6.5 µM for L-TNOA2 (Shimamoto et al., 2000).
To

date

the

most

potent

TBOA

[trifluoromethyl)benzoylamino]benzyloxy}aspartate

analogue,

(2S,3S)-3-{3-[4-

(TFB-TBOA,

Figure

6)
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displays IC50 values of 22 nM, 17 nM and 300 nM for EAAT1-3, respectively
(Shimamto et al., 2004).

O
HO 2 C

OH

H 2N

HO 2 C

CO 2 H

THA

H 2N

O
CO 2 H

L -T B O A

HO 2 C
H 2N

O

N
H

CO 2 H

CF 3

TFB-TBOA

Figure 6. β-threo hydroxy aspartate and derivatives.
Another approach to inhibitor design is to utilize conformationally
constrained analogues. This allows for the better prediction of functional group
positions as well as decreases the possible binding conformations, which often
leads to an increase in selectivity. This method has been shown to be quite
robust at enhancing the potency and selectivity of analogues at EAAT2 (Bridges
and Esslinger, 2005).
Pyrrolidine dicarboxylate (PDC) and PDC derivatives are conformationally
constrained analogues of glutamate similar in structure to dihydrohainate (DHK),
an analogue of kainic acid (Figure 7). Kainic acid was isolated in 1953 from red
algae in Japan and is a potent, specific agonist of the Kainate Receptor. DHK is
an EAAT2 selective non-substrate inhibitor which not surprisingly shows cross
reactivity at the Kainate Receptors due to its similarity to KA (Shimamoto et al.,
1998).
The PDC derivatives, 2,4 and 2,3 dicarboxylate PDC, were designed as
conformationally constrained mimics of glutamate and aspartate, respectively.
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The lead molecule, L-trans-2,4 PDC, is a substrate of EAAT1-4 and a nonsubstrate of EAAT5. When a methyl group is introduced at the 4 position of 2,4
PDC (4-Me-L-trans 2,4 PDC) the compound exhibits increased potency and can
no longer be translocated at EAAT2, transforming the substrate to a nonsubstrate inhibitor. By switching the position of the carboxylate group of L-trans2,4 PDC from the 4 position to the 3 position (L-trans-2,3 PDC), the selectivity for
EAAT2 increases approximately 10 fold (Ki in Xenous Oocytes of roughly 12 µM)
and displays non-substrate activity at EAAT1-4 (Willis et al., 1996, Bridges et al.,
1999). In order to gain insight into the binding site of EAAT2 and in particular to
elucidate the differences between substrate and non-substrate inhibitors a
pharmacophore model was created. A pharmacophore model is “the ensemble
of steric and electrostatic features of different compounds which are necessary to
ensure optimal supramolecular interactions with a specific biological target
structure and to trigger or to block its biological response” (Langer and Wolber,
2004). An overlay of EAAT2 substrate inhibitors revealed a tight overlap of the αamine, α-carboxyl and distal carboxyl groups as well as a constrained volume
that the backbones occupied within the binding site. When non-substrate EAAT
inhibitors were fit onto the model, such as DHK and TBOA, the non-substrate
inhibitors aligned with the α-amine, α-carboxyl and distal carboxyl groups but had
density outside of the volume taken up by the substrates (Koch et al., 1999;
Esslinger et al., 2002; Esslinger et al., 2005). These results suggest that the
steric bulk outside of the volume taken up by substrates is responsible for the
non-substrate activity.
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N
CH 3

COOH
L-trans 2,4 PDC

HOOC
L-trans 2,3 PDC

COOH
4-Me-2,4 PDC

Figure 7. Pyrrolidine dicarboxylates.

In addition to steric bulk, the preferred conformation of the analogue plays
an important role in how well the compound will bind to the active site, as well as
the ability of the compound to be translocated across the plasma membrane. To
address this important issue, Esslinger et al., 2002 synthesized conformationally
“locked” analogues of 2,4 PDC. The mimics were designed to capture the most
extreme conformations 2,4 PDC may adopt, the folded (pseudo-axial)
conformation and the extended (pseudo-equatorial) conformation.

The folded

conformation was achieved by synthesizing a methyl bridge from carbon 3 and 4
of the pyrrolidine ring (3,4-MPDC). If the methyl bridge is placed between carbon
2 and 4 (2,4 MPDC) the ring is forced into an extended conformation (Figure 8).
The biological results from these compounds were striking with 3,4 MPDC acting
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as a non-substrate inhibitor with a Ki of roughly 5 µM in rat forebrain
synaptosomes and 2,4 MPDC displaying better substrate activity than Lglutamate, as measured by synaptosomal efflux of 3H-D-aspartate (Koch et al.,
1999). These results reveal that both conformations effectively bind to the active
site but their conformations determine if they are translocated (substrate) or not
(non-substrate) across the plasma membrane (Esslinger et al, 2002).

H
N

HOOC

HOOC

H
N COOH

COOH
2,4 MPDC

3,4-MPDC

Figure 8. Bridged Pyrrolidines.
In spite of the progress made in the field of glutamate transport inhibitors
one problem remains: specificity.

It has proven to be very difficult to create

inhibitors that show more than modest selectivity.

The only EAAT1 inhibitor

available to date is L-serine-o-sulfate (L-SOS), an EAAT1 and EAAT3 substrate.
The ki values of L-SOS display modest selectivity for EAAT1: 107 µM, 1157 µM
and 150 µM for EAAT1-3, respectively (Bridges et al., 1999; Vandenberg et al.,
1998; Arriza et al., 1994).
The most selective and potent EAAT inhibitors are active at EAAT2. This
likely follows from EAAT2 being the first EAAT intensely studied due to its
prevalence in synaptosomal preparations, the earliest and most common system
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used to characterize the EAATs.

Two inhibitors that show modest to good

selectivity for EAAT2 are DHK and WAY-855 (3-amino-tricyclo[2.2.1.02.6[heptane1,3-dicarboxylic acid). WAY-855 is an EAAT2 preferring non-substrate inhibitor
with IC50 values in Xenopus laevis oocytes of 125.9 µM, 1.3 µM, and 52.5 µM in
EAAT1-3, respectively (Dunlop et al., 2003).
Recently a series of compounds designed to be structurally distinct from
other well known inhibitors were synthesized. The compounds were constructed
by attaching a lipophilic group to the terminal amine of 2,3 diaminopropionic acid
and to the terminal carboxyl of aspartic acid. Both series of compounds are
potent, competitive, non-substrate inhibitors of EAAT2.

The most potent

compound (figure 9a) [N4-[4-(2-bromo-4,5,difluorophenoxy)phenyl]-L-asparagine
(WAY 213613) does not interact with metabotropic or ionotropic glutamate
receptors and displays an IC50 value of about 85nM and a 59 and 45 fold
selectivity over EAAT1 and EAAT3 respectively (Greenfield et al., 2005; Dunlop
et al., 2005).
In 2006, Greenfield and Dunlop published a review reporting the discovery
of

a

preferential

EAAT3

inhibitor,

(S)-4-(9H-fluoren-2ylamino)-2-amino-4-

oxobutanoic acid (NBI-59159, figure 9b) (Dunlop et. al., 2006).

In Xenopus

oocytes expressing EAAT1-3 this compound acts as a non-substrate inhibitor
with IC50 values of .212 µM, .055 µM and .023 µM, respectively. In HEK cells
expressing EAAT1-3 the compound also displays a preference for EAAT3
yielding IC50 values of 1.03 µM, 1.4 µM and .09 µM, respectively (Dunlop et al.,
2006).
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b. NBI-59159

Figure 9. Aspartamide acid analogues displaying preference for EAAT2 (a) and
EAAT3 (b).

Based upon previous inhibitors of the EAATs and their corresponding
structure activity data, we hypothesize that the conservation of the alpha
carboxylate, alpha amine, and distal carboxylate mimic are crucial for protein
recognition of the ligand. In addition, we envision that the positioning of a bulky
lipophilic group around the backbone will result in increased potency and nonsubstrate activity of the analogue. By restricting the movement of this lipophilic
group in three-dimensional space we suggest that the compounds will show
greater selectivity for one EAAT subtype over another. If specific inhibition of
one EAAT subtype can be achieved this will aid in the creation of a binding site
24

map as well as in the elucidation of the EAATs role in CNS function. To achieve
the stated goal, the Specific Aims follow a re-iterative strategy of synthesis,
assay of activity and molecular modeling.

Specific Aim 1:

Design and synthesize L-β-Benzyl Aspartate (described in

chapter 2) and L-β-Benzyl Aspartate analogues in order to increase interaction
with an adjacent lipophilic domain of EAAT3.
Specific Aim 2:

Determine the concentration dependence with which the

analogues block 3H-D-aspartate uptake in mammalian C17.2 cells expressing
EAAT1, 2 or 3.
Specific Aim 3: Apply the structure activity data generated from Aim 2 to refine
the EAAT3 binding site map using advanced computational molecular modeling
techniques.
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ABSTRACT
The excitatory amino acid transporters (EAATs) play key roles in the regulation of
CNS L-glutamate, especially related to synthesis, signal termination, synaptic
spillover, and excitotoxic protection. Inhibitors available to delineate EAAT
pharmacology and function are essentially limited to those that non-selectively
block all EAATs or those that exhibit a substantial preference for EAAT2. Thus, it
is difficult to selectively study the other subtypes, particularly EAAT1 and EAAT3.
Structure activity studies on a series of β-substituted aspartate analogues identify
L-β-benzyl-aspartate (L-β-BA) as among the first blockers that potently and
preferentially inhibits the neuronal EAAT3 subtype. Kinetic analysis of 3H-Daspartate uptake into C17.2 cells expressing the hEAATs demonstrate that Lthreo-β-BA is the more potent diastereomer, acts competitively, and exhibits a
10-fold preference for EAAT3 compared to EAAT1 and EAAT2.
Electrophysiological recordings of EAAT-mediated currents in Xenopus oocytes
identify L-β-BA as a non-substrate inhibitor. Analyzing L-threo-β-BA within the
context of a novel EAAT2 pharmacophore model suggests: 1) a highly conserved
positioning of the electrostatic carboxyl and amino groups, 2) nearby regions that
accommodate select structural modifications (cyclopropyl rings, methyl groups,
oxygen atoms) and 3) a unique region occupied by the benzyl moieties of LTBOA, L-β-threo-BA and related analogs. It is plausible that the preference of Lβ-threo-BA and L-TBOA for EAAT3 and EAAT2, respectively, could reside in the
latter two pharmacophore regions.

Key Words: Glutamate uptake, transport inhibitors, pharmacophore model
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1. INTRODUCTION

The high-affinity, sodium-dependent excitatory amino aid transporters
(EAATs) are readily acknowledged as key players in the regulation of
extracellular L-glutamate levels in the mammalian CNS (for review see: Danbolt,
2001; Maragakis and Rothstein, 2004; Bridges and Esslinger, 2005).

This

regulation takes on considerable significance given that L-glutamate is the
primary excitatory neurotransmitter in these systems and capable of participating
not only in standard fast synaptic communication, but also in the higher order
types of signal processing linked to development, synaptic plasticity, learning and
memory (for review see multiple chapters in Balazs et al., 2005). Besides its
action in neuronal signaling, excessive levels of L-glutamate can also trigger a
host of pathological pathways in the CNS through the process of excitotoxicity.
In this manner, glutamate-mediated neuronal damage is thought to be a
contributing pathological mechanism in both acute CNS injury (e.g., stroke, head
trauma, spinal cord injury) and chronic neurodegenerative disease (e.g.,
amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease) (for
review see: Choi, 1994; Mattson, 2003; Olney, 2003; Maragakis and Rothstein,
2004).

Consequently, the ability of the EAATs to efficiently sequester L-

glutamate into neurons and glia, places these integral membrane proteins in a
position where they can influence the amount and/or time course with which Lglutamate is in contact with EAA receptors within the context of either normal
signaling or pathologic injury.
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The EAATs are members of a distinct family sodium-dependent solute
carriers (SLC1) that includes five subtypes of glutamate transporter (EAATs 1-5),
as well the neutral amino acid transporters ASCT1 and ASCT2 (Kanai and
Hediger, 1992; Pines et al., 1992; Storck et al., 1992; Arriza et al., 1994; Fairman
et al., 1995; Eliasof et al., 1998; Hediger et al., 2004). While the EAATs share a
level of homology of about 50-60% with one another, as well as a dependency on
sodium and a high-affinity for L-glutamate (Km values in the µM range), each
exhibits a distinct anatomical and cellular distribution (Furuta et al., 1997;
Gegelashvili and Schousboe, 1998; Seal and Amara, 1999; Danbolt, 2001;
Maragakis and Rothstein 2004). The presence of distinct EAAT subtypes raises
obvious questions regarding potential differences in their physiological roles,
especially within the context of excitatory signaling and excitotoxic protection. In
turn, such questions highlight the need for selective inhibitors and substrates that
could be used to differentiate the EAATs and delineate their individual
contributions to glutamate-mediated signaling. Significant advances have been
made in generating inhibitors and substrates that can be used to assess EAAT
activity with little or no cross-reactivity with EAA receptors, such as L-trans-2, 4pyrrolidine dicarboxylate (L-trans-2, 4-PDC) and β-threo-benzyloxy-aspartate
(TBOA) (Bridges and Esslinger, 2005)). Much of this success has been the
direct result of synthetic efforts to produce novel conformationally constrained
analogues of glutamate and aspartate (Chamberlin et al., 1998). Limiting the
positions that can be occupied by required functional groups (e.g., carboxylate
and amino groups) has the potential to both increase potency, as well as reduce
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cross-reactivity. It is this same approach that has so effectively been exploited in
development of selective agonists and antagonists for the EAA receptors.
Additionally, the fact that the functional groups on these rigid and semi-rigid
analogues can be accurately mapped in three-dimensional (3D) space allows for
the construction of 3D pharmacophore models (Gelin, 1995; Martin, 1998). In
this respect, our transporter workgroup has been focused on rigorously probing
the structural commonalities and differences amongst EAAT selective ligands
(especially EAAT2, see; Esslinger et al., 2002; Bridges and Esslinger, 2005;)
through the fabrication of multidimensional superposition pharmacophore models
(Perkins and Dean, 1993; Dean and Perkins, 1998; Martin, 1998).
Unfortunately, identifying compounds that readily differentiate among the
individual EAAT subtypes has proven to be more elusive than developing
analogues that discriminate glutamate transporters from glutamate receptors.
The exception to this limitation has been the progress made in pharmacologically
delineating EAAT2, particularly within the context of the most commonly studied
EAATs 1-3. Thus, glutamate analogues, such as dihydrokainate (DHK), L-antiendo-3,4-methanopyrrolidine dicarboxylate (L-anti-endo-3,4-MPDC) (Bridges et
al., 1994), S-2-amino-3-(3-hydroxy-1,2,5-thiadiazol-5-yl)propionic acid (TDPA)
(Brauner-Osborne et al., 2000) and 3-amino-tricyclo[2.2.1.02.6]heptane-1,3dicarboxylate (WAY-855) (Dunlop et al., 2003) potently and preferentially interact
with EAAT2 to a high enough degree that they can be used to distinguish its
activity from the other EAAT subtypes. In the instance of the other EAATs, only
more subtle indications point to chemical templates that might be used to create
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subtype selective blockers. For example, EAAT 1 has the distinguishing feature
of being able to effectively use 4-methyl-glutamate and L-serine-O-sulfate as
substrates and to exhibit a sensitivity to inhibition by (R,S)-2-amino-3-(1-hydroxy1,2,3-triazol-5-yl)propionate (Arriza et al., 1994; Vandenberg, 1998; Stensbol et
al., 2002). Similarly, hints to the potential selectivity of EAAT3 may be traced
back to the pioneering characterizations of glutamate uptake, where it was
reported that L-aspartate β-hydroxamate was more effective at inhibiting
glutamate uptake into neurons than into glia (Roberts and Watkins, 1975). In the
present work we carry out a structure activity study on a series of aspartate
analogues that have been modified at the β-carbon position. We find that one of
these analogues, L-β-benzyl-aspartate, may be among the first transport
blockers to be identified that potently and preferentially inhibits the neuronal
EAAT3 subtype. Further, molecular modeling studies in which this new inhibitor
has been positioned within a current EAAT2 pharmacophore suggest that its
specificity of action may be the result of the side chains of L-β-benzyl-aspartate
and L-β-TBOA interacting with similar lipophilic residues within the substrate
binding domain of the EAATs in addition to distinct residues between EAAT
isoforms. These finding represent an important step in developing the reagents
that are critically needed to elucidate the physiological roles played by the
neuronal EAAT3 glutamate transporter within the processes of excitatory
transmission and excitotoxicity.
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2.

METHODS

2.1.

Chemicals and Reagents
General cell culture supplies were purchased from Becton Dickinson

(Franklin Lakes, NJ), Corning (Corning, NY), and Life Technologies (Grand
Island, NY). D-[3H]Aspartic acid was purchased from Dupont NEN (Boston, MA).
L-Aspartate, L-β-threo-hydroxy-aspartate (L-β-THA), and D,L-threo-methylaspartate were obtained from Sigma (St. Louis, MO). D,L-β-threo-Benzyloxyaspartate was obtained from Tocris (Ballwin, MO).

L-trans-2,3-Pyrrolidine

dicarboxylate (L-trans-2,3-PDC) was prepared as described (Humphrey et al.,
1994).

The cis-3-methyl-L-trans-2,3-PDC (cis-3-Me-L-trans-2,3-PDC) was

prepared in a similar manner by A.R. Chamberlin via methylation of the β-enolate
of protected 2,3-PDC, giving a 2:1 mixture of diastereomers from which the
desired major isomer was isolated, deprotected, and purified. The synthesis of
L-β-benzyl-aspartate was performed by Terri Mavencamp under the mentorship
of Dr. Esslinger.

The following pharmacological comparisons are included

because they provide a basis for interpreting structure activity relationship (SAR)
data. This analysis is crucial to both the full evaluation of L-β-BA as well as to
the design of a second round of L-β-benzyl aspartate derivatives. The synthesis
of L-β-BA begins with L-aspartic acid and utilizes methodology similar to that
previously reported (Humphrey et al., 1994). Protection as dimethyl ester using
thionyl chloride in methanol, followed by N-tritylation with trityl chloride and
triethylamine afforded the protected aspartate derivative.

Base promoted
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alkylation at the beta carbon afforded a ca. 2:1 ratio of diastereomers as
distinguished by

1

HNMR and correlated to a similar compound previously

reported (Humphrey et al., 1994). Deprotection using refluxing 6N HCl followed
by ion exchange chromatography afforded the target compound L-β-benzyl
aspartate (L-β-BA) as the mixture of diastereomers and aspartate free, as
determined by 1HNMR analysis.

Optical activity of the mixture ([α]=+29.8o)

suggests the alpha carbon stereochemical integrity remained intact. Separation
of the two diastereomers by preparative HPLC using a C18 column in 0.1M
ammonium acetate buffer pH 6.4 afforded the individual threo and erythro
diastereomers.

Full experimental details for these syntheses are reported in

Mavencamp et al., 2008. All other chemicals were purchased from Sigma (St.
Louis, MO).

2.2.

EAAT Expression and Cell Culture
EAAT1, and EAAT3 cDNA were PCR amplified from pBlueScript-hEAAT1

and pBlueScript-hEAAT3 (provided by Dr. M Kavanaugh) using primer pairs
(forward;

5’ATAAGGATCCA-TGACTAAAAGCAACGGA3’

5’TATTGATAT-CCTACATCTTGGTTTCACT3’)
5’ATAAGGATCCATGGGGAAACCGGCGAGG3’

and
and

and

reverse
(forward:
reverse

5’TATTGATATCCTAGAACTGTGAGGTCTG3’) respectively. Each primer pair
introduced BamHI sites at the 5’ ends and EcoRV sites at the 3’ ends of each
amplified fragment. The PCR fragments were then subcloned into the BamHI and
EcoRV sites within the polylinker of the AAV vector pAM-CAG-WPRE (kindly
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provided by Dr. Mathew During, University of Auckland, NZ) to create pAM-CAGEAAT1-WPRE and pAM-CAG-EAAT3-WPRE. Final clones were confirmed by
double stranded sequencing. A 1.9kb EcoRI fragment containing the hEAAT2
cDNA clone was subcloned from pBlueScript-hEAAT2 (Dr. M Kavanaugh) into
the EcoRI site of pAM-CAG-WPRE by standard molecular biology techniques to
create pAM-CAG-EAAT2-WPRE.
C17.2 cells (obtained from Dr. Evan Snyder, Burnham Inst., La Jolla, CA)
between passages 10-20 were seeded at 1 X 105 cells/well in 12 well plates and
grown in complete DMEM supplemented with 10% fetal bovine serum, 1mM
sodium pyruvate, 0.1 mM nonessential amino acids solution, and 0.05%
Penicillin-Streptomycin (5,000 units/ml) and Gentamicin sulfate (0.05mg/ml). At
24 hours after plating, cells were transfected using Lipofectamine 2000
Transfection Reagent (Invitrogen, Carlsbad, CA) in a ratio of 4µl of Lipofectamine
to 3µg of purified plasmid DNA in accordance with manufacturers instructions.
After 24 hours, the relative levels of functional 3H-D-Asp uptake were determined
by the method of Martin and Shain (1979 as described below).

2.3.

Transporter Activity in C17 Cells
C17.2 cell assays were performed by the Bridges lab. Transfected C17.2

cells were grown in DMEM containing 10% FCS in a humid atmosphere of 5%
CO2. Near-confluent cells (plated at 7x104 -1x105 cells/well) were rinsed with a
physiological buffer (138 mM NaCl, 11 mM D-glucose, 5.3 mM KCl, 0.4 mM
KH2PO4, 0.3 mM Na2HPO4, 1.1 mM CaCl2, 0.7 mM MgSO4, 10 mM HEPES, pH
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7.4) and allowed to preincubate at 37oC for 5 min.

Uptake was initiated by

replacing the pre-incubation buffer with buffer containing 3H-D-aspartate (5-100
µM) and inhibitors (10-100 µM). Following a 5 min incubation, the media was
removed by rapid suction and the cells rinsed 3 times with ice-cold buffer. The
cells were dissolved in 0.4N NaOH for 24 hours and analyzed for radioactivity by
LSC and protein by the BCA (Pierce) method. Transport rates were corrected for
background: i.e., radiolabel accumulation at 4oC. Initial studies confirmed that
uptake quantified in this manner was linear with time and protein levels and that
uptake in untransfected C17.2 cells was indistinguishable from background.
Kinetic analyses of the transport inhibitors were carried out using k•cat kinetic
computational software (BioMetallics Inc.) to generate Lineweaver-Burk plots
with curve-fit weighting based on constant relative error. Ki values were also
determined using this software on the basis of a replot of Km,app values.

2.4.

Transporter Activity in Xenopus Oocytes
Capped cRNA was transcribed from the human brain glutamate

transporter EAAT1-3 cDNAs as described (Arriza at al., 1994). Transcripts were
microinjected into Xenopus oocytes (50 ng per oocyte) and membrane currents
were recorded by the Kavanaugh lab 3-6 days later. Ringer recording solution
contained 96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, and 5 mM
HEPES (pH 7.4). Two microelectrode voltage-clamp recordings were performed
at 22°C with an Axon Instruments GeneClamp 500 amplifier interfaced to a PC
using a Digidata 1200 converter controlled using the pCLAMP program suite
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(version 6.0; Axon Instruments). Microelectrodes were filled with 3 M KCl solution
and had resistances of 0.5 to 2 Mohm. Steady state data were sampled at 1 kHz
and low pass filtered at 500 Hz. Data were fitted by least squares using
Kaleidagraph v3.0 (Synergy Software) to the Michaelis-Menten function. L-β-BA
was applied 10-30 sec before glutamate for competition experiments; recovery
from block was complete within 1 min following inhibitor washout.

2.5.

Molecular Modeling
Computational work was performed by Shailesh Agarwal of the Bridges

lab on Silicon Graphics, Inc. (SGI) Octane workstations with R12,000 processors
coupled to an SGI Origin 2000 server.

The software application suite Sybyl

(versions 6.8-7.0), with the Advanced Computation module (Tripos; St. Louis,
MO), was used adjunct with the industrially derived stochastic random search
algorithm AESOP (Masek, 1998). Molecular databases were prepared in Sybyl
formats. Data extracted from the molecular spreadsheets were occasionally
exported for sorting and other manipulations in PERL and C code formats that
were subsequently automated. Inspections of conformations and multifit
superpositions were performed in Sybyl stereoview with CrystalEyes viewers.
The pharmacophore models were constructed as steric-strain, gas-phase
derived conformation compositions employing established comprehensive
conformational analysis methods (Marshall, 1995; Oprea et al., 1995) with four
EAAT2 inhibitor training set ligands, i.e. L-anti-endo-3,4-methanopyrrolidine-3,4dicarboxylate

(L-anti-endo-3,4-MPDC),

cis-5-methyl-L-trans-2,3-pyrrolidine
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dicarboxylate

(cis-5-Me-L-2,3-trans-PDC),

(2S,3R,4S)-2-(carboxy-

cyclopropyl)glycine (CCG-IV) , and L-β-threo-benzyloxy-aspartate (L-TBOA) (for
comparative pharmacological properties see Bridges et al., 1999; Bridges and
Esslinger, 2005). The important EAAT2 inhibitor classes were carefully
considered for inclusion in the training set and those selected satisfied the major
criteria of high potency, structural diversity amongst common moieties, and
relatively high selectivity, as well as little or no substrate activity.
Conformational space of the EAAT inhibitors was comprehensively
searched employing two computational protocols: random search (Tripos Sybyl)
and the stochastic technique AESOP (Masek, 1998) (See Figure 1). The random
search procedure locates energy minima by randomly adjusting the selected
bonds and minimizing the energy of the resulting geometry. Chiral centers, ring
closure distances, and energy ranges were checked for consistency. This
comparison was based on an RMS match between non-hydrogen atoms in the
previously found conformers and the current conformer. Three random searches
(or more) were performed on each training set ligand and other test cases. Data
from the Sybyl random searches were deposited into a molecular database.
AESOP is an alternative stochastic derived program used to search
conformational space. It applies high temperature to the molecule (which results
in molecule being torqued and tensed), and was set to capture a conformer
snapshot every 5 femtoseconds. Temperatures and times were set between
1600-1800 0K and 60-80K femtoseconds. Data from the AESOP spreadsheets
was deposited into the databases established earlier. Subsequently, all
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conformers from both search protocols were minimized to zero energy change
defining their nearest energy well profile.

Conformer database entries were

sorted as a function of conformer total energy and cases of degenerate energy
profiles were crosschecked as plausible duplicates, based on select distances
and angles defined in an exported Molfile spreadsheet.

Duplicate or nearly

identical conformers (e.g., some non-essential rotamers for TBOA) were
eliminated. Some conformations would not have been found if only one
conformer search routine had been used.
Four final training set ligand conformational molecular databases were
derived. An extended closed form analysis method, which used the
conformational data, was developed to select one conformer of each of the four
ligands to form the 3D superposition models. To compare one conformation of
one ligand to all conformations of each of the remaining three training set
ligands,

an

all-combination

comparison

regime

was

used

by

forming

conformational comparison groups (shown as double headed arrows in Fig. 1).
For each comparison group, six distinct measures were assessed between each
ligand conformer, thus permitting an assessment of molecular similarity. These
six measures included the three distances and angles between the α-carboxylate
carbon, C1; α-amino nitrogen, N and distal carboxylate carbon, C2 common to
each training set ligand (see Figure 4). Additional molecular spreadsheets were
also constructed in which i) the ether oxygen of L-TBOA and ii) the cyclopropyl
centroid of L-CCG-IV were substituted for point C2 to consider alterative relative
alignments.
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The resulting 3.4 X 106 conformational comparison groups were analyzed
for 3D molecular similarity using a relative difference scoring function (Figure 1),
defined as a sum of the average of the four conformations (as per the allcombination regime and denoted as nconformers) using absolute value relative
difference measurements (nmeasures). Averaging precluded the use of weighting
factors. The relative difference comparison measures between the conformers in
a group (double headed arrows, Figure 1) included three distance and three
angle values. The six conformer-to-conformer measurements were extracted
from the molecular database spreadsheets and the calculations of the scoring
function values were made. Conformer energies were not used in these
calculations, thus making the scoring function energy independent. The
comparison group that had a low scoring function value (least amount of
differences amongst the six variable conformer measures in 3D space) was
identified. Thus, the lower the score the more similar the conformers are to one
another, representing molecular similarity of their space groupings. The selected
ligand conformer set was brought together with a 1 cal spring constant, and the
superposition models were appraised in stereoview using CrystalEyes viewers.
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Training set ligands: MPDC, PDC, CCG-IV, and TBOA
>2 Sybyl random searches
2000 iterations

Conformer
Number

>2 AESOP stochastic search
60-80 K fsec, 1600-1800? K

MPDC

PDC

100

107

Energy Range 107.16Kcal/mol
157.48

CCG-IV

TBOA

151

208

10.0091.62

103.59109.67

1.64>500

Conformer spreadsheet databases established for each ligand
Conformers: merged, duplicates eliminated, zero energy change

Compare each comformer of 4 ligand data sets to each other
within comparsion groups. Measurements were assessed
using the summed relative difference Equation 1 to generate
a scoring function for each comparison of the alignment
scenario under study. Four alignment scenarios tested.
6

MPDC

PDC

6
6

6
6

nconfs

Σ

nvar

Σ

|Vx - Vy|____

i=1 (|Vx | + |Vy |) / 2

i=1

CCG-IV

TBOA

Eqn 1

nvar

n

confs
6
Eqn 1: V are 6 variable measures ( 3 distances and 3 angles) as
compared for ligand x vs. ligand y; nvar = 6 (measures); nconfs = 6 as per
comparison group regime (double headed arrows).

Plot Eqn 1 scoring function values for each comparison group
and select low scoring conformer set = similar points in 3D space
Repeat process for other
ligand alignments
Selected final conformer of each of the four ligands
1 cal spring constant multi-fit superposition

Superposition
pharmacohore
models

Figure 1. Computational paradigm used to generate the EAAT2 pharmacophore
model.
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3. RESULTS

3.1. L-threo-Benzyl-aspartate preferentially inhibit the EAAT3 transporter
subtype
To delineate the pharmacological specificity of the individual EAATs, the
Bridges lab utilized a relatively new expression system that employed C17.2
neuroprogenitor cells and a vector adapted from an Adeno-associated virus
(AAV) packaging plasmid (Stone et al., 2005). The vector contains a number of
elements that facilitate the expression of the EAATs, including a ubiquitous CAG
promoter and a 567 bp woodchuck hepatitis regulatory element (WPRE) that
stimulates the expression of intronless viral messages.

We and other have

observed that the insertion of the WPRE sequence between the stop codon and
the poly-A sequence results in a substantial increase in stable transgene
expression (Loeb et al., 1999; Paterna et al., 2000). This system proved to be
both easy and efficient (approximately 50% transfection), as C17.2 cells
transfected 24 hrs after plating with the desired EAAT vector exhibited robust and
reproducible levels of activity 48 hrs later. When uptake was quantified with 3HD-aspartate in untransfected cells, the levels of uptake were indistinguishable
from background determined either at 4oC or in the absence of sodium (see
Methods, data not shown).
transport of

In cells expressing the individual subtypes the

3

H-D-aspartate exhibited KM and VMax values (mean ± SEM),

respectively, of: 40 ± 4 µM (n ≥ 5) and 501 ± 72 pmol/min/mg protein (n ≥ 5) for
EAAT1, 44 ± 3 µM (n ≥ 5) and 1997 ± 270 pmol/min/mg protein (n ≥ 5) for
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EAAT2, and 19 ± 3 µM (n ≥ 5) and 334 ± 52 pmol/min/mg protein (n ≥ 5) for
EAAT3.
A series of β-substituted aspartate analogues, that included L-benzylaspartate (L-BA), were screened at 10 µM and 100µM for the ability to inhibit the
uptake of 3H-D-aspartate (25 µM) into C17.2 cells expressing EAAT1, EAAT2 or
EAAT3. The data are reported in Table 1 as the mean % of Control (± SEM)
measured in the absence of inhibitors. Several of these compounds are well
known blockers of the EAATs, (e.g., β-THA, TBOA), and were included in the
present study so that structure activity comparisons would be based on assay
data collected under identical conditions.

Consistent with previous reports

(summarized in Bridges et al., 1999) the introduction of a hydroxyl group at the βcarbon of L-aspartate (β-THA) produced a small increase in inhibitory activity
when compared to L-aspartate (more easily observed at 10 µM). While the Lenantiomer of THA was used in the present study, earlier work quantifying 3H-Lglutamate uptake into synaptosomes reported that the L- and D enantiomers of
THA were approximately equipotent as inhibitors (Robinson et al., 1993).

A

similarly placed methyl group (D,L-β-threo-methyl-aspartate), also produced a
level of inhibition essentially equivalent to its unsubstituted counterpart.
Significantly, all three of these compounds produced comparable levels of
inhibition at each of the three EAAT subtypes.
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Compound

Conc.

EAAT1
3
H-D-Asp Uptake
(% of Control)

EAAT2
3
H-D-Asp Uptake
(% of Control)

EAAT3
3
H-D-Asp
Uptake
(% of Control)

L-Aspartate

100 µM

4 ± 2 (3)

16 ± 4 (3)

15 ± 3 (3)

10 µM

70 ± 9 (3)

82 ± 4 (3)

87 ± 11 (3)

100 µM

33 ± 4 (3)

32 ± 3 (3)

42 ± 2 (3)

10 µM

6 5 ± 13 (3)

76 ± 4 (3)

74 ± 51 (3)

100 µM

5 ± 3 (3)

10 ± 3 (3)

9 ± 3 (3)

10 µM

47 ± y (3)

53 ± 4 (3)

61 ± 7 (3)

100 µM

102 ± 9 (3)

81 ± 5 (3)

89 ± 11 (3)

100 µM

51 ± 2 (3)

12 ± 5 (3)

15 ± 2 (3)

10 µM

71 ± 5 (3)

44 ± 3 (3)

63 ± 3 (3)

100 µM

5 ± 2 (3)

2 ± 1 (3)

9 ± 3 (3)

10 µM

50 ± 4 (3)

30 ± 2 (3)

53 ± 5 (3)

100 µM

20 ± 4 (3)

15 ± 3 (3)

4 ± 2 (3)

25 µM

50 ± 9 (3)

39 ± 5 (3)

20 ± 4 (3)

10 µM

63 ± 9 (3)

70 ± 1 (3)

46 ± 3 (3)

100 µM

8 ± 1 (3)

9 ± 1 (3)

1 ± 1 (3)

10 µM

50 ± 3 (3)

53 ± 2 (3)

30 ± 4 (3)

100 µM

59 ± 4 (3)

48 ± 2 (3)

14 ± 2 (3)

10 µM

7 9 ± 3 (3)

90 ± 5 (3)

66 ± 8 (3)

NH2
COOH
HOOC

D,L-β-threo-CH3Asp
NH2
COOH
HOOC
CH3

L-β-threo-OHAsp
NH2
COOH
HOOC
OH

L-trans-2,3-PDC
COOH

10 µM

COOH

N
H

cis-3-CH3-Ltrans-2,3-PDC
H3C

COOH

COOH

N
H

D,L-β-threo-BOA
NH2
COOH
HOOC
O

L-β-Benzyl-Asp
NH 2
COOH
HOOC

L-β-threo-BA
NH 2
COOH
HOOC

L-β-erythro-BA
NH 2
COOH
HOOC

TABLE 1. Inhibitory activity of β-substituted aspartate analogues at EAAT1,
EAAT2 and EAAT3.
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Embedding L-aspartate into a 5-membered pyrrolidine ring (L-trans-2,3PDC) produced a substantial decrease in the inhibitory activity exhibited at each
of the EAATs. This is in marked contrast to the analogous modification to Lglutamate, where L-trans-2,4-PDC proved to be a potent inhibitor of each
subtype, especially EAAT2 (Bridges et al., 1991; Arriza et al., 1994).
Interestingly, however, when a methyl group is introduced at the β-carbon
equivalent of L-trans-2,3-PDC (i.e., carbon 3), there is a substantial increase in
potency as an inhibitor of 3H-D-aspartate uptake. Further, it appears as if cis-3Me-L-trans-2,3-PDC, like almost all of the pyrrolidine dicarboxylate-based
analogues, preferentially blocks uptake through EAAT2 (Bridges and Esslinger,
2005). A similar pharmacological profile is exhibited by D,L-TBOA, one of the
more potent EAAT blockers identified to date (Shimamoto et al., 2000).
L-β-BA stands apart from all of the other aspartate analogues tested in
that it more potently inhibited uptake mediated by EAAT3 than either EAAT1 or
EAAT2.

As reported in Table 1, this effect could be seen at each of the

concentrations examined. Thus, in the presence of 25 µM L-β-BA EAAT3 activity
(≈ 20% of Control) was about half that observed with EAAT1 (≈ 40% of Control)
or EAAT2 (≈ 50% of Control). L-β-BA produced similar levels of inhibition at both
EAAT1 and EAAT2 and in each case, it was less than that observed with D,LTBOA. On the other hand, L-β-BA and D,L-TBOA exhibited comparable levels of
inhibition at EAAT3. Direct comparisons of potency, however, must be made
cautiously, as L-β-BA was included in this assay as a mixture of its threo and
erythro diaseteromers (i.e., 2:1, respectively), while D,L-TBOA was a mixture of
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its L and D enantiomers (1:1, respectively). Prompted by its preferential action at
EAAT3, the diastereomers of L-β-BA were separated and tested individually.
Similar to the trend observed with THA and TBOA (Shimamoto et al., 2000), the
majority of the inhibitory activity resided with the threo diastereomer (Table 1).
To calculate Ki values, as well as to verify that L-β-threo-BA acts as a
competitive inhibitor, more detailed kinetic studies examined the concentration
dependence with which the analogue inhibited the uptake of 3H-D-aspartate into
C17.2 cells expressing each of the three EAAT subtypes. As illustrated in the
Lineweaver-Burk plots depicted in Figure 2, L-β-threo-BA blocked uptake of 3HD-aspartate mediated by EAAT3 in a manner that was consistent with that of a
competitive inhibitor. Similar patterns of inhibition were also observed for EAAT1
and EAAT2. The resulting Ki values, reported as mean ± SEM from at least 3
separate kinetic assays for each transporter were found to be: 8.7 ± 2.6 µM for
EAAT1, 10.0 ± 2.0 µM for EAAT2 and 0.8 ± 0.2 µM for EAAT3. These findings
confirm the results of the initial pharmacological screening and suggest that L-βthreo-BA is not only one of the more potent inhibitors of EAAT3 identified to date,
but also one that exhibits approximately a 10-fold preference for the EAAT3
compared to EAAT1 and EAAT2.
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(A)

(B)

(C)

46

Figure 2. Representative Lineweaver-Burk plots of single experiments
demonstrating L-threo-BA as a competitive inhibitor of 3H-D-aspartate uptake by
(A) hEAAT1, (B) hEAAT2 and (C) hEAAT3 expressed in C17.2 cells. Data was
collected and analyzed as described in Methods and Materials. The inset within
each graph shows a replot of KMapp vs L-threo-BA that was used to determine the
indicated KI value for the depicted experiment. At least three such experiments
for each transporter were carried out and averaged to derive the KI, KM and VMax
values reported in the text.
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3.2. L-Benzyl-aspartate is a preferential competitive inhibitor of EAAT3 that
does not exhibit substrate activity at any of the EAATs

The actions of L-β-BA, cis-3-Me-L-trans-2,3-PDC and L-glutamate at
human EAAT1, EAAT2 and EAAT3 expressed on X. laevis oocytes were
examined by the Kavanaugh lab in real time using electrophysiological recording
techniques. As the EAAT-mediated co-transport of L-glutamate and its requisite
ions is electrogenic, substrate-induced currents serve as a direct measure of the
translocation process (Wadiche et al., 1995). This provides a distinct advantage
over radiolabeled flux assays, where inhibitory activity is indicative of binding, but
does not directly address the issue of whether or not a particular inhibitor also
acts as an alternative substrate for the transporter. As illustrated in Figure 3A,
the application of L-glutamate (100 µM) to a voltage-clamped oocyte expressing
EAAT3 produced the expected inward current.

When L-glutamate was co-

applied with β-L-BA (2:1 mixture of threo and erythro diastereomers) the
glutamate-induced currents were inhibited in a concentration-dependent manner.
Similar curves were produced when cis-3-Me-L-trans-2,3-PDC was co-applied
with L-glutamate (individual traces not shown). The application of either β-L-BA
or 3-Me-L-trans-2,3-PDC alone did not produce a current. These results are
consistent with the ability of the analogue to bind to the glutamate substrate site
but not be transported. The concentration dependence with which the analogues
blocked these glutamate-mediated currents was also determined. The parallel
shifts observed in the dose-response curves for all of the compounds tested with
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increasing concentrations of the inhibitors are consistent with competitive
inhibition (representative traces shown for β-L-BA at EAAT3, Figure 3B). KD
value were determined using Schild analysis (representative curves for β-L-BA at
EAAT1-3 are shown in Figure 3C). As was observed with the radiolabel flux
assays, 3-Me-L-trans-2,3-PDC exhibited the highest affinity for EAAT2, yielding
KD values at EAAT1, EAAT2 and EAAT3 of 31 µM, 1 µM, and 7 µM, respectively.
Schild analysis of β-L-BA, on the other hand, yielded KD values at EAAT1,
EAAT2 and EAAT3 of 12 µM, 9 µM, and 2 µM, once again demonstrating the
preferential action of β-L-BA at EAAT3.
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Figure 3. (A) Inhibition of hEAAT3 transport by L-β-BA in a representative oocyte
voltage-clamped at –30 mV (glutamate and inhibitor applied for the durations
indicated by corresponding bars above traces). (B) Parallel glutamate doseresponse shift with increasing [3-benzylaspartate] is consistent with competitive
inhibition. Data points represent mean +/- SEM for 3-5 oocytes. (C) Schild
analysis of L-β-BA inhibition in analogous competition experiments with EAATs
1,2, and 3 (slope values constrained to 1) gave ) yielded KD values of 12, 9, and
2 µM, respectively.
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3.4. Conformational molecular modeling with L-threo-Benzyl-aspartate
identifies potential points of divergence between the pharmacophores for
EAAT2 and EAAT3.
The molecular modeling was performed by Shailesh Agarwal under the
guidance of Dr. Bridges and Dr. Gerdes and is described in the Methods section.
The described regimen led to the identification of four plausible pharmacophore
models for EAAT2. While the positions of the two carboxylate carbons and the
amino nitrogen in L-anti-endo-3,4-MPDC and cis-5-Me-L-trans-2,3-PDC were
remarkably aligned in all four models, each differed with respect to the
positioning of these same groups in CCG-IV and L-TBOA. The model shown in
Figure 4 was selected from among the four because it afforded the best
alignments of both carboxylate groups, the amino moieties, and the carbon
backbone. The other models, which were based upon the superpositioning of i)
the ether-O of L-TBOA at the C2 carboxylate position, ii) the centroid of the
cyclopropyl ring of L-CCG-IV at the C2 carboxylate position, or iii) both, were
discounted because they resulted in an inappropriate positioning of the carbon
backbone and/or relevant side chains. For example, when the centroid of the
cyclopropyl ring of L-CCG-IV was superpositioned on the C2 carboxylate
position, the carbon backbone markedly deviated outside the bounds defined by
the other analogues. The model that was selected as the most plausible EAAT2
pharmacophore (and used to evaluate the selectivity of L-β-threo-BA, see
Discussion) is shown in Figure 4, with critical distances and angles between the
various functional groups listed in an inset. The model conformer energy profiles
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were: L-anti-endo-3,4-MPDC, 107.16 -157.48 Kcal/mol; cis-5-Me-L-trans-2,3PDC, 10.00-91.62 Kcal/mol; CCG-IV, 103.59-109.67 Kcal/mol and L-TBOA, 1.64>500 Kcal/mol. The almost identical positioning of the two carboxylate Cs among
the inhibitors suggests a very regimented interaction (i.e., electrostatic) between
these groups and corresponding residues in the binding. Another notable feature
of this pharmacophore is the planar arrangement of the α-C, β-C, amino-N and
distal carboxylate-C atoms (i.e., x-y plane of the graphical representation shown
in Figure 4). The positioning of the cyclopropyl ring of CCG-IV and L-anti-endo3,4-MPDC, as well as the inhibitory activity observed when this ring is replaced
with a cyclohexenyl group (see analogues in (Denton et al., 2002)), suggest a
unique role for possible Π bond-like interactions with the protein. Lastly, the area
delineated by the phenyl ring highlights regions facilitating lipophilic interactions
between the analogues and transporter binding site.
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N-C1
N-C2
C1-C2
N-C1-C2
N-C2-C1
C1-N-C2

Distance (A)
2.52 ± 0.16
3.38 ± 0.24
3.42 ± 0.23
Angle
66.02 ± 0.41
43.01 ± 1.32
70.97 ± 1.28
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Fig 4. EAAT2 Binding-Site Pharmacophore Model. Views (A) and (B) of the
superpositioned (1cal spring constant), color-coded four training-set ligands that
highlight the spatial placements of the amino nitrogen (N), α-carboxyl carbon
(C1) and the distal carboxyl carbon (C2), along with other key structural features.
A graphical representation depicting the averaged position of these structural
features is also shown, with the averaged specific angle and distance
measurements reported in the inset.
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4. DISCUSSION
The ability to pharmacologically manipulate EAAT activity, and thereby
assess its potential contribution to given processes, such as shaping an
excitatory post synaptic signal or affording excitotoxic protection, is dependent
upon the development of potent and selective inhibitors.

Indeed, transport

inhibitors such as L-trans-2,4-PDC and TBOA have been used to differentiate
those synaptic connections in which EAATs likely contribute to signal shaping or
termination (e.g., excitatory inputs on cerebellar Purkinje neurons) from those
where uptake may not play such a role (e.g., excitatory signaling in CA1
hippocampal pyramidal neurons) (Isaacson and Nicoll, 1993; Sarantis et al.,
1993; Barbour et al., 1994; Wadiche and Jahr, 2001). These or similar inhibitors
have also been employed to demonstrate that compromised EAAT activity
increases the likelihood and/or extent of excitotoxic damage (Robinson et al.,
1993; Rothstein et al., 1993). Significantly, the compounds presently available
for such applications have been limited to those that non-selectively block all of
the EAATs or those that exhibit a substantial preference for EAAT2, thus leaving
in question the specific contributions of EAAT1 and EAAT3. In the present work
we identify L-β-BA as one of the first EAA analogues that inhibits EAAT3 activity
more potently than it does EAAT1 or EAAT2. This effect was observed with
EAATs expressed in two different cells systems, Xenopus oocytes and C17.2
neuroprogenitor cells, where, in each case, its mechanism of inhibition was
confirmed as competitive. Consistent with the actions of the other β-substituted
aspartate-based inhibitors, the threo configuration proved to be the more potent

56

diastereomer, exhibiting a sub-micromolar Ki at EAAT3 representative of about a
10-fold preference for the subtype. L-β-BA did not induce currents in oocytes
expressing EAAT3 (or any of the EAATs), though it did block glutamate-mediated
currents, further delineating its action as a non-substrate inhibitor.
The actions of L-β-BA are similar to those of TBOA in several respects.
Significantly, each is a relatively effective inhibitor of all three EAAT subtypes, yet
L-β-BA exhibits a preferential activity at EAAT3, while reports of TBOA activity
have typically reported a preference for EAAT2 (Shimamoto et al., 2004). While
the observed 10-fold preference of L-β-threo-BA for EAAT3 is not sizeable
enough to be classified as an EAAT3-specific inhibitor, its action raises
interesting questions regarding what properties it has in common with other
inhibitors of EAATs1-3 and what might be the basis for increased activity at
EAAT3. Phrased another way, can L-β-BA and TBOA provide any insight into
where the pharmacophores (and consequently the structural domains of the
transporters) for EAAT2 and EAAT3 diverge?

Given the lack of EAAT3-

preferring ligands compared to those selective for EAAT2 and our previous SARmodeling studies of EAAT2, we have begun to examine these issues by
analyzing L-β-BA within the context of an EAAT2 pharmacophore model.
The EAAT2 pharmacophore model was constructed (see Methods for
details) using four potent competitive non-substrate EAAT2 inhibitors that were
as structurally diverse as possible. As shown in Figures 4 and 5, the nearly
equivalent superposition of the three selected electrostatic bearing moieties (the
two carboxyl groups and the amine moiety) of the training set ligands (as well as
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in L-β-threo-BA) in 3D space suggests that these regions may define a critical
ligand triad that serves as an initial recognition group plane.

Thus, the

electrostatic triad might initially interact with a limited collection of complimentary
residues located at the EAAT protein binding site, most likely in combination with
select ions.

Additionally, other structural properties beyond this electrostatic

configuration may serve to influence more subtle pharmacological properties,
such as substrate versus non-substrate activity, potency, and EAAT subtype
selectivity. In this respect, three additional regions exclusive of the carboxyl and
amino functionalities are found within distinctive regions of 3D model space. The
region occupied by introduction of a hydroxyl group (L-β-THA), methyl group (cis3-Me-L-trans-2,3-PDC) or most prominently the extended arm of a benzyloxy
group (TBOA) at the β-carbon of aspartate suggests the presence of a lipophilic
pocket, consistent with our earlier work (Esslinger et al., 2002), or a related
region of lipophilic protein contacts near the initial recognition binding site
residues. The sheer size of aromatic rings that appears to be tolerated at the
binding site (i.e., see the recently described series of TBOA analogs in
Shimamoto et al., 2004) support the notion of regional protein contacts (e.g.,
along various transmembrane residues) rather than a distinctive lipophilic pocket.
Some of these same residues may also interact with a methyl group of cis-4methyl-L-trans-2,4-PDC. Interestingly, the addition of the methyl moiety to Ltrans-2,4-PDC has little effect on potency, but converts this substrate into a nonsubstrate inhibitor of EAAT2 (Esslinger et al., 2002). Taken together with the
activity of TBOA, this suggests that interaction with these domains may
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determine whether or not a bound ligand can be translocated. The orientation of
this lipophilic domain relative to the carboxyl-carboxyl-amine group triad may
occur in two ways, as suggested by the L-BOA erythro and threo stereoisomer,
(see Figure 5B). Since the threo form exhibits greater potency, it is thought that
the benzyl group projected within this model orientation (Figures 4 and 5)
presents a ligand motif that is more favorable for complimentary interaction with
residues at the binding site. Another feature of L-TBOA that may come into play
is the arm linking the phenyl group to the aspartate backbone. Thus, the regioand stereochemical placement of the ether oxygen of L-TBOA is suggestive of
possible H-bonding at the binding site, potentially conferring enhanced ligand
potency and/or influencing L-TBOA selectivity. The close 3D proximity of the two
cyclopropyl rings of MPDC and CCG-IV are suggestive of a Π-bond like
character to the region shown in Figure 4B that may also influence binding.
Consistent with this proposition, the cyclohexenyl-based inhibitor structurally
similar to the CCG class of compounds also shows increased selectivity for
EAAT-2 (Denton et al., 2002).

Lastly, the unique regio- and stereochemical

placement of the methyl group of cis-5-Me-L-trans-2,3-PDC, away from the
benzyl extension of L-TBOA (or L-β-BA), points to the possibility of an additional
region where modest lipophilic groups are tolerated.

It remains less clear

whether this area is a distinct lipophilic pocket associated with the EAAT protein
(s).
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Fig 5. Assessment of conformations and activities of L-β-threo-BOA, L-β-erythroBOA, L-β-threo-BA and L-β-erythro-BA against the EAAT2 binding-site
pharmacophore. The pharmacophore model is shown in (A) without either TBOA
or L-β-BA. In (B) the superposition (1cal spring constant) of L-β-threo- and L-βerythro-BOA with the model illustrating the better fit of aspartyl backbone of the
threo diastereomer with other aligned molecules, in addition to the distinct
placements of the ether ‘O’ and the benzyl group that might influence the potency
and selectivity for this inhibitor at EAAT2.

A similar conclusion is reached

regarding L-β-threo-BA, when the two diastereomers of the L-β-BA are compared
(C). The superposition of L-β-threo-BOA and L-β-threo-BA with the model (D)
suggesting that possible points of divergence between the EAAT2 and EAAT3
pharmacophores may include subtle differences in the size, location and/or
orientation of the aromatic ring or in the oxygen atom present in the linking group
of L-β-threo-BOA, but not L-β-threo-BA.
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Similar analyses for the novel L-β-BA analogue (Figure 5), leads to the
conclusion that the benzyl group of the more potent threo diastereomer is
locating to similar regions as its L-TBOA conformer counterpart. This suggests
that like EAAT2, EAAT3 proteins may accommodate these lipophilic groups to
various extents, providing ligand-protein residue contacts lending to their
respective potency profiles.

The subtype selectivity, however, indicates that

there are differences between the ways in which L-β-threo-BA and L-TBOA bind
more favorably to EAAT3 and EAAT2, respectively. One underlying factor may
reside in subtle difference in the size, location and/or orientation of the aromatic
ring with respect to the lipophilic residues on the transporters.

It is also

interesting to consider that the specificity may be a result of the aromatic ring
linkage to the aspartyl backbone relative to the protein residues that interact with
this ligand region.

Thus, the oxygen atom of L-TBOA may be preferentially

hydrogen bonding with a residue in EAAT2, whereas within EAAT3 there may be
reduced hydrogen bonding, yet preserved lipophilic contacts. Conversely, the
carbon linking atom of the benzyl aspartate ligand is devoid of hydrogen bonding
opportunity within the EAAT 2 binding domain, yet, may interact favorably with a
lipophilic side chain residue within EAAT3 binding region. Hence, selectivity for
one EAAT relative to another may be driven by both favorable and unfavorable
ligand-protein residue side chain interactions involving the ligand benzyl group
linking region.
Collectively, the superposition model coupled to ligand potency and
selectivity data results in the following distinctive pharmacophore region map: 1)
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a discrete three point area (triad) that is comprised of the electrostatic carboxyl
and amino groups that are conserved in space across substrates and inhibitors
and may be essential for initial ligand protein recognition, 2) areas nearby this
electrostatic group triad that can accommodate select structural modification
(e.g., cyclopropyl ring, methyl groups, and oxygen atoms), and 3) the unique 3D
region consumed by the pendant benzyl ring moieties of L-TBOA, L-β-threo-BA
and related analogs.

These first two model regions suggest there exists an

intimate and highly ordered region of the EAAT protein binding domain that may
be associated with initial ligand recognition.

Conversely, the area that

accommodates the pendant benzyl groups is distinct and extended from the
initial ligand recognition site, and also is more tolerant of steric bulk (e.g.,
additional aromatic rings and functional groups). It is particularly notable in this
respect that the recent report of a crystal structure for a eukaryotic glutamate
transporter homologue may now set the stage for the potential integration of
emerging structural models of the EAATs (Yernool et al., 2004; Kanner and
Borre, 2002) with proposed pharmacophore models.

From a functional

perspective, the benzyl appended ligands may lend to greater lipophilic ligandprotein contacts thereby enhancing potency, but at a loss in the ability of the
transporter to translocate the compound. Based on the comparison of these
model details relative to the profiles described for the ligands in Table 1, it
appears that respective preferential action of L-β-threo-BA and L-TBOA at
EAAT3 and EAAT2, likely resides in the latter two distinctive pharmacophore
regions, and in particular, a function of atom type (oxygen or carbon) extending
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from the β-aspartyl backbone position. All of these SAR details are valuable for
the subsequent design of more refined EAAT inhibitor ligands.

Since the

stereochemically defined pendant aromatic region is a more tolerant one, it is this
area of the pharmacophore model that we are currently exploring to develop
additional inhibitors to differentiate among the EAAT subtypes.
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Chapter 3.
Synthesis and preliminary pharmacological evaluation of novel derivatives
of L-β-threo-benzylaspartate as inhibitors of the neuronal glutamate
transporter EAAT-3.

Terri L. Mavencamp, Joseph F. Rhoderick, Richard J. Bridges, C.Sean
Esslinger
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Abstract
A series of β-benzylaspartate derivatives were prepared from N-trityl-L-aspartate
dimethyl ester and evaluated as inhibitors of neuronal glutamate transporter
EAAT3. The result of the structure-activity studies suggest that the position
occupied by the aromatic ring of β-benzylaspartate within the binding site of
EAAT3 may be different from that occupied by comparable groups in previously
identified inhibitors, such as L-threo-benzyloxy aspartate (TBOA). Further,
halogen substitutions at the 3-postition of the aromatic ring of β-benzylaspartate
can increase the potency with which the analogues inhibit EAAT3.
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1. Introduction
L-Glutamate is the most abundant excitatory neurotransmitter in the
mammalian CNS and, as such, contributes to neuronal signaling and cognitive
function through its activation of a wide variety of ionotropic and metabotropic
excitatory amino acid (EAA) receptors (Balazs, R., Bridges, R. J. and Cotman,
2006). If extracellular glutamate concentrations in the CNS become excessive, it
can lead to the over-activation of EAA receptors and the triggering of numerous
neuropathological pathways (Balazs, R., Bridges, R. J. and Cotman, 2006; Hynd
et al., 2004; Foster and Kemp, 2006). Termed excitotoxicity, glutamate-mediated
neuronal injury is believed to contribute to CNS pathology in acute insults
(ischemia, traumatic injury), as well as chronic neurological disorders (e.g., ALS,
Alzheimer's disease, epilepsy, and Huntington's disease). Excitatory amino acid
transporters (EAATs) present on neurons and glia play a critical role in regulating
extracellular levels of glutamate and are thereby positioned to influence: i) the
access of neurotransmitter to synaptic and extrasynaptic EAA receptors, ii) the
recycling of the neurotransmitter and iii) the accumulation of excitotoxic levels of
glutamate (Danbolt, 2001; Bridges and Esslinger, 2005).

The expression of

EAATs has also been found to be altered in neurological disorders such as
epilepsy, ischemia, spinal cord injury, amyotrophic lateral sclerosis (ALS),
Alzheimer’s and schizophrenia (Beart and O’Shea, 2007).

Much of our

understanding of the function of the EAATs has been dependent upon the
development of substrates and inhibitors with which to probe transporter function
and the physiological consequences of decreased activity.
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Five distinct glutamate transporters (EAATs 1-5) have been identified by
molecular cloning that, along with the sodium-dependent neutral amino acid
transporters ASCT1-2, comprise a novel gene family (i.e., SLC1 in the Human
Genome Organization HUGO nomenclature) (Hediger et al., 2004).

Uptake

through the EAATs occurs via an alternate access mechanism that is
electrogenic and driven by ionic gradients across the cell membrane. In this
manner, the transport of one molecule of

glutamate into a cell is

stoichiometrically coupled to the import of three Na+ ions and one H+, and to the
counter transport of one K+ (Zerangue and Kavanaugh, 1996). While the EAATs
share a similar mechanisms and ionic dependence, each exhibits a distinct
localization (Danbolt, 2001). EAAT1 and EAAT2 are primarily considered to be
glial transporters that exhibit a preferential distribution in the cerebellum and
forebrain, respectively. In contrast EAAT3 is present on neurons and is enriched
in forebrain areas. EAAT4 is localized to purkinje neurons in the cerebellum and
EAAT5 is restricted to the retina.

To a large degree the EAATs can be

pharmacologically distinguished from one another based upon the comparative
actions of a number of substrates and inhibitors, although EAAT2 stands alone
with respect to readily available, well-characterized subtype-selective inhibitors
(Bridges and Esslinger, 2005; Kanner et al., 2001).

Not surprisingly,

considerable effort has been focused on the development of inhibitors that can
be used to selectively modulate the activity of the other individual transporters.
Toward this goal our laboratories prepared L-β-benzylaspartate (L-β-BA)
and identified it as one of the few EAAT inhibitors that exhibits a marked
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selectivity for EAAT3 (Esslinger et al., 2005). The more potent enantiomer, Lthreo-β-benzylaspartate

((2S,3S)

3-benzylaspartate,

L-t-β-BA),

shows

an

approximate 10-fold preference for blocking EAAT3 compared to either EAAT1 or
EAAT2 in C17.2 cells expressing the human isotypes. This contrasts with activity
of the closely related and widely used inhibitor L-threo-benzyloxy aspartate
(TBOA) which has been reported to more potently inhibit the activity of EAAT2
than EAAT3 (Shimamoto et al., 2000; Shimamoto et al., 2004; Humphrey et al.,
1994). In the present study a new series of L-β-benzylaspartate derivatives has
been prepared from the easily accessible precursor N-trityl-L-aspartate dimethyl
ester.

The analogues were evaluated as inhibitors of 3H-D-aspartate uptake in

C17.2 neuroprogenitor cells transiently transfected to express human EAAT3.
We report that structure activity profile of these inhibitors is quite different from
TBOA-based analogues suggesting that subtle variations in size, substituents
and orientation of the aromatic ring appended to the β-position of aspartate can
noticeably influence activity at the EAATs. In particular, substitutions at the 3position of the aromatic ring of L-t-β-BA are most favorable for imparting potency
at EAAT3.
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2. Results and Discussion

2.1. Preparation of β-substituted Aspartates
The starting material N-trityl-L-aspartate dimethyl ester (2) was prepared
following a general procedure. The aspartate dimethyl ester was formed using
thionyl chloride in methanol.

N-Tritylation is achieved with triphenylmethyl

chloride and triethylamine (Zervas and Theodorpoulos, 1956).

The resulting

starting material was purified by two subsequent crystallizations from methanol.
The triphenylmethyl protecting group was chosen due to ease of preparation,
mild

deprotection

conditions,

and

the

protection

against

alpha-carbon

deprotonation it imparts to the molecule to avoid alpha-racemization (Scheme 1).
Initially, beta addition was achieved by the addition of lithium
hexamethyldisilyl amide (LiHMDS, 2 equivalents in THF) to a 1M solution of 2 in
anhydrous THF at -32°C under inert atmosphere.

This was followed by

quenching with the desired substituted-benzylic bromide (2-3 equivalents) and
allowing the temperature to rise to 0°C (Humphrey, 1994). Substituted-benzylic
bromides are shown in Table 2 as R, A-J. The reaction was terminated by the
addition of 2N ammonium chloride. This produced a mixture of 3, SS:SR with SR
as the major component in a 1:2 to 1:1 mixture of diastereomers. This was
verified by detailed NMR analysis and compared to similar systems with similar
reaction conditions reported that were accompanied by in-depth stereochemical
determinations (Fernandez-Megia et al., 1994).
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H3N

CO2H

1) MeOH, SOCl2

CO2

2) TrCl, Et3N

1

MeO2C

+

TrN
H

CO2Me

THF
conditions

HO2C

CO2Me
3i (S,S)

base, E+

2

Ar

TrN
H

MeO2C

TrN
H

CO2Me

H3N
1) HCl

CO2Me
3ii (S,R)

CO2

4i (S,S)
+

2) ion exchange
Ar

Ar

HO2C
H3 N

Ar
CO2

4ii (S,R)

Scheme 1. Synthesis of β-benzyl aspartates. Tr = triphenyl methyl. See
Table 1 and Experimental Section for base, E+, and conditions.
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N-Protecting
group +
additives
1. Trityl

Temp
°C

Base: E+

Time of
rxn (hrs)

E+

S,S : S,R
(i:ii)

% yield

-35→0

4

3F

1:2

57%

2. Trityl

-55

6

3F

1:11

55%

3. Trityl

-55→0

2:2
LiHMDS
2:2
LiHMDS
2.5:3
LiHMDS
2:3
LiHMDS
2:2
LiHMDS
2:3
LiHMDS
2.1:2.3
KHMDS
2.1:2.3
KHMDS
2.1:2.3
KHMDS

6

3F

1:2

65%

21

3Cl

3:1

74%

21

3Cl

1:11

68%

21

3Cl

1:11

76%

21

3Nitro

99:1

51%

21

3F

99:1

58%

21

3Br

2.5:1

88%

4. Trityl

DMPU

-55

5. Trityl

-65

6. Trityl

-65

7. Trityl

-55

8. Trityl

-55

9. Trityl

-55→0

Table 1.

Conditions used and results obtained in the benzylation reactions.

S,S:S,R ratios as determined by 1H NMR.
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R-group
Compound

+H3N

CO2-

HO2C

R

EAAT3 Uptake
3
H-D-Asp (25
µM)
(% of Control)

L-β-Benzylasp
4A

4+2

L-β-Benzylasp
S,S-4i

1+1

L-β-Methyl2-napthylasp
4B

68 + 6

L-β-3,5
Dimethylbenzyl-asp
4C
L-β-3Methylbenzyl-asp
4D

CH3

36 + 7

H3C

33 + 3
H3C

R-group
Compound

L-β-3-Brbenzyl-asp
4F
L-β-3-Fbenzyl-asp
4G

+H3N

CO2-

HO2C

R

8+3
Br

0+0
F

L-β-4-Fbenzyl-asp
4H

L-β-3-Nitrobenzyl-asp
4I

L-β-4-Nitrobenzyl-asp
4J

EAAT3 Uptake
3
H-D-Asp (25
µM)
(% of Control)

7±3
F

29 + 5
O2N

65 + 8
NO2

Cl

L-β-2,6Dichlorobenzyl-asp
4E

Table 2.

Cl

86 + 5

Percent of control uptake in the presence of L-β-benzyl aspartate

derivatives (control uptake with no inhibitor present is 100%). C17.2 Cells
assayed for their ability to block 25µM 3H-D aspartate uptake in the presence of
100µM inhibitor, n≥3. Inhibitors in an approximate 1:1 ration of (S,S) : (S,R)
unless specified.
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HPLC separation of L-β-BA diastereomers 4A gave NMR spectra consistent with
previous reports of similar aspartate syntheses (Humphrey et al., 1994;
Fernandez-Megia et al., 1994; Hanessian et al., 1998; Sakaguchi et al., 2004).
At this step, yields of the mixture ranged from 13.5% to 87% following
chromatography. Yields generally improved with greater equivalents of
substituted-benzylic bromide, Table 1: 5 vs. 6, as well as higher temperatures, 2
vs. 3, though diastereoselectivity decreased with increasing temperature. We
found that the ratio of SS:SR increases to 1:11 if the temperature is decreased to
-55°C and quenched at this cold temperature (entries 5 and 6, Table 1). If the
reaction temperature is allowed to rise to 0°C after addition of substitutedbenzylic bromide the ratio of SS:SR decreases to 1:2 to 1:1. Interestingly we
found that adding DMPU to the starting material reverses the stereochemistry to
give SS:SR in a 3:1 mixture of diastereomers (Hanessian et al., 1998).
When KHMDS was used in place of LiHMDS we observed a switch in
diastereoselectivity similar to that observed by Humphrey et al., with N-benzyl-N9-phenylfluoren-9-yl dimethyl aspartate (Humphrey et al., 1994). We propose
that Li complexes tightly to the enolate but may be forming a loose cyclic chelate
between the enolate oxygen and the nitrogen (Figure 1), similar to that
suggested by Fernàndez-Megía and Sardina (Fernàndez-Megía et al., 1994).
This is supported by the decrease in selectivity observed at higher temperatures,
as well as the reversal of diastereoselectivity observed upon addition of DMPU.
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Re

Si

OMe

H H
MeO2C

H
N

O

MeO

H

H

O

Li

Lithium Enolate

K

O

OMe

NH

Potassium Enolate

Figure 1. Low temperature chelation controlled diastereomeric outcome of
enolates using lithium and potassium bases.
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This reversal of selectivity suggests that the metal is being complexed by DMPU,
thereby disrupting the nitrogen oxygen chelate and allowing the molecule more
rotational flexibility. This would increase the probability that the Si face is open
for attack. We hypothesize that potassium forms a cyclic enolate - α-ester
chelation as previously proposed (Humphrey et al., 1994; Fernàndez-Megía et
al., 1994), giving the (S,S) product (Figure 1).
Deprotection was achieved by heating the alkylated product (3) in 6N HCl
to afford the chloride salt of the product. The reaction was then neutralized to a
pH of 7, loaded on an anion exchange resin (acetate form, 10g resin per gram
product), and eluted using a gradient of 1-5N acetic acid. The zwitterion was
obtained by concentrating the ninhydrin positive fractions followed by chasing the
product with deionized water several times. Alternatively, the product can be
precipitated out of ethyl acetate then water to give final product.

2.2. Inhibitory Activity at EAAT3
The compounds were evaluated in collaboration with the Bridges lab as
inhibitors of EAAT3. This was achieved by quantifying their ability to reduce the
uptake of 3H-D-asparate in standard competition assays10. In each instance the
analogues (SS:SR ratio of an approximately 1:1) were added simultaneously with
the radiolabel to achieve a final concentration of 100 µM and 25 µM, respectively.
The results are summarized in Table 2 as % of Control activity, i.e., uptake in the
absence of any inhibitor. The replacement of the benzyl group on L-β-BA with a
napthyl moiety (4B) resulted in a marked reduction of inhibitory activity.
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Interestingly, when an analogous substitution is made with L-TBOA to produce Lthreo-β-(1-napthyl)methyloxaspartate

(L-TNOA1)

and

L-threo-β-(1-

napthyl)methyloxaspartate (L-TNOA2), the inhibitory activity was retained (or
increased) as reflected by a decrease in the IC50 with which the compounds
blocked the uptake of

14

C-glutamate into COS-1 cells expressing EAAT3 (i.e., L-

TBOA, 7.0 µM; L-TNOA1, 4.8 µM; L-TNOA2, 6.5 µM) (Shimamoto et al., 2000).
This would suggest that the proposed lipophilic regions adjacent to the substrate
binding domain on EAAT3 with which the benzyl groups of either L-TBOA or L-tβ-BA interact, can only accommodate a larger napthyl group when its orientation
is dictated by the methoxy linkage of TBOA and not the methylene linking group
of L-t-β-BA. Recent structural insight into these substrate binding domains has
emerged from crystallographic studies in which the archaeal aspartate
transporter Gltph from Pyrococcus horikoshii has been crystallized in the
presence of either L-aspartate or L-TBOA (Boudker et al., 2007).

It was

concluded that the binding site is positioned between two hairpin loops that
extend from opposite sides of the membrane and likely participate in the gating of
substrate movement. While non-substrate inhibitors such as L-TBOA or L-t-β-BA
can fit into this site normally occupied by L-glutamate, interaction with nearby
lipophilic residues in the vicinity of the HP2 loop may preclude subsequent
conformational movements that are necessary for substrate translocation, such
as the closure of the external HP2 gate or providing access of external sodium to
its requisite binding site. Interestingly, the ability of an inhibitor to interact with
EAAT3 in this manner may increase its potency as an inhibitor, but decrease its
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ability to act as an alternative substrate. Comparisons between the naphthyl
derivatives of L-TBOA or L-β-BA, suggest, however, that the exact placement of
the aromatic rings within the binding site of EAAT3 is probably distinct and may
additionally point to structural differences between the EAAT3 and EAAT2
subtypes.
The addition of a methyl (4D) or nitro (4I) group to the 3 position of of L-βBA, as well as a methyl group to both the 3 and 5 positions (4C), resulted in a
retention of some inhibitory activity, although to a lesser degree than found in the
parent molecule (e.g. about 30% of Control uptake vs. 4%). Again, this may be
indicative of a more constrained binding arena surrounding the aromatic ring of
L-β-BA when compared to L-TBOA. In contrast to these compounds, the disubstitution of chloro groups at the 2 and 6 position (4E) produced an almost
complete loss of inhibitory activity. In this instance the decreased ability to bind
to EAAT3 may be attributable to steric clashes with the transporter itself or, given
the locations on the aromatic ring, between the substituents and the carbon
backbone of aspartate when it assumes the requisite conformation for binding.
Comparisons among additions made at the 3 position revealed a rank order of
inhibitory activity of: methyl (4D) ≈ nitro (4I) < bromo (4F) < fluoro (4G). Lastly, Lβ-3-F-BA (4G) and L-β-4-F-BA (4H) inhibited EAAT3-mediated uptake to a
similar or greater extent than observed with either L-β-3-Br-BA or the parent L-βBA. This would be consistent with the steric argument that the lipophilic region
interacting with the benzyl group of L-β-BA in the binding site of EAAT3 is
spatially confined, as well as reflect the ability of fluoro groups to favorably
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interact with both regional sidechain R groups and backbone peptide bonds
(Muller et al., 2007).
To illustrate the diastereomeric preference of EAAT3 for ligand binding as
well as highlight the diastereoselectivity of the benzylation reaction depending on
base used, the individual diastereomers (S,S)4Gi and (S,R)4Gii of L-β-3-F-BA
4G were synthesized and evaluated as inhibitors of EAAT3. Competitive binding
curves were obtained using 3H-D-asparate at 1µM and varying the concentration
of inhibitor (Figure 2). Curve fitting using GraphPad Prism 4.0 software to the
equation Y = 1/(1+10^(X-logIC50)), where Y is the fractional % of control and X is
the log[Inhibitor] in M, IC50 values were obtained for the two diastereomers. As
reported previously, the (S,S) diastereomer is the more potent (Esslinger et al.,
2005; Shimamoto et al., 2000), and in this case (S,S)4Gi exhibits a 10-fold higher
affinity for EAAT3 than (S,R)4Gii.

79

% of Control

IC50 Curves for S,S-3-F-β
β BA
and S,R-3-F-β
β BA
1.00

S,S- βBA

0.75

S,R- βBA

0.50
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0.00
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-2.5

log[I]

Figure 2. IC50 curves for (S,S)-3-F-β BA and (S,R)-3-F-β BA with [3H-Daspartate] = 1 µM. (S,S) 3-F-βBA IC50 = 2.46+/-0.9 µM (S,R)-3-F-β BA
IC50 = 21.1+/-9.2 µM (IC50 +/- SEM).
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2.3 Molecular Modeling
The recently published crystallographic study in which L-TBOA is bound to
the archaeal aspartate transporter Gltph provides a strategy to conformationally
compare these two inhibitors (Boudker et al., 2007). The similarities are readily
apparent when the bound conformation of L-TBOA is extracted from crystal
structure and overlaid with a computationally minimized (Esslinger et al., 2005)
conformation of L-threo-β-BA (Figure 3). While the aromatic rings are positioned
in a similar direction it also appears that the benzyl group of L-threo-β-BA is
considerably closer to the carbon backbone of the amino acid than that of LTBOA.

In this respect the aromatic rings of the two analogues are likely

interacting with subtly different lipophilic regions within the binding domain on
EAAT3. Our SAR data would suggest that the in the instance of L-threo-β-BA,
this region of the protein is less accommodating of steric bulk than the
comparable region delineated by L-TBOA. Further, it is tempting to speculate
that the ability of L-threo-β-BA to interact with these portions of the binding site
may be a factor in its selectivity for EAAT3.
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Figure 3a. Overlay of L-TBOA and L-threo-β-BA using the bound
conformation of L-TBOA and similar conformation of L-threo-β-BA. Viewed
by looking down perpendicular to the plane of the aromatic ring.

Figure 3b. Overlay of L-TBOA and L-threo-β-BA using the bound
conformation of L-TBOA and similar conformation of L-threo-β-BA. Viewed
by looking parallel to the plane of the aromatic ring.
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3. Conclusions

A series of L-β-benzylaspartate derivatives have been prepared from Ntrityl-L-aspartate dimethyl ester in which diastereomeric control was achieved
using either lithium hexamethyldisilazide to yield predominantly the (2S,3R)
adduct in one example or potassium hexamethyldisilazide to yield predominantly
the (2S,3S) adduct in one example and evaluated as inhibitors of the neuronal
glutamate transporter EAAT3. SAR data, including the inactivity of L-β-methyl-2napthyl-aspartate (4B) and the increased activity of L-β-3-F-benzylaspartate
relative to the lead analogue L-β-benzylaspartate, suggest a confined interaction
between lipophilic domains of EAAT3 and the aromatic moiety of L-βbenzylaspartate that is distinct from previously characterized inhibitors, such as
L-TBOA. These finding will be further explored in pursuit of more potent and
selective ligands for the EAAT subtypes.
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4. Experimental Section

In order to verify the purity and composition of the compounds product
analysis was performed by high resolution mass spectrometry. Intermediates
were treated with trifluoroacetic acid prior to mass spectrometry to remove the
trityl group so the signal of the molecular ions could be detected. Proton and
carbon NMR were taken on a Varian 400 MHz NMR in CDCl3, D2O or DMSO
with TMS as the internal standard. NMRs were reported as mixtures of SS:SR
with each diastereomer being identified where possible.

Diastereomers on

carbon NMR are indicated in parentheses where carbon peaks of each molecule
are resolved. Chirality was verified by optical rotation on a Perkin-Elmer 241
Polerimeter in 1N HCl unless otherwise specified in a 1.0dm tube. Reagents
were purchased from Sigma (St. Louis, MO) and were used without further
purification. Microanalyses were performed for C, H, and N (Midwest Microlab,
Indianapolis, IN) and were within ± 0.4% of theoretical values.

Compounds

showing potency equal to or greater than L-β-Benzyl-Aspartate (approximate 1:1
S,S:S,R mixture) were resolved by semi-preparative reverse phase HPLC. The
detection method was a Waters 486 tunable absorbance detector set at 254 nm.

4.1. N-tritylamino dimethyl ester aspartate (2)
L(+)-Aspartic acid (26 g, 100 mmol) was stirred in a round bottom flask in a 1M
solution of Methanol (200 ml). Thionyl chloride (22 ml, 140 mmol) was added
dropwise.

The solution was stirred at room temperature for 48 hours.

The
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resulting dimethyl ester aspartate hydrochloride was washed 3 times with
methanol, 3 times with methylene chloride, 2 times with toluene and once with
water. The dimethyl ester aspartate was then suspended in methylene chloride
(200ml) and dried with magnesium sulfate. Triphenyl methyl chloride (53 g, 95
mmol) was added followed by the dropwise addition of triethyl amine (83.6 g, 300
mmol). The reaction was stirred overnight then diluted with ether and filtered
through a silica plug with a 30/70 solution of ethyl acetate/hexanes. The filtrate
was concentrated and rinsed 2 times with methylene chloride and recrystalized
from methanol to yield N-tritylamino dimethyl ester aspartate 2 (70%). 1H NMR
(400 MHz, CDCl3) δ: 7.54-7.48 (m, 6H), 7.32-7.15 (m, 9H), 3.77-3.71 (m, 1H),
3.69 (s, 3H), 3.28 (s, 3H), 2.99-2.91 (s, 1H), 2.73-2.62, (m, 1H), 2.58-2.48 (m,
1H).

13

C NMR (100 MHz, CDCl3) δ: 173.86, 170.95, 145.61, 128.71, 127.83,

126.48, 71.13, 53.63, 51.91, 51.71, 40.16. [α]21D = 13.3° ( ethyl acetate).

4.2. General procedure for alkylation:
Compound 2 was placed in a flame dried round bottom flask equipped with a stir
bar. 1 M anhydrous THF was added under argon and the reaction was supercooled.

Once cooled 1M LiHMDS in THF (2-3 equivalents) was added via

needle and syringe.

After approximately 20 minutes the desired substituted-

benzylic bromide (2-3 equivalents) was added.

The temperature was then

allowed to rise to 0ºC (unless specified) and the reaction was stirred until
quenched (4-24 hours) with 2N NH4Cl. Water and ethyl acetate (or ether) were
added for separation. The water layer was subsequently washed three times
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and the organic layers were combined and concentrated. Flash chromatography,
when needed, through silica gel using hexane:ethyl acetate in an approximate
85:15 ratio gave the desired protected substituted benzylaspartate in good to
moderate yields.
4.3. N-tritylamino dimethyl ester β-benzylaspartate (3a)
To 2 (1.55 g, 3.84 mmol) in 1M THF under Argon at -23°C was added LiHMDS
(9.6 ml, 11.53 mmol). After 15minutes benzyl bromide (1.15 ml, 9.6 mmol) was
added and temperature allowed to rise to 0ºC at which time it was stirred for a
subsequent 2.5 hours. The reaction was quenched and ether was added for
separation followed by a silica plug (85:15 Hexanes:ethyl acetate) (82.7%: 1.57
g).

1

H NMR (400 MHz, CDCl3) δ : 7.57-7.48 (m, 6H), 7.32-7.20 (m, 14H), (3.94-

3.90 (m, .5 H, S,S), 3.75-3.72 (m, .5 H, S,R)), (3.65 (s, 1.5H, S,S), 3.60 (s, 1.5H,
S,R)), (3.28 (s, 1.5H, S,S), 3.23 (s, 1.5H, S,R)), 3.19-2.88 (m, 3H).

13

C NMR

(100 MHz, CDCl3) δ: 172.77, 172.51, 145.43, (139.15, 138.96), 129.12, 128.72,
127.71, 126.40, 126.22, (71.07, 70.93), (58.11, 57.67), 52.82, (51.65, 51.95),
(51.53, 51.48), (34.05, 33.47).

HRMS m/e calcd. for C13H17NO4+ 252.1236,

found 252.1225.
4.4. N-tritylamino dimethyl ester β-2-napthylmethyl-aspartate (3b)
To 2 (2.5 g, 6.2 mmol) in 1M THF under Argon at -35°C was added LiHMDS
(18.6 mmol). 20 minutes later 2-napthyl methyl bromide was added (3.4 g, 15.5
mmol) as a solid all at once. Temperature was allowed to rise to 0ºC, at which
time it was stirred for an additional 4 hours before being quenched with 2N NH4Cl
(9 ml). Ethyl acetate was added for separation, followed by silica column 85:15
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hexane:ethyl acetate (1.68 g, 50%). 1H NMR (400 MHz, CDCl3) δ : 7.84-7.74 (m,
3 H), 7.66-7.59(m, 1 H), 7.47-7.43 (m, 7H), 7.37-7.29 (m, 1 H), 7.18-7.26 (m,
8H), 7.16-7.11(m, 1 H), 7.09-6.99 (m, 1 H) (3.91-3.87 (m, .4H, S,S), 3.73-3.70
(m, .6H, S,R)), (3.61 (s, 1.2 H, S,S), 3.56 (s, 1.8 H, S,R)), (3.27 (s, 1.2 H, S,S),
3.22 (s, 1.8 H, S,R)), 3.19-2.90 (m, 3H). 13C (100 MHz, CDCl3) δ: 173.20, 172.93,
145.76, 135.32, 133.38, 129.80, 129.07, 129.01, 128.93, 128.19, 128.08, 128.04,
127.96, 127.00, 126.81, 126.72, 126.64, (71.41, 71.31), 60.63, 52.98, 52.02,
49.66, 34.30. HRMS m/e calcd. for C17H20 NO4+ 302.1392, found 302.1388.
4.5. N-tritylamino dimethyl ester β-3,5 dimethyl-benzylaspartate (3c)
To 2 (3.2 g, 8.02 mmol) in 1M THF under Argon at -55°C was added LiHMDS (24
mmol). 20 minutes later 3,5 dimethyl benzyl bromide was added (6.4 g, 32.1
mmol) as a solid all at once. Temperature was allowed to rise to 0ºC, at which
time it was stirred for an additional 1.5 hours before being quenched with 2N
NH4Cl (12 ml). Ethyl acetate was added for separation, followed by silica column
85:15 hexane:ethyl acetate (61%, 3.9 g). 1H NMR (400 MHz, CDCl3) δ : 7.47 (m,
6H), 7.29-7.20 (m, 9H), 6.85-6.76 (m, 3H), (3.86-3.83 (m, .66 H, S,S), 3.72-3.68
(m, .33H, S,R)), (3.63 (s, 1H, S,S), 3.60 (s, 2H, S,R)), (3.25 (s, 1H, S,S), 3.20 (s,
2H, S,R)), 3.03-2.74 (m, 3H), (2.29 (5 H app. singlet, S,S), 2.17 (1H app. singlet
S,R)).

13

C (100 MHz, CDCl3) δ: (173.05, 172.96), (172.80, 172.69), 145.52,

(139.05, 138.93), (137.78, 137.69), (128.81, 128.69), 127.93, 127.87, 127.78,
127.17, 126.72, 126.58, 126.48, 126.37, (71.16, 70.93), (58.19, 57.79), (52.86,
52.77), (51.78, 51.72), (51.65, 51.60), (33.93, 33.36), 21.21. HRMS m/e calcd.
for C13H18NO4 + 280.1549, found 280.1540.
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4.6. N-tritylamino dimethyl ester β-3 methyl-benzylaspartate (3d)
To 2 (1.86 g, 4.61 mmol) in 1M THF under Argon at -30°C was added LiHMDS
(13.8 mmol) slowly. 20 minutes later 3 methyl benzyl bromide was slowly added
(1.56 ml, 11.5 mmol). Temperature was allowed to rise to 0ºC, at which time it
was stirred for an additional 4 hours before being quenched with 2N NH4Cl (7
ml). Ethyl acetate was added for separation, followed by silica column 85:15
hexane:ethyl acetate (1.05 g, 45%).

1

HNMR (400 MHz, CDCl3) δ: 7.48-7.45 (m,

7H), 7.32-7.13 (m, 10H), 7.03-6.93 (m, 2H), (3.86-3.81 (m, .66H, S,R), 3.68-3.64
(m, p. obsc., .33H, S,S)), (3.63 (s, 1H, S,S), 3.59 (s, 2H, S,R)), (3.24 (s, 1H, S,S),
3.19 (s, 2H, S,R)), 3.08-2.77 (m, 3H), (2.33 (s, 2H, S,R), 2.30 (s, 1H, S,S)).
13

CNMR (100 MHz, CDCl3) δ: 172.99, 172.74, 145.55, 139.15, 139.01, 129.71,

128.83, 127.81, 126.51, 125.82, (71.16, 70.98), (58.19, 57.79), (52.89, 52.86),
(51.84, 51.77), (51.71, 51.65), (34.02, 33.46), 21.38.

HRMS m/e calcd. for

C14H19NO4+ 266.1392, found 252.1225.
4.7. N-tritylamino dimethyl ester β-2,6 dicloro-benzylaspartate (3e)
To 2 (4.35 g, 10.78 mmol) in 1M THF under Argon at -35°C was added LiHMDS
(32.3 mmol). After stirring at -35°C for 15 minutes, 2,6-diclorobenzyl bromide
was added by removing the septa and quickly adding the dry reactant (6.47 g,
26.95 mmol). Temperature was allowed to rise to 0ºC, at which time it was
stirred for an additional 5 hours before being quenched with 2N NH4Cl (15 ml).
Ethyl acetate was added for separation. No starting material was observed by
TLC and NMR showed disappearance of starting material with no breakdown to
aspartic acid.

1

HNMR (400 MHz, CDCl3) δ: 7.53-7.49 (m, 6H), 7.29-7.15 (m,
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11H), 7.10-7.06 (m, 1H), (3.94-3.90 (m, .5H, S,R), 3.78 (m, .5H, S,S)), (3.63 (s,
1.5H, S,S), 3.62, (s, 1.5H, S,R)), 3.55-3.38 (m, 2H), (3.20 (s, 1.5H, S,S), 2.19 (s,
1.5H, S,R)), 3.06-3.02 (m, 1H).

13

CNMR (100 MHz, CDCl3) δ: (172.72, 172.51),

(172.31, 172.17), 145.46, 135.75, 135.29, 134.90, 129.40, 128.84, 127.74,
127.22, 127.02, 126.42, 126.34, (71.25, 70.90), (58.08, 57.70), (51.86, 51.74),
(51.68, 51.60), (50.11, 49.25), (30.28, 29.62).

HRMS m/e calcd. for

C13H15Cl2NO4+ 320.0456, found, 320.0441.

4.8. N-tritylamino dimethyl ester β-3 bromo-benzylaspartate (3f)
To 2 (2.27 g, 5.63 mmol) in 1M THF under Argon at -35°C was added LiHMDS
(16.9 mmol) slowly. 20 minutes later 3-bromo-benzyl bromide was added (3.5 g,
14.1 mmol) as a solid all at once. Temperature was allowed to rise to 0ºC, at
which time it was stirred for an additional 2.5 hours before being quenched with
2N NH4Cl (5 ml). Ethyl acetate was added for separation, followed by silica
column 85:15 hexane:ethyl acetate (56%, 1.8 g). Spectra S,R, separated via
column chromatography. S,R comes off first followed by S,S. Spectra reported
for S,R 1HNMR (400 MHz, CDCl3) δ: 7.46-4.44 (m, 5H), 7.34-7.29 (m, 5H), 7.267.08 (m, 9H), 3.86-3.82 (m, 1H), 3.58 (s, 3H), 3.21 (s, 3H), 2.99-2.78 (m, 3H).
13

CNMR (100MHz, CDCl3) δ: 173.04, 172.55, 145.68, 141.96, 132.15, 130.16,

129.72, 129.05, 128.11, 127.85, 126.82, 122.63, 71.34, 58.32, 52.77, 51.96,
33.21. HRMS m/e calcd. for C13H16BrNO4+ 330.0341, found 330.0336.
4.9. N-tritylamino dimethyl ester β-3 fluoro-benzylaspartate (3g)
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To 2 (.5 g, 1.24 mmol) in 1M THF under Argon at -35°C was added LiHMDS (2.5
ml) slowly. 20 minutes later 3-fluoro-benzyl bromide was slowly added (.304 ml,
2.40 mmol). Temperature was allowed to rise to 0ºC, at which time it was stirred
for an additional 4 hours before being quenched with 2N NH4Cl (3 ml). Ethyl
acetate was added for separation, followed by silica column 85:15 hexane:ethyl
acetate (57%, .363 g).

1

HNMR (400 MHz, CDCl3) δ: 7.47-7.43 (m, 6H), 7.32-

7.18 (m, 10H), 6.98-6.83 (m, 3H), (3.86-3.82 (m, .66H, S,R), 3.64-3.60 (m, .33H,
S,S)); (3.64 (s, 1H, S,S), 3.59 (s, 2H, S,R)); (3.25 (s, 1H, S,S), 3.20 (s, 2H, S,R));
3.05-2.87 (m, 3H).

13

CNMR (100 MHz, CDCl3) δ: 173.04, 172.64, 161.81,

145.86, 142.09, 130.02, 129.05, 128.11, 126.82, 124.82, (116.13, 115.91),
(113.62, 113.41), 71.32, 58.30, 52.86, 52.08, 51.99, 33.33. HRMS m/e calcd. for
C13H16FNO4+ 270.1142, found 270.1141.

4.10. N-tritylamino dimethyl ester β-3 fluoro-benzylaspartate (3g, S,S)
Trityl aspartate (.555 g, 1.38 mmol) was placed in a flame dried round bottom
flask equipped with stir bar. Anhydrous THF (5.5 ml) was added under argon
and reaction was cooled to -35°C. Once cooled 20% KHMDS in THF (3.2 ml)
was slowly added, 20 minutes later 3-Floro benzyl bromide was slowly added
(.39 ml, 3.16 mmol). The reaction was stirred for an additional 21 hours before
being quickly quenched with 2N NH4Cl (4 ml). Separate by adding water and
ethyl acetate. Wash water layer two more times with ethyl acetate, combine
organic layers and concentrate. Purification by chromatography on silica gel
using ethyl acetate and hexanes 15:85 gave product in 58% yield (.407 g).
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1

HNMR (400MHz, CDCL3) δ: 7.51-7.46 (m, 7H), 7.27-7.20 (m, 11H), 7.00-6.86

(m, 1H), 3.69 (s, 3H), 3.64-3.60 (p.obsc. m, 1H-α), 3.28 (s, 3H), 2.95 (m, 1H-β);
(2.69-2.65 (m, 1H), 2.54-2.50 (m, 1H,).

13

CNMR (100MHz, CDCl3) δ: 173.04,

172.64, 161.81, 145.86, 142.09, 130.02, 129.05, 128.11, 126.82, 124.82,
(116.13, 115.91), (113.62, 113.41), 71.32, 58.30, 52.86, 52.08, 51.99, 33.33.

4.11. N-tritylamino dimethyl ester β-3 fluoro-benzylaspartate (3g. S,R)
Trityl aspartate (.5 g, 1.24 mmol) was placed in a flame dried round bottom flask
equipped with stir bar.

Anhydrous THF (5 ml) was added under argon and

reaction was cooled to -55°C. Once cooled LiHMDS in THF (2.5 ml) was slowly
added, 20 minutes later 3-Floro benzyl bromide was slowly added (.3 ml, 2.48
mmol). The reaction was stirred for an additional 21 hours before being quickly
quenched with 2N NH4Cl (4 ml). Separate by adding water and ethyl acetate.
Wash water layer two more times with ethyl acetate, combine organic layers and
concentrate. Purification by chromatography on silica gel using ethyl acetate and
hexanes 15:85 gave product in 55% yield (.35 g).

1

HNMR (400MHz, CDCL3) δ:

7.51-7.46 (m, 6H), 7.31-7.27 (m, 9H), 7.22 (d, 1H, J=7.33), 7.00 (d, 1H, J=7.33),
6.94-6.92 (m, 2H), 3.95 (m, .1H, S,S), 3.68 (m, .9H, S,R), 3.65 (s, .3H, S,S), 3.60
(s, 2.7H, S,R,), 3.27 (s, .3H, S,S), 3.22 (s, 2.7H, S,R), 3.08-2.85 (m, 3H).
4.12 N-tritylamino dimethyl ester β-4-fluoro-benzylaspartate (3h)
To 2 (.536 g, 1.33 mmol) in 1M THF under Argon at -30°C was added LiHMDS
(2.66 mmol) slowly. 20 minutes later 4-fluoro-benzyl bromide was added (.33 ml,
2.66 mmol) dropwise. Temperature was allowed to rise to 0ºC, at which time it
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was stirred for an additional 2 hours before being quenched with 2N NH4Cl (6
ml). Ethyl acetate was added for separation, followed by silica column 85:15
hexane:ethyl acetate (.517 g, 76%).

(Found: C, 75.06; H, 6.00; N, 2.74

C32H30FNO4 requires C, 75.13; H, 5.91; N, 2.74).

1

H NMR (400 MHz, CDCl3) δ:

7.48-7.44 (m, 6H), 7.29-7.15 (m, 9H), 7.13-7.05 (m, 2H), 6.99-6.89 (m, 2H),
(3.86-3.82 (m, .5H, S,R), 3.69-3.65 (m, .5H, S,S)), (3.63 (s, 1.5H, S,S), 3.58 (s,
1.5H S,R)), (3.24 (s, 1.5H, S,S), 3.19 (s, 1.5H, S,R)), 3.09-2.78 (m, 3H).

13

C

NMR (100 MHz, CDCl3) δ: (172.83, 172.78), 172.51, (172.71, 160.28), 145.44,
(134.85, 134.82), (134.65, 134.62), (130.45, 130.38), (130.35, 130.27), 128.77,
128.65, 127.78, 126.52, 126.42, (115.26, 115.20), (115.05, 115.01), (71.13,
70.99), (58.05, 57.52), 53.00, (51.89, 51.75), (51.72, 51.65), (33.26, 32.67).
4.13. N-tritylamino dimethyl ester β-3-nitro-benzylaspartate (3i)
To 2 (3.546 g, 8.8 mmol) in 1M THF under Argon at -23°C was added LiHMDS
(26.4 mmol) slowly. 20 minutes later 3-nitro-benzyl bromide was added (4.7 g,
21.97 mmol) as a solid all at once. Temperature was allowed to rise to 0ºC, at
which time it was stirred for an additional 4 hours before being quenched with 2N
NH4Cl (13 ml). Ethyl acetate was added for separation, followed by silica column
85:15 hexane:ethyl acetate (13.5%, .64g).

1

H NMR (400 MHz, CDCl3) δ: 8.20-

8.10 (m, 3H), 8.07-8.04 (m, 1H), 7.60-7.17 (m, H), (3.95-3.90 (m, .75H, S,R),
3.76-3.70 (m, .15H, S,S)), (3.66 (s, .45H, S,S), 3.63, (s, 2.55H, S,R)), (3.28 (s,
.45H, S,S), 3.25 (s, 2.55H, S,R)), 3.08-2.98 (m, 3H), 2.91 (s, .75H), 2.88 (s,
.25H).

13

C (100 MHz, CDCl3) δ: 172.68, 182.36, 145.32, 135.47, 135.40, 129.81,

129.25, 128.77, 128.63, 128.33, 128.18, 127.93, 127.87, 126.99, 126.69, 126.55,
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123.88, 123.75, 121.64, 121.56, 71.23, (57.99, 57.59), 52.25, 52.12, 51.92,
(33.71, 32.70). HRMS m/e calcd for C13H16N2O6+, 297.087, found 297.1076.
4.14. N-tritylamino dimethyl ester β-3-nitro-benzylaspartate (3i, S,S)
Trityl aspartate (.5 g, 1.34 mmol) was placed in a flame dried round bottom flask
equipped with stir bar. Anhydrous THF (5 ml) was added under argon and the
solution was cooled to -55°C. Once cooled KHMDS (20% in THF, 2.6 mmol) was
slowly added, 20 minutes later 3-nitro-benzyl bromide was added (.634 g, 2.9
mmol) as a solid all at once. The reaction was stirred for an additional 21 hours
before being quenched with 2N NH4Cl (6 ml).

Ethyl acetate was added for

separation. The water layer was washed two more times and the organic layers
were concentrated down for separation on silica in 15% ethyl acetate, 85%
hexanes (51%, .34 g).

1

H NMR (400 MHz, CDCl3) δ:

8.26-8.00 (m, 1H), 7.52-

7.37 (m, 4H), 7.52-7.16 (m, 15H), 3.63 (s, 3H), 3.58 (m, 1H β), 3.30 (s, 3H), 3.273.25 (m, 1H α), 3.22-3.15 (m, 2H), 3.03-2.94 (m, 2H).

13

C (100 MHz, CDCl3) δ:

172.36, 145.34, 141.06, 135.47, 129.01, 128.77, 128.63, 127.87, 127.66, 126.55,
123.75, 121.64, 71.23, 57.59, 52.24, 52.10, 51.91, 33.71.

4.15. N-tritylamino dimethyl ester β-P-nitro benzylaspartate (3j)
Compound 2 (3.123 g, 7.74 mmol) in 1 M anhydrous THF under argon was
cooled to -40°C. Once cooled 1M LHMDS (23.2 mmol) was added. After 20
minutes P-nitro benzyl bromide, dissolved in anhydrous THF, was added (4.18 g,
19.35 mmol). The temperature was then allowed to rise to 0ºC and the reaction
was stirred for 4 hrs at which time the reaction was quenched with 2N NH4Cl

93

(10ml).

Water and ether were added for separation.

The water layer was

subsequently washed three times and the ether layers were combined and
concentrated down. Chromatography through silica gel (90% hexanes 10% ethyl
acetate and .5% triethyl amine), methylene chloride was for easier loading to give
(3.63g, 87.0%) as a yellow solid.

1

H-NMR (400 MHz, CDCl3) δ: (8.14(d, 1.55 H,

S,R, J=8.06), 8.08 (d, .44H, S,S, J=8.06)), 7.43 (dd, 6H, J=7.33, 8.79), 7.34 (d,
2H, J=8.79), 7.28 (dd, 2H, J=7.33), 7.26 (m, 2H), 7.26 (d, 1.55H, S,R, J=8.06),
7.22 (d, .44H, S,S, J=8.06), 7.21 (d, 2H, J=7.33), 7.19, (d, 1H, J=7.33). 3.90-3.87
(m, .8H, S,R), (3.63 (s, .65H, S,S), 3.57 (s, 2.33H, S,R)), (3.25 (s, .65H, S,S),
3.24 (d, 2.33H, S,R)), 3.03-2.94 (m, 3H).

13

C (100 MHz, CDCl3) δ: 172.65,

171.98, 145.34, 129.83, 128.77, 127.92, 126.69, 123.62, 58.03, (52.25; 51.92),
(32.94, 30.88). HRMS m/e Calcd for C13H16N2O6+, 297.087, found 297.1076.

4.16. N-tritylamino dimethyl ester β-3-chloro benzylaspartate
Trityl aspartate (.50 g, 1.2 mmol) was placed in a flame dried round bottom flask
equipped with stir bar. Anhydrous THF (5 ml) was added under argon and the
solution was cooled to -65°C. Once cooled 1M LHMDS in THF (2.5 ml) was
slowly added, 20 minutes later 3-cloro-benzyl bromide was added (.47 ml, 3.6
mmol) at which time the reaction was stirred for an additional 21 hours before
being quenched with 2N NH4Cl (6 ml). Ethyl acetate was added for separation.
The water layer was washed two more times and the organic layers were
concentrated down for separation on silica in 15% ethyl acetate, 85% hexanes
(63%, .654 g). 1H NMR (400 MHz, CDCl3) δ: 7.46-7.42 (m, 6H), 7.25-7.22 (m,
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7H), 7.19-7.16 (m, 5H), 7.06-7.05 (m, 1H), (3.85-3.83 (m, 1H), (3.61 (s, .3H, S,S),
3.56 (s, 2.7, S,R)), (3.23 (s, .3H, S,S), 3.19 (s, 2.7, S,R)), 3.02-2.78 (m, 3H).

13

C

(100 MHz, CDCl3) δ: 173.10, 172.66, 146.81, 145.37, 141.31, 134.05, 129.59,
128.93, 128.74, 127.81, 127.13, 126.54, 71.02, 58.00, 52.48, 51.77, 51.71,
32.94. HRMS m/e calcd. for C13H16ClNO4+ 286.0846, found 286.0840.

4.17. General Procedure for Deprotection:
The protected β-substituted aspartate was taken up in 6N HCl and refluxed for 312 hours. The reaction was then diluted with water and washed three times with
ether.

The water layer was concentrated and neutralized with NH4OH and

loaded onto an Ag 1X 8 acetate form ion exchange resin in the ratio of 1g
product to 10g resin. The product was eluted with varying concentrations of
acetic acid from .1 to 5N. Product came off around 2N. Water was lyophilized 23 times to remove the acetic acid.

4.18. β-Benzylaspartate (4A)
The protected benzyl aspartate (1.496 g) was taken up in 6N HCl and refluxed
for 3 hours. Product came off at 2N as indicated by NMR (8.6 %, .058 g).

1

H

NMR (400 MHz, D2O) δ: 7.32-7.21 (m, 2H), 7.25-7.21 (m, 3H), (4.04 (d, .25H,
S,S, J=3.88), 3.96 (d, .75H, S,R, J=3.88)), (3.40 (ddd .75H, S,R, J=3.88, 6.47,
9.06), 3.24 (ddd, .25H, S,S, J=3.88, 6.47, 9.06)) 3.09-3.01 (m, 1H), 2.95-2.89 (m,
1H).

13

C (100 MHz, CDCl3) δ: 172.69, 169.64, (139.69, 138.69), 129.07, 128.42,
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126.54, (54.85, 52,91), (49.66, 47.87), (33.46, 32.99).

HRMS m/e calcd. for

C11H14NO4+ 224.0923, found 224.0923. [α]21D = +29.8°.

4.19. S,S L-β-Benzylaspartate (4A)
The solvent system comprised of a buffered solution of ammonium acetate and
water (0.1 M at pH 6.4). Reversed phase C18 3u analytical and 10u semi-prep
columns were used with a retention time for S,S being 2.59 minutes and 16.00
minutes, respectively and for S,R 3.19 minutes and 21.00 minutes, respectively.
1

H NMR (400MHz, D2O) δ: 7.29-7.25 (m, 2H), 7.21-7.17 (m, 3H), 3.89 (d, 1H,

J=3.24), 2.99 (ddd, 1H, J=3.24, 4.53, 11.00), 2.79-2.66 (m, 2H).

13

C NMR

(400MHz, D2O) δ: 22.00, 33.46, 49.41, 55.96, 126.96, 128.96, 139.02, 176.693.
S,S: [α]25D = +14.11.

4.20. β-2 Napthylmethylaspartate (4B)
The protected β-alkylated aspartate (1.68 g, 3.09 mmol) was taken up in 6N HCl
and refluxed for 4 hours. Ethyl ether was added for separation; the water layer
was washed 3 times and concentrated. Product crashes out of solution upon
neutralization with NaOH. The pH was adjusted to about 12 and precipitated out
of methanol (.5g, 51%).

1

HNMR (400MHz, D2O) δ: 7.83-7.78 (m, 3H), 7.66

(app.singlet, 1H), 7.47-7.35 (m, 3H), 3.60 (m, 1H, S,S), 3.27-3.25 (m, 1H, S,R),
3.03-2.94 (m, 1H), 2.86-2.83 (m, 1H), 2.69-2.60 (m, 1H).

13

CNMR (100MHz,

DMSO) δ: (172.93. 172.82), (170.44, 170.12), 136.99, 133.65, 132.50, 129.93,
129.29, 128.29, 128.13, 127.70, 127.50, 126.65, 126.11, (55.27, 53.18) (50.54,
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48.62), (33.53, 31.39). 18.27 = acetic acid. HRMS m/e Calcd for C15H16 NO4+
349.9889, found 349.9902. [α]21D = +9.8.
4.21. β-3,5 Dimethyl-benzylaspartate (4C)
The protected β-alkylated aspartate (1.29 g, 2.47 mmol) was taken up in 6N HCl
and heated for 24 hours at 70°C. Ethyl ether was added for separation; the
water layer was washed and concentrated. NH4OH was added to adjust the pH
to 7 and loaded onto an anion exchange resin. Product came off at 2N (.032 g,
8%).

1

H NMR (400 MHz, D2O) δ: (6.92 (app. Singlet, .67H, S,R.); 6.91 (app.

Singlet, .33H, S,R)), (6.88 (1.33H, app. Singlet, S,R,); 6.87 (.66H, app singlet,
S,S)), (4.08-4.07 (m, .33H, S,S), 4.00-3.99 (m, .66H, S,R)), (3.45-3.40 (m, .66H,
S,R), 3.26-3.21 (m, .33H, S,S)), 3.05-2.98 (m, 1H), 2.89-2.81 (m, 1H), (2.18 (br
singlet, 5H), 2.12 (br singlet, 1H S,S)).

13

C (100MHz, D2O) δ: (172.54,172.07),

(169.43,169.37), (138.52,138.20), (137.34,137.14), (128.05,127.87; 126.78,
(52.68,52.36), (47.90,47.46), (34.23, 32.03), 21.00.

HRMS m/e calcd. for

C13H18NO4+ 252.1236 found 252.1230. [α]21D = +34.8°.
4.22. β-3 Methyl-benzylaspartate (4D)
The protected β-alkylated aspartate (.9 g, 1.77 mmol) was taken up in 6N HCl
and heated for 24 hours at 70°C. Ethyl ether was added for separation; the
water layer was washed and concentrated.

NH4OH was added until the pH

reached 6. THF was added for solubility and the product was loaded onto an Ag
1X 8 acetate form ion exchange resin in the ratio of 1g product to 10g resin.
Product was eluted with varying concentrations of acetic acid from .1 to 5N in a
4:1 ratio of water:THF. Product comes off around 2N. (.0765 g, 18.3%). 1HNMR
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(400MHz, D2O) δ: 7.24-7.19 (m, 1H), 7.11-7.05 (m, 3H), (4.14-4.13 (m, .36H,
S,S), 4.09-4.08 (m, .64H, S,R)), (3.52-3.47 (m, .64H, S,R), 3.31-3.28 (m, .36H,
S,S)), 3.12-3.07 (m, 1H), 2.98-2.88 (m, 1H), 2.25 (s, 3H).

13

CNMR (100MHz,

CDCl3) δ: 174.89, 170.46, 139.13, 137.49, 129.78, 128.96, 127.93, 126.06,
52.86, (47.55, 46.88), (33.76, 33.65), 20.47. HRMS m/e calcd. for C12H16NO4+
238.1079, found 238.1079.

[α]21D = +7.8° (in DI H2O, adjusted to 7.5 with

NaOH).
4.23. β-2,6 Dicloro-benzylaspartate (4E)
The protected β-alkylated aspartate was dissolved in THF and 6N HCl and
refluxed for 5 hours. The reaction was washed with ethyl acetate and the water
layers were combined and concentrated. The reaction was neutralized to pH 5
using NaOH, loaded onto an anion exchange resin and eluted with 4:1 H2O:THF
mixture followed by a gradient of acetic acid prepared from concentrated acetic
acid in the same 4:1 H2O:THF ratio to give a gradient from .1N to 5N. Product
was isolated from 2N and 5N acetic acid (1g, 37.2%). 1HNMR (400MHz, D2O) δ:
7.37-7.32 (m, 2H), 7.21-7.14 (m, 1H), (4.05 (m, .4H, S,S), 3.96 (m, .6H, S,R)),
3.47-3.33 (m, 2H), 3.24-3.21 (m, .6H), 3.12-3.09 (m, .4H)..

13

CNMR (100MHz,

CDCl3) δ: 171.75, 169.40, 135.23, 134.03, 129.18, 128.37, 52.80, 46.16, 28.07.
HRMS m/e calcd. for C11H12Cl2NO4+ 320.0456, found 320.0441. [α]21D = +31.7°.
4.24. β-3 Bromo-benzylaspartate (4F)
The protected β-alkylated aspartate(.5 g, .873mmol) was taken up in 6N
HCl and heated for 24 hours. Ethyl ether was added for separation; the water
layer was washed 3 times and concentrated. NH4OH is added until the pH is 7.
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THF is added for solubility and is loaded onto an Ag 1X 8 acetate form ion
exchange resin in the ratio of 1g product to 10g resin. Product is eluted with
varying concentrations of acetic acid from .1 to 5N in a mixture of water:THF in a
ratio of 4:1. Product comes off around 2N. Lyophilize off water 2-3 times to
remove the acetic acid (.1 g, 38.5%). 1HNMR (400 MHz, DMSO) δ: 7.47 (m, 1H),
7.41-7.38 (m, 1H), 7.28-7.22 (m, 2H), 4.01 (br s, .85H, α S.S) 3.82, (br s, .15H, α
S,R), 3.25-3.21 (m, .15H, β S,R), 3.12-3.10 (m, .85H, β S,S), 3.04-3.00 (m 1H),
3.28-2.74 (m, 1H).

13

CNMR (100MHz, DMSO) δ: 171.80, 169.23, 141.69,

131.65, 130.42, 129.27, 128.22, 121.52, 52.68, (48.16, 47.35, β C), (31.62,
30.76, CH2), acetic acid 21.15, 172.33.

HRMS m/e calcd for C11H13BrNO4+

302.0028, found 302.0014. [α]21D = +26.9°.
4.25. β-3 Fluoro-Benzylaspartate (4G)
The protected β-alkylated aspartate (.678 g, 1.33 mmol) was taken up in 6N HCl
and heated for 24 hours at 70°C. Ethyl ether was added for separation; the
water layer was washed 3 times and concentrated. NH4OH was added until the
pH reached 7 and loaded onto an ion exchange resin where product comes off
around 2N (.115 g, 36.2%).

1

H NMR (400 MHz, DMSO) δ: 7.34-7.29 (m, 1H),

7.08-6.99 (m, 3H), (3.99 (d, .33H, S,S, J=4.40), 3.88 (d, .66H, S,R, J=4.40)),
(3.33 (ddd, .66H, S,R, J=4.40, 6.59, 9.52), 3.20 (ddd, .33H, S,S, J=4.40, 5.86,
10,26)), 3.08-2.86 (m, 2H).

13

C (100 MHz, DMSO) δ: (172.54, 171.89), 169.17,

(163.18, 160.77), (141.60, 141.53), (130.15, 130.03, 129.94), 125.05, (115.63,
115.42), (113.31, 113.16, 112.94), (52.97, 52.48), (48.89, 47.25), (33.70, 32.03,
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30.65). HRMS m/e for C11H13FNO4+ calcd. 242.0829, found 242.0834. [α]21D =
+40°.
The mixture of diasteromers was resolved by HPLC as well as synthetically
prepared in ratios of 99:1, S,S:S,R and 11:1 S,R:S,S. For HPLC resolution the
solvent system comprised of a buffered solution of ammonium acetate and water
(0.1 M at pH 6.4). Reversed phase C18 3u analytical and 10u semi-prep columns
were used with a retention time for S,S being 2.3 minutes and 18.48 minutes,
respectively and for S,R 2.8 minutes and 27.22 minutes, respectively.
4.26. β-3 Fluoro-Benzylaspartate (4G, S,S)
1

H NMR (400 MHz, D2O) δ: 7.30-7.26 (m, 1H), 7.06-6.94 (m, 3H), 3.94 (m, 1H),

3.08-3.05 (m, 1H), 2.88-2.81 (m, 1H), 2.77-2.73 (m, 1H).
δ:

13

C (100 MHz, DMSO)

178.20, 172.02, 164.62, 162.21, 143.35, 131.50, 126.19, 116.81, 114.49,

56.53, 49.31, 33.91. [α]21D = +18.3°
4.27. β-3 Fluoro-Benzylaspartate (4G, S,R)
1

H NMR (400 MHz, D2O) δ: 7.32-7.25 (m, 1H), 7.05-6.95 (m, 3H), 3.64-3.59 (m,

1H), 3.07-3.02 (m, 1H), 2.96-2.88 (m, 2H).

13

C (100 MHz, DMSO) δ: 179.81,

172.63, 163.22, 160.81, 140.12, 129.93, 125.11, 115.43, 112.90, 52.68, 49.74,
28.22. [α]21D = +38.23°
4.28. β-4 Fluoro-benzylaspartate (4H)
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The protected β-alkylated aspartate (.457 g, .893 mmol) was taken up in 6N HCl
and heated for 24 hours at 75°C. Ethyl ether was added for separation; the
water layer is washed and concentrated. NH4OH is added until the pH reached
7. THF 1:7 ratio was added for solubility and loaded onto an Ag 1X 8 acetate
form ion exchange resin. Product is eluted with varying concentrations of acetic
acid in a mixture of water:THF in a ratio of 4:1. Product comes off at 2N and 5N
acetic acid. Lyophilize off water 2-3 times to remove the acetic acid (.156, 73%).
Found C, 53.48; H, 4.83; N, 5.60; C11H11FNO4 1/3 H2O requires C, 53.66; H,
4.78; N, 5.69.

1

HNMR (400 MHz, D2O) δ: 7.26-7.20 (m, 2H), 7.06-7.00 (m, 2H),

(3.98 (d, .5H, S,S, J=3.24), 3.88 (d, .5H, S,R, J=3.24)), (3.31 (ddd, .5H, S,R,
J=3.24, 7.12, 9.71), 3.18 (ddd, .5H, S,S, J=3.24, 5.18, 9.06)), 3.05-2.84 (m, 2H).
13

CNMR (100 MHz, D2O) δ: (176.21, 176.00), (172.29, 171.81), (163.01, 162.93),

(160.60, 160.53), (133.80, 133.39), (130.72, 130.68), (130.65, 130.59), (115.69,
115.58), (115.47, 115.37), 54.74, (48.19, 48.03), (33.82, 32.82). [α]21D = +116.6°
in DI H2O adjusted to 7.5 with NaOH.
4.29. β-3 Nitro-benzylaspartate (4I)
The protected β-alkylated aspartate (.24 g, .446 mol) was taken up in 6N HCl and
heated for 24 hours at 65°C. Ethyl ether was added for separation; the water
layer was washed and concentrated. NH4OH was added until the pH reached 7.
THF was added for solubility and loaded onto an ion exchange resin. Product
was eluted with a mixture of water:THF in a ratio of 4:1. Product came off around
2N. Lyophilized off water 2-3 times to remove the acetic acid (.022 g, 18.4%).
Product was sparingly insoluble in H2O.

1

H NMR (400 MHz, D2O) δ: 8.13-8.06
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(m, 2H), 7.67-7.61 (m, 1H), 7.54-7.48 (m, 1H), (3.99 (d, .6H, S,S, J=3.88), 3.87
(d, .4H, S,R, J=3.88)), (3.30 (ddd, .4H, S,R, J=3.88, 5.18, 9.17), 3.21 (ddd, .6H,
S,S, J=3.88, 5.18, 9.06)), 3.11-3.05 (m, 1.4H), 2.97 (d,, .45 H, J=5.18) 2.94 (d,
.25H, J=5.18).

13

C (100 MHz, DMSO) δ: (173.92, 172.48), (169.50, 168.75),

(146.79, 146.56), 139.37, 136.19, (131.76, 130.60), (123.72, 123.55), (122.23,
122.02), 52.92, 48.83, 29.69. HRMS m/e calcd for C11H13N2O6 269.0774, found
269.0779. [α]21D = + 2.7° in DI H2O adjusted to 7.5 with NaOH. [α]21D = -20°.
4.30. β-3 Nitro-benzylaspartate (4I, S,S)
The protected β-alkylated aspartate(.325 g, .603 mmol) is taken up in 6N HCl
with a little acetone and heated for 24 hours at 65°C. The reaction is then
concentrated down, washed with water 2 times and placed under vacuum. Ethyl
acetate is added and product precipitates out, white powder. For ease this was
centrifuged down for 10 minutes at 4000 rpm and the supernant poured off. The
precipitate was dissolved in a small amount of water from which it almost
immediately crashed out as white crystals.

This is washed with water and

concentrated down 2 more times (.045 g, 28%). 1H NMR (400 MHz, D2O) δ: 8.10
(s, 1H), 8.06 (d, 1H, J=8.06), 7.64 (d, 1H, J=7.33), 7.50 (t, 1H, J=8.06,7.33), 4.13
(1H, α), 3.40-3.36 (m, 1H, β), 3.28-3.23 (m, 1H), 3.11-3.06 (m, 1H).

13

C

(100MHz, D2O) δ: 172.28, 169.29, 147.75, 141.07, 136.05, 129.69, 123.67,
121.64, 52.79, 47.28, 33.85.

4.31. β-para nitro benzylaspartate (4J)
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The protected β-alkylated aspartate (1.35 g, 2.51 mmol) was placed in a round
bottom flask with 6N HCl and THF, to dissolve. Reaction was refluxed for three
hours then washed with ethyl acetate. The ethyl acetate layer was washed 2
more times and the aqueous layer was concentrated down. 7.4g AgX1-8 resin
200-400mesh size was loaded into a column and washed with two columns of
water. Product was loaded and the column was washed with a gradient of acetic
acid from .1N to 5N. Faction’s 1-5 are lyophilized down (.378 g, 56%).

1

H-NMR

(400 MHz, D2O) δ: 8.04-8.00 (m, 2H), 7.39-7.34 (m, 2H), (3.99-3.88 (d, .65H,
S,S), 3.92-3.91 (d, .35H, S,R)), (3.35-3.33 (m, .35H, S,R), 3.23-3.22 (m, .65H,
S,S)), 3.12-2.91 (m, 2H).
(173.37,172.64),

13

CNMR (100MHz, D2O) δ: (178.86,178.41),

(147.30,146.96),

(146.42,146.35),

(129.92,129.83),

(123.86,123.80), (55.73,55.67), (49.40,48.99), (36.12,33.29). HRMS m/e Calcd
for C11H14N2O6+ calcd. 252.1236, found 252.1225. [α]21D = +18.52°.

4.32. β-3 Chloro-benzylaspartate S,R
1

H-NMR (400 MHz, D2O) δ: 7.30-7.24 (m, 3H), 7.18-7.17 (m, 1H), (3.96 (app. d,

.07H, S,S), 3.81 (app. d, .93H, S,R)), (3.27-3.22 (m, .91H, S,R), 3.15-3.10 (m,
.09H, S,S)), (3.02-2.89 (m, 1.9H, S,R), 2.83-2.79 (m, .1H, S,S).

13

CNMR

(100MHz, D2O) δ: 172.01, 169.34, 141.26, 132.73, 130.06, 128.65, 127.75,
126.34, 52.44, 49.61, 32.14. [α]21D = +25.7°.

4.33 EAAT3-Mediated transport in C17.2 cells
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EAAT3 was transiently expressed in C17.2 cells (obtained from Dr. Evan Snyder,
Burnham Inst., La Jolla, CA) using an AAV-based vector (kindly provided by Dr.
Mathew During, University of Auckland, NZ) pAM-CAG-EAAT3-WPRE as
previously described (Esslinger et al., 2005). Cells between passages 10-20
were seeded at 5 X 104 cells/well in 12 well plates and grown in complete DMEM
supplemented with 10% fetal bovine serum, 1mM sodium pyruvate, 0.1 mM
nonessential amino acids solution.

At 24 hours after plating, cells were

transfected using FuGENE6 Transfection Reagent (Roche, Indianapolis, IN) in a
ratio of 4µl of FuGENE6 to 3µg of purified plasmid DNA in accordance with
manufacturers instructions. The cells were used in transport assays 24 hours
following transfection as described by Esslinger et al., 2005. Briefly, transfected
C17.2 cells were grown in DMEM containing 10% FCS in a humid atmosphere of
5% CO2. Near-confluent cells (plated at 5x104 cells/well) were rinsed with a
physiological buffer (138 mM NaCl, 11 mM D-glucose, 5.3 mM KCl, 0.4 mM
KH2PO4, 0.3 mM Na2HPO4, 1.1 mM CaCl2, 0.7 mM MgSO4, 10 mM HEPES, pH
7.4) and allowed to preincubate at 37oC for 5 min.

Uptake was initiated by

replacing the pre-incubation buffer with buffer containing 3H-D-aspartate (25µM)
and inhibitors at the concentrations indicated. Following a 5 min incubation, the
media was removed by rapid suction and the cells rinsed 3 times with ice-cold
buffer. The cells were dissolved in 0.4N NaOH for 24 hours and analyzed for
radioactivity by LSC and protein by the BCA (Pierce) method. Transport rates
were corrected for background: i.e., radiolabel accumulation at 4oC. Initial studies
confirmed that uptake quantified in this manner was linear with time and protein
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levels and that uptake in untransfected C17.2 cells was indistinguishable from
background.
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Chapter 4.
L-β-Benzyl-aspartate derivatives; pharmacological characterization and
computational evaluation of a novel class of preferential EAAT3 inhibitors.

Terri Mavencamp, Joseph F. Rhoderick, David Holley, John Gerdes, Michael
Kavanaugh, C. Sean Esslinger and Richard J. Bridges
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Abstract
Derivatives of L-β-benzyl aspartate were prepared and characterized for the
ability to inhibit 3H-D-aspartate uptake into hEAAT1-3 expressing C17.2 cells.
This series comprises one of the first families of EAAT3 preferring inhibitors
identified to date. The three most potent compounds contain a halogen
substitution at the 3-position of the aromatic ring. IC50 values at EAAT1-3 have
been determined for L-β-3- (bromo-, chloro- and fluoro-) benzyl aspartate. IC50
values of the most potent, L-β-3-fluoro-benzyl aspartate are 7.50 µM ± 2.12, 5.56
µM ± 0.65 and .1.95 µM ± 0.37 respectively. Potency decreases when
substitutions are made at the 4-postition as well as with increasing size of the
substituent. Computational modeling and analysis of structure activity data
suggest the area the aromatic moiety of L-β-benzyl aspartate derivatives probe is
1) 3-dimentionally confined, 2) more tolerant of substitutions at the 3 and 5
positions than the 4 position, 3) at least partially distinct from the area probed by
L-TBOA and 4) more accessible in the EAAT3 protein than EAAT1 and EAAT2.
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1. Introduction
Glutamate is the major excitatory neurotransmitter in the mammalian
central nervous system (CNS). It is capable of participating in standard fast
synaptic communication as well as in higher order signal processing linked to
development, synaptic plasticity, learning and memory (for review see: Balaz et
al., 2006). The interaction of glutamate with the ionotropic and metabotropic
glutamate receptors mediates signal transmission, yet overstimulation of these
receptors has been shown to result in excitotoxic conditions that could result in
cell death. This is believed to play a key role in disorders of the CNS such as
stroke, epilepsy, spinal cord injury, ALS, and Alzheimer’s disease (for reviews
see: Rao and Weiss 2004; Won et al., 2002; Malva et al., 2003; Hynd et al.,
2004). The excitatory amino acid transporters (EAATs), clear glutamate from the
synaptic cleft, thereby influencing the amount and/or time course that Lglutamate is in contact with the excitatory amino acid (EAA) receptors.
Five glutamate transporters have been identified by molecular cloning and
functional expression and share about 50-60% homology at the amino acid level.
EAAT1-5 along with two neutral amino acid transporters comprise the sodium
dependent solute carrier family (SLC1) and are referred to as: EAAT1(GLAST),
EAAT2(GLT-1), EAAT3(EAAC1), EAAT4, EAAT5, ASCT1 and ASCT2 (Storck et
al., 1992; Pines et al., 1992; Kanai & Heidger, 1992; Arriza et al., 1994; Fairman
et al., 1995; Arriza et al., 1997; Kanai and Hediger, 2004).
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Advancements in determining the structure of the EAATs have been made
through the crystallization of a transporter homologue from Pyrococcus
horikoshii, Gltph.

Data suggests that the transporter is a trimer with a bowl

shaped basin facing the extracellular space.

Three binding sites lay at the

bottom of the basin, 1 per monomer. Each site is covered by two helical hairpins
(HP1 and HP2) extending from
opposite sides of the membrane
HP2 loop

(Yernool

et

transporter

2004).

The

homologue

was

al.,

recently crystallized with bound
aspartate (closed state) and bound

HP1 loop

L-β-threo-benzyloxy-aspartate
(TBOA) (open state). TBOA and
aspartate were observed to bind

Figure 1. TBOA in the active site of the
EAAT3 homology model.

by the same recognition points. This validates that TBOA works in a competitive
manner and gives credence to modeling based on the belief that the protein
recognizes compounds by at least 3 points, the α carboxyl group, C1; the distal
carboxyl group, C2 and the nitrogen, N. The authors predict that two sodium
ions bind with aspartate, one sodium coupled to the hairpin loop on the
intracellular side HP1 and the other coupled to the hairpin loop on the
extracellular side, HP2, of the protein. The bulky aromatic group of TBOA is
believed to interfere with the closing of HP2; not allowing the second sodium to
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bind thereby effectually blocking further conformational changes (Boudker et al.,
2007).
Amino acid residues positioned to make numerous protein-substrate
interactions in Gltph are also present in the EAATs. Functional studies of Asp444
and Arg447 in EAAC1 support the importance of these residues in substrate
binding.

Asp444 is conserved among members of the SCL1 family but is

replaced by a serine in the dicarboxylic acid transporters DctA. When Asp444 is
mutated in EAAC1, even to similar residues such as glutamate, almost complete
loss of transport is observed (Teichman and Kanner, 2007). This suggests that
the ligand amine group is engaging in key hydrogen bonds to Asp444.
Another residue shown to be crucial for transport is Arg447. Arg447 is
conserved in eukaryotic and bacterial glutamate transporters as well as in DctA,
but is not conserved in the two neutral amino acid transporters ASCT1 and
ASCT2. Arg447 is involved in binding the substrate distal carboxylate group, C2.
Mutation of Arg447 to a neutral or negative amino acid residue abolishes
transport of L-glutamate and D- and L-aspartate but leaves cysteine transport
intact, converting the transporter to a neutral amino acid transporter (Bendahan
et al., 2000).
Due to the high degree of conservation among amino acid residues
implicated in substrate binding, the development of inhibitors that act selectively
at one EAAT over another is an ongoing challenge.

Recently important

advancements have been made by the addition of two potent EAAT2 preferring
non-substrate inhibitors.

WAY-855 (3-amino-tricyclo[2.2.1.02.6[heptane-1,3-
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dicarboxylic acid) and WAY-213613 (S)-2CO2H

amino-4-(4-(2-bromo-4,5-

H

H

HO2C
H3N

difluorophenoxy)phenylamino)-4oxobutanoic

H

acid (Figure 2).

WAY-855 and WAY-213613

a. WAY-855
Br

display potent activities at EAAT2 (1.3 µM and
.08 µM, respectively and a 40 and 46 fold

O

O

F

N
H
H2N

F

preference for EAAT2 over EAAT3) (Dunlop et

CO2H

b. WAY-213613

al., 2003; Dunlop et al., 2005).

O

An EAAT3 preferring compound was
synthesized that belongs to the same class of
compounds as WAY-213613, (S)-4-(9H-fluoren2ylamino)-2-amino-4-oxobutanoic
59159).

acid

(NBI-

One major difference between NBI-

HN
H2N

CO2H

c. NBI-59159

Figure 2. Aspartamide acid
analogues displaying
preference for EAAT2 (a,b)
and EAAT3 (c).

59159 and WAY-213613 is the fused ring
system found in the EAAT3 preferring compound versus the phenoxy benzene
ring structure in the EAAT2 preferring compound (Figure 2). NBI-59159 displays
non-substrate activity In Xenopus oocytes expressing EAAT1-3 (inhibitory IC50
values of 212 nM, 55 mM and 23 nM respectively) and in HEK cells expressing
EAAT1-3 (inhibitory IC50 values of 1.03 µM, 1.4 µM and 0.09 µM, EAAT1-3
respectively) (Dunlop et al., 2006).
Prior to the reporting of the above compounds, our laboratories published
the characterization of one of the first preferential EAAT3 inhibitors, L-β-benzylaspartate (L-β-BA). Kinetic analysis of 3H-D-aspartate uptake into C17.2 cells

111

expressing the hEAATs demonstrated that L-threo-β-BA is the more potent
diastereomer (Ki values 9 µM for EAAT1, 10.0 µM for EAAT2 and 0.8 µM for
EAAT3), acts competitively, and exhibits a 10-fold preference for EAAT3
compared to EAAT1 and EAAT2. Electrophysiological recordings of substrate
mediated currents in Xenopus oocytes expressing EAATs identified L-β-BA as a
non-substrate inhibitor. It was initially hypothesized, prior to publication of the
Gltph crystal structure, that the observed EAAT3 preference was due to 1) the
highly conserved positioning of the α carboxyl group, C1; the distal carboxyl
group, C2 and the nitrogen, N, 2) nearby regions that accommodate select
structural modifications (cyclopropyl rings, methyl groups, oxygen atoms) and 3)
a unique region occupied by the benzyl moieties of L-TBOA, L-β-threo-BA and
related analogs.
In this chapter we present the in vitro pharmacological characterization of
a family of novel analogues of L-β-BA prepared by enolate addition of a lipophilic
head group to protected aspartate (Mavencamp et al., 2008). The compounds
were assayed for their ability to inhibit D-[3H] aspartic acid uptake into C17.2
cells. We found that the L-β-BA scaffold presents a unique opportunity to build a
family of EAAT3 preferring molecules.

Modeling studies were carried out in

which select compounds were docked into an EAAT3 homology model using the
program GOLD.

The results from the docking studies suggest L-β-BA and

derivatives bind in a manner distinct from TBOA due to the absence of the
oxygen on the β-substituent.
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2. Methods

2.1 Chemicals and reagents
General cell culture supplies were purchased from Becton Dickinson
(Franklin Lakes, NJ), Corning (Corning, NY), and Life Technologies (Grand
Island, NY). D-[3H]Aspartic acid was purchased from Dupont NEN (Boston, MA).
L-Aspartate. D,L-β-threo-Benzyloxy-aspartate was obtained from Tocris (Ballwin,
MO).

The syntheses of L-β-benzyl-aspartate derivatives were performed as

described in (Mavencamp et al., 2008).

2.2 EAAT Expression and Cell Culture
C17.2 cells (obtained from Dr. Evan Snyder, Burnham Inst., La Jolla, CA)
between passages 10-20 were seeded at 1 X 105 cells/well in 12 well plates and
grown in complete DMEM supplemented with 10% fetal bovine serum, 1mM
sodium pyruvate, 0.1 mM nonessential amino acids solution, and 0.05%
Penicillin-Streptomycin (5,000 units/ml) and Gentamicin sulfate (0.05mg/ml). At
24 hours after plating, cells were transfected using Transfection Reagent (Roche,
Molecular Biochemicals) in a ratio of 4µl of FuGene to 3µg of purified plasmid
DNA in accordance with manufacturer’s instructions. After 24 hours, the relative
levels of functional 3H-D-Asp uptake were determined by the method of Martin
and Shain (1979 as described below).
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2.3

Transporter Activity in C17 Cells
Transfected C17.2 cells were grown in DMEM containing 10% FCS in a

humid atmosphere of 5% CO2. Near-confluent cells (plated at 7x104 - 1x105
cells/well) were rinsed with a physiological buffer (138 mM NaCl, 11 mM Dglucose, 5.3 mM KCl, 0.4 mM KH2PO4, 0.3 mM Na2HPO4, 1.1 mM CaCl2, 0.7 mM
MgSO4, 10 mM HEPES, pH 7.4) and allowed to preincubate at 37oC for 5 min.
Uptake was initiated by replacing the pre-incubation buffer with buffer containing
3

H-D-aspartate (5-100 µM) and inhibitors (10-100 µM).

Following 5 min

incubation, the media was removed by rapid suction and the cells rinsed 3 times
with ice-cold buffer. The cells were dissolved in 0.4N NaOH for 24 hours and
analyzed for radioactivity by LSC and protein by the BCA (Pierce) method.
Transport rates were corrected for background: i.e., radiolabel accumulation at
4oC. Initial studies confirmed that uptake quantified in this manner was linear with
time and protein levels and that uptake in untransfected C17.2 cells was
indistinguishable from background. Dose response curves for IC50 determination
were prepared for the three most potent compounds. Concentrations of inhibitors
were selected to span 2 log units above and below the estimated IC50.

3

H-D-

aspartate was included at 1 µM (Shimamoto et al., 2004; Dunlop et al., 2005).
IC50 values were determined using Kalidegraph and fit to the equation y = 1(m0/(m2+m0)) where 1 is the maximum, m0 is the concentration of inhibitor and
m2 is the IC50 value.
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2.4 Computational Modeling
Human

EAAT3

sequence

(obtained

from

GenBank,

http://www.ncbi.nlm.nih.gov) was aligned with the Protein Data Bank (PDB)
sequences for an archaeal homologue (GltPh ,2NWW.pdb) according to Yernool,
et al., 2004; Boudker et al., 2007. The EAAT3 homology model was constructed
by threading the aligned sequence along 2NWW coordinates using the SwissProt
server

(http://swissmodel.expasy.org//SWISS-MODEL.html).

The

resulting

model was optimized through local energy minimizations of regions with high
steric and electrostatic interference using the AMBER7 force field in the Tripos
SYBYL7.3 platform. Representations of TBOA, 2-NOA, BA, 2-napth, and 3-F-BA
were docked using GOLD (http://www.ccdc.cam.ac.uk/) into the EAAT3 model.
Each of the top twenty poses for each of four separate docking runs were
evaluated for their capacity to hydrogen bond with EAAT3 R447 and D444
residues. The top ranked poses determined by GOLDScore were incorporated
into the homology model and visualized using PyMol1.0.

3. Results
3.1 L-β-Benzyl Aspartate derivatives preferentially inhibit the EAAT3
transporter subtype.
To delineate the pharmacological specificity of the individual EAATs, the
Bridges Lab employed the same expression system as was used to characterize
L-β-benzyl aspartate, C17.2 neuroprogenitor cells and a vector adapted from an
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Adeno-associated virus (AAV) packaging plasmid (Stone et al., 2005; Esslinger
et al., 2005).
A series of L-β-substituted aspartate analogues, that included L-β-benzylaspartate (L-β-BA), were screened by Fred Rhoderick of the Bridges lab, at 100
µM for the ability to inhibit the uptake of 3H-D-aspartate (25 µM) into C17.2 cells
expressing EAAT1, EAAT2 or EAAT3.

L-β-BA and L-β-BA derivatives were

included in the assays as approximate 2:1 mixtures of their threo and erythro
forms (2S,3S and 2S,3R).

The data are reported in Table 1 as the mean % of

Control (± SEM) measured in the absence of inhibitors. D,L-TBOA and L-βmethyl aspartate were included in the present study so that structure activity
comparisons would be based on assay data collected under identical conditions.
L-β-Methyl aspartate is approximately equipotent at the three EAATs, with
a statically non-significant preference for EAAT3.

Consistent with literature

reports, D,L-TBOA, a well know EAAT blocker preferentially inhibits EAAT2. In
accord with L-β-methyl aspartate and D,L-TBOA, L-β-benzyl aspartate utilizes β
substitution on the aspartate backbone. It was recently shown that L-β-BA is a
preferential EAAT3 inhibitor. In agreement with what is observed for TBOA, the
threo diasteromer of L-β-BA was shown to be more active than the erythro
diasteromer.
It can be seen from Table 1 that all of the L-β-BA analogues synthesized
show a preference for EAAT3 except for 2,6-dichloro benzyl aspartate, entry 16,
which shows very little activity at any of the transporters.

In general,

substitutions made at the 3 position were more potent than those at the 4
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position.

This is illustrated by comparing L-β-3-nitro-BA with L-β-4-nitro-BA,

entries 10 and 14. L-β-3-Nitro-BA inhibits uptake to roughly 30% of control,
about twice the inhibition as seen with L-β-4-nitro-BA (ca. 65% of control).
Similarly, L-β-3-floro-BA completely inhibits 3H-D-aspartate uptake at 100 µM,
while the 4-floro substitution inhibits uptake to about 9% of control (entries 9 and
13 respectively).

Adding a substituent to the symmetrical position, 5 of the

aromatic ring does not appear to affect potency or selectivity. L-β-3-Methyl-BA,
entry 11, inhibits uptake at EAAT3 to about 33% of control and at EAAT1 and
EAAT2 to about 70% of control. When an additional methyl group is introduced
to the 5 position (L-β-3,5-dimethyl-BA, entry 12) inhibitory activity is not
significantly effected. In general, smaller substituents showed greater potency.
This is most easily observed among the 3-substituted halogen derivatives,
entries 6-9. The halogens have similar physical characteristics but range in size
from the small fluoro to the large iodo. The size of the substitutions is reflected in
the potency of inhibition, ranging from complete inhibition of uptake at EAAT3 to
about 20% inhibition for L-β-3-iodo-BA. A striking example of a decrease in
potency with an increase in size can be observed with 1-and 2- β substituted
naphthyl aspartates (L-β- 1 & 2-NA) (entries 18 and 19). Both compounds show
a large reduction in potency from BA. In contrast, 1 and 2 naphthyl analogues of
TBOA,

threo-β-(1-naphthyl)-methoxyaspartate

and

threo-β-(2-naphthyl)-

methoxyaspartate (TNOA-1 and TNOA-2), exhibit a slight increase in potency
over the parent compound TBOA (Shimamoto et al., 2000).
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Cmpd.
#

Compound
(100 µM)

1

L-Aspartate
NH2
COOH

HOOC

2

EAAT1
3
H-D-Asp Uptake
(% of Control)

EAAT2
3
H-D-Asp Uptake
(% of Control)

EAAT3
3
H-D-Asp Uptake
(% of Control)

4±2

16 ± 4

15 ± 3

43 ± 8

49 ± 6

32 ± 15

5±2

2±1

9±3

20 ± 4

15 ± 3

4±2

8±1

9±1

1±1

50 ± 6

64 ± 3

19 ± 6

45 ± 6

22 ± 5

8±3

21 ± 7

23 ± 2

7±4

11 ± 1

23 ± 3

0±0

L-β-Methyl-Asp
NH2
COOH

HOOC

CH3

3

D,L-β-threoBenzyloxy-Asp
(TBOA)
NH2
COOH

HOOC
O

4

L-β-Benzyl-Asp
(BA)
NH2
COOH

HOOC

5

L-β-threo-BA
NH2
COOH

HOOC

6

L-β-3-Iodo-BA
NH2

COOH

HOOC
I

7

L-β-3-BromoBA
NH2
COOH
HOOC
Br

8

L-β-3-ChloroBA
NH2
COOH
HOOC
Cl

9

L-β-3-Fluoro-BA
NH2
COOH
HOOC
F

Table 1. Inhibitory activity of β-substituted aspartate analogues at EAAT1,
EAAT2 and EAAT3, all experiments were done a minimum of 3 times with the
exception of 4-F-BA.
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Cmpd
#

Compound
(100 µM)

10

L-β-3-Nitro-BA
H 2N

EAAT1
H-D-Asp Uptake
(% of Control)

CO 2 H

EAAT2
H-D-Asp Uptake
(% of Control)

EAAT3
H-D-Asp Uptake
(% of Control)

3

3

3

62 ± 8

75 ± 6

29 ± 5

60 ± 4 (3)

48 ± 3

33 ± 1

72 ± 4

69 ± 7

36 ± 7

21 (2)

40 (2)

9 (2)

80 ± 7

82 ± 12

65 ± 8

57 ± 2

57 ± 4

21 ± 3

76 ± 1

100 ± 6

86 ± 5

HO 2C

NO 2

11

L-β-3-MethylBA
H3N

CO2

HO2C
CH3

12

L-β-3,5Dimethy-BA
H2N

CO 2 H

CH 3

HO 2C

CH 3

13

L-β-4-Fluoro-BA
H2N

CO2H

HO2C
F

14

L-β-4-Nitro-BA
H2N

CO2H

HO2C
NO2

15

L-β-4-Amino-BA
H2 N

CO2H

HO2C
NH3

16

L-β-2,6Dichloro-BA
H2N

CO2H Cl

HO2C
Cl

Table 1. cont.
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Cmpd
#

Compound
(100 µM)

17

L-β-1-NapthylBenzyl-Asp
H2N

EAAT1
H-D-Asp
Uptake
(% of Control)
3

EAAT2
H-D-Asp
Uptake
(% of Control)
3

EAAT3
H-D-Asp
Uptake
(% of Control)
3

84 ± 5

92 ± 6

60 ± 4

99 ± 6

92 ± 13

68 ± 6

CO2H

HO2C

18

L-β-2-NapthylBenzyl-Asp
H2N

CO2H

HO2C

Table 1. cont.
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3.2. IC50 determination for L-β-3-Cl-, 3-Br- and 3-F- benzyl aspartate.
Structures of L-β-3-cloro-benzyl aspartate, (L-β-3-Cl-BA), L-β-3-bromobenzyl aspartate (L-β-3-Br-BA) and L-β-3-floro-benzyl aspartate (L-β-3-F-BA) are
shown in Table 2. IC50 values were determined by the Bridges lab for the three
compounds at EAATs 1, 2 and 3 in C17.2 cells expressing the human EAAT1-3
in the presence of 1 µM 3H-D-aspartate. The compounds were evaluated as
mixtures of their threo and erythro (S,S:S,R) forms in an approximate 2:1 ratio.
IC50 values were below 10 µM at EAAT3 for all three compounds, IC50 values for
EAAT1 and EAAT2 are also presented in Table 2 with log concentration
response curves shown in Figure 3. L-β-3-Cl-BA is the most selective of the
compounds with an approximate 4 and 5 fold preference for EAAT3 over EAATs
1 and 2 respectively, 3-BrBA is 9 and 2 times more selective and L-β-3-F-BA is 4
and 3 times more selective for EAAT3 over EAAT1 and EAAT2 respectively. Lβ-3-F-BA is the most potent of the compounds with an IC50 value at EAAT3 of
1.95 ±.37 µM.
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Figure 3. Log
concentration response
curves for the effects of
3-Br-, 3-Cl- and 3-F-BA
on 3H-D-aspartate
uptake in C17.2 cells
expressing hEAAT1 (●),
hEAAT2 (■) and
hEAAT3 (♦). Data are
expressed as the
percent of control
uptake measured in the
absence of inhibitors
and represent the mean
± SEM from at least
three independent
experiments.
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Compound

EAAT1

EAAT2

EAAT3

µM

L-β-3-BromoBenzyl Aspartate
65.1 ± 25.9

16.5 ± 4.06

7.04 ± 1.33

39.6 ± 15.4

31.3 ± 10.1

8.03 ± 2.15

7.50 ± 2.12

5.56 ± 0.65

1.95 ± 0.37

CO 2H

H 2N
HO 2C
Br

L-β-3-ChloroBenzyl Aspartate
H2N

CO 2H

HO 2C
Cl

L-β-3-Floro-Benzyl
Aspartate
H 2N

CO 2H

HO 2C
F

Table 2. IC50 values for the inhibition of 3H-D-aspartate uptake by hEAAT1-3
expressed in C17.2 cells.
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3.3 Computational studies.
Computational studies were carried out in collaboration with Dave Holley
in the Gerdes lab. Inhibitors L-β-3-F-BA, L-β-BA, L-β-2-naphthyl aspartate (L-β2-NA), TBOA and the naphthyl derivative of TBOA, threo-β-(2-naphthyl)methoxyaspartate (TNOA-2) (Shimamoto et al., 2000) were docked in an EAAT3
protein homology model based on the crystal structure of TBOA bound Gltph
using the program GOLD (Boudker et al., 2007). In order to attempt correct
evaluations of different poses we took a heuristic approach that incorporated
known hydrogen bonding interactions involving Arg447 and Asp444 shown to be
critical for affinity and transport (Teichman and Kanner, 2007; Bendahan et al.,
2000).
TBOA docked into the EAAT3 model aligned with the alpha carboxyl,
amine and distal carboxyl of TBOA bound in the Gltph crystal structure and was
able to achieved H-bonding interactions with Arg447 and Asp444. Arg447 Hbonds between docked TBOA (dark blue) and TBOA in the crystal structure (light
blue) are shown in figure 4. In order to emphasize the H-bonding interactions
between Arg447 and the ligand, H-bonding interactions between the alpha
carboxyl group and Asp444 were not highlighted, though these hydrogen bonds
were formed. Docked poses of TBOA revealed an interesting ability of the ether
group to substitute for the distal carboxyl in the H-bond interaction with Arg447.
In addition to acting as a substitute for the distal carboxyl the ether group was
observed to participate in H-bonding interactions of the distal carboxyl with
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Figure 4. TBOA from the crystal structure TBOA-Gltph is shown in light blue and
TBOA docked by GOLD into the EAAT3 model is shown in dark blue.

125

Arg447. Figure four illustrates the ability of the distal carboxyl group and/or the
ether of TBOA to hydrogen bond with Arg447, red dashed line.

This is

complementary to the crystal structure which shows interaction of the distal
carboxyl group and Arg447, yellow dashed line.

Docked poses placed the

aromatic portion of TBOA in a lipophilic pocket near Leu408 and Met411 in hair
pin loop 2 (HP2) and Tyr365 in trans membrane 7 (TM7) in a distinct position
from the crystal structure.
Of the three L-β-BA analogues, docked poses of L-β-3-F-BA and L-β-BA
met the criteria for correct orientation as described above (figure 5). Docked
poses of L-β-2-NA revealed that H-bonding interactions with either the distal
carboxyl group and Arg447 or the alpha amine group and Asp444 predominately
occurred. Simultaneous H-bonding interactions were rarely observed. On the
infrequent occasions that both H-bonding interactions were achieved, the
GoldScore was much lower than the scores observed for the other compounds.
In order to determine potential differences between the mechanisms for
binding between the TBOA structures and the L-β-BA structures we docked the
naphthyl derivative of TBOA, TNOA-2. In agreement with what was observed for
L-β-2-NA, TNOA-2 rarely made H-bonding interactions with both the distal
carboxyl group and Arg447 and the alpha amine group and Asp444. Significantly
TNOA-2 could form simultaneous H-bonds between the ligand alpha amine and
Asp444 and between the ligand ether and Arg447, effectively supplanting the
distal carboxyl interactions (figure 6).
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Figure 5. Docked TBOA, shown in dark blue and L-β-3-F-BA,
BA, shown in pink, in
the active site of the EAAT3 model. H
H-bonding
bonding interactions shown for L-β-3-F-BA
with Asp444 and Arg447 are shown in yello
yellow.
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NA (purple) and TNOA
TNOA-2 (light blue) in the active
ctive site of the
Figure 6. L-β-2-NA
EAAT3 model. The amine group of L-β-2-NA,
NA, shown in blue, is positioned away
from Asp444 and cannot make the necessary H-bond
bond interaction.
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4. Discussion

In the present study we introduce one of the first known set of compounds
displaying a consistent preference for EAAT3.

The data was evaluated

pharmacologically and computationally and results suggest the reason for the
observed selectivity is due to necessary H-bonding interactions of L-β-BA with
key residues in the binding site. These interactions position the aromatic moiety
in a specific area of the protein which is more accessible in EAAT3.
Pharmacological data lent insight to the physical characteristics of the
binding site, particularly the area that supports the aromatic moiety of L-β-BA and
L-β-BA derivatives. Two reliable trends were observed among the analogues:
decreased potency with larger substituents and a consistent preference for
EAAT3 compared to EAAT1 and EAAT2. Dramatic reductions in potency were
observed for the largest additions made to the aspartate backbone e.g., 1- and 2β naphthyl aspartate (L-β- 1- and 2-NA).

Significantly, 1- and 2-substituted

naphthyl TBOA derivatives (TNOA-1 and -2) show an increase in potency from
the original benzyl analogue (TBOA) (Shimamoto et al., 2000), reinforcing the
conclusion that the area BA analogues probe is, at least partially, distinct from
the area probed by TBOA analogues. Substitutions that positions the ring away
from the aspartate backbone are not tolerated (L-β-2,6-dichloro BA) within the
transporter binding sites (EAAT1-3). This may be due to steric clashes with the
protein when the aromatic moiety is forced into a different configuration. There
appears to be more room in the lipophilic pocket for substitutions at the 3 and 5
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positions than at the 4 position of the aromatic ring. This is supported by the loss
of activity when comparing 3 and 4 substitutions (L-β-3- and 4-F-BA; L-β-3 and 4nitro-BA). The retention of activity observed for L-β-3,5-dimethyl-BA compared to
L-β-3-methyl-BA further suggests that there is more area in the lipophilic pocket
to tolerate small groups at the 3 and 5 positions than at the 4 position. Small
hydrophobic substituents were found to be optimal at the C-3 position on the
benzene ring. The most potent and selective compound of this series, L-β-3fluoro-BA (L-β-3-F-BA), shows similar potency and selectivity as L-β-BA. The
fluoro- substitution increases the lipophilicity of the aromatic ring while imparting
a small amount of steric bulk. This can be compared to larger substitutions, such
as the less potent iodo derivative, which also increase the lipophilicity of the
aromatic moiety but with greater steric bulk. This emphasizes the importance of
both the size and position of the substitutions, as well as the consistent trend
among EAAT inhibitors of increased potency with increased lipophilicity.
Computational analysis suggests that the difference in selectivity observed
between L-β-BA analogues and TBOA analogues is likely due to the positioning
of the aromatic moiety within the protein.

It has been suggested that the

positioning of the aromatic moiety is affected by essential H-bonding interactions
between the ligand α-amine and Asp444 and the ligand distal carboxyl group and
Arg447 (Teichman and Kanner, 2007; Bendahan et al., 2000). We hypothesize
that the wide range of inhibitory activity observed with TBOA lies in the ability of
the ether group to substitute for the distal carboxylate in H-bonding interactions
with Arg447. This allows the aromatic region to be placed in an area of the
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protein that appears to be capable of tolerating more steric bulk. BA and its
derivatives do not have an H-bond acceptor positioned to make this key
interaction. Therefore the aromatic region of BA is forced into a lipophilic pocket
which is more accessible in EAAT3, but which is 3-dimentionally confined and
can only tolerate a limited amount of steric bulk. We tested this hypothesis by
docking ligands into an EAAT3 homology model using the program GOLD.
GOLD is a computational program that optimizes the position of the ligands in the
binding site by giving the ligands maximal flexibility while allowing the protein
partial flexibility. The poses are scored by GoldScore which is optimized for the
prediction of ligand binding positions and takes into account factors such as van
der Waals energy, H-bonding energy and ligand torsion strain (From Gold
Support

Online;

http://www.ccdc.cam.ac.uk/products/life_sciences/gold/faqs/scientific_faq.php).
L-β-2-NA and TNOA-2 (L-TNOA-2 is slightly more potent at EAAT1-3 than
L-TBOA) present a unique opportunity to explore differences between the binding
sites of the EAAT3 and EAAT2 proteins. The only structural difference between
these two compounds is the presence of an ether group on the β-substituent of
TNOA-2. As expected from TBOA docking exercises, the ether group in TNOA-2
allowed for H-bonding interactions with Arg447, while the ligand α-amine Hbonded to Asp444. The distal carboxyl of TNOA-2 rarely achieved H-bonding
interactions while the α-amine was engaged in H-bonding interactions with
Arg444.

Larger groups appear to have more difficulty making these H-bond

interactions as supported by L-β-2-NA and TNOA-2, which rarely achieve them.
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We propose that TNOA-2 maintains potency and wide spectrum inhibitory activity
at the EAATs due to the ability of the ligand to make this key interaction between
Arg447 and the ether of the β-substituent. This substitution allows the ligand to
place the naphthyl ring in the larger lipophilic pocket, in a more favorable binding
orientation. Interestingly (2S,3S) ethyl phenyl aspartate, a TBOA derivative with
a carbon replacing the oxygen on the β-substituent is slightly less potent an
inhibitor than TBOA, but shows a 2 fold preference for EAAT3 over EAAT2
(Sakaguchi et al., 2004). This lends credence to the idea that the absence of the
ether on the β-substituent places the aromatic moiety into a defined area of the
protein, an area which is more accessible in EAAT3.

We suggest that the

reasons our docked poses of TBOA were different from the crystal structure may
be attributed to: differences in the transporters and/or the crystal structure
captured one of multiple binding orientations TBOA may achieve.

We

hypothesize that the docked orientation of TBOA may be preferred in the EAATs
and that when the aromatic moiety is larger, such as with the naphthyl (TNOA-2),
the position shown in our docking studies is the only position TNOA-2 may take.
A space filling model of TBOA and L-β-BA docked in the active site of
EAAT3 (figure 7) further illustrates these points.

Figure 7 illustrates the

lipophilicity of the regions the benzyl moieties of TBOA and L-β-BA reside in
(hydrophobic residues are shown in blue). The lipophilic region the benzyl group
of TBOA is placed in appears larger than the area the benzyl group of L-β-BA
resides in.

In support of the pharmacological data, examination of figure 7

suggests that there is more room to support substitutions at the 3 and 5 positions
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than the 4 position. Results from the docking studies support the hypothesis that
L-β-BA
BA has a specific manner in which it can interact with the protein and a
restricted area in which the benzyl moiety is tolerated. We suggest these points
explain the selectivity observed among L-β-BA and L-β-BA
BA derivatives.

Figure 7. Space filling mod
model of TBOA (blue) and L-β-BA
BA (light pink) docked in
the binding site of the EAAT3 model. Hydrophobic residues are shown in blue.
The HP2 loop is along the right side of the picture.
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5. Conclusions

This work describes the synthesis and the initial characterization of the
biological activity of one of the first identified EAAT3 selective inhibitors, L-βbenzyl aspartate.

L-β-BA was synthesized in an approximate 2:1 ratio of

diasteromers (threo:erythro), using base promoted enolate addition (Mavencamp
et al., 2008).

Kinetic analysis of

3

H-D-aspartate uptake into C17.2 cells

expressing the hEAATs demonstrated that L-threo-β-BA is the more potent
diastereomer (Ki values of 9 µM for EAAT1, 10.0 µM for EAAT2 and 0.8 µM for
EAAT3), acts competitively, and exhibits a 10-fold preference for EAAT3
compared to EAAT1 and EAAT2.

Electrophysiological recordings of EAAT-

mediated currents in Xenopus oocytes further identified L-β-BA as a nonsubstrate inhibitor.

Thus, the analogue binds to the transporter but is not

translocated as a substrate. The structure of L-β-benzyl aspartate is similar to
TBOA, a well known wide spectrum EAAT inhibitor with a preference for EAAT2.
This allows L-β-BA to be directly compared to TBOA, presenting an excellent
opportunity to examine subtle differences between the EAAT3 and EAAT2
binding sites. L-β-BA differs from TBOA by the absence of an oxygen atom on
the β-substituent.

Two hypotheses can be drawn from the analysis of the

structure activity data with respect to TBOA. The positioning of the aromatic
group of L-β-BA in the protein binding site is different from that of TBOA due to
the absence of the oxygen on the β-substituent and/or the difference in length of
the β-arm. The selectivity observed for L-β-BA is due to the unique positioning of
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the aromatic group in the protein binding site, which appears to be better
tolerated in EAAT3 than in EAAT1 and EAAT2.
L-β-BA derivatives were designed and synthesized to answer key
questions about the binding site. 1) The steric tolerance of the binding site was
probed by making larger aromatic substitutions to the aspartate backbone, as
well as by varying the sizes of substitutions on the benzene ring.

2) The

lipophilicity of the pocket was examined by making substitutions to the ring that
both increased and decreased the lipophilicity. 3) Substitutions to the ring were
made that could act as a H-bond donor or as an acceptor. 4) Substitutions were
made in different positions around the aromatic ring to help determine the
topology of the lipophilic pocket.
The L-β-β-BA derivatives showed a consistent preference for EAAT3,
suggesting that the protein region the compounds probe is more accessible in
the EAAT3 protein than in the EAAT1 and EAAT2 proteins. In addition, the
derivatives revealed that the EAAT3 lipophilic pocket occupied by L-β-BA is likely
smaller than that occupied by TBOA and that it could not tolerate much steric
bulk over that of the benzene ring. The lipophilicity of the binding pocket was
determined to be important due to the increase in potency observed for
substituents which increased the lipophilicity of the aromatic ring over those
which decreased lipophilicity. Substitutions to the aromatic ring suggested that
H-bonding interactions between the ligand aromatic group and the protein were
not likely playing a determinative role in selectivity or potency.

The three

dimensional constraints of the pocket were determined by substitutions to the
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aromatic ring in both the 3 and 5 positions as well as the 4 position.
Pharmacological results suggest that the pocket expands in the direction of the 3
and 5 positions but is constrained in the region probed by 4-substitutions.
The most potent and selective L-β-BA derivative, L-β-3-F-BA, highlights
these conclusions about the EAAT3 binding site.

The 3-fluoro substitution

resulted in an analogue displaying increased potency and selectivity over L-β-BA.
This is hypothesized to be due to the increase in lipophilicity of the aromatic ring
by a small substitution at the preferred 3-position.
Historically, selective, conformationally constrained analogues were used
to gain insight into the EAAT binding sites. An EAAT2 pharmacophore model
was constructed using the low energy conformations of well known EAAT2 nonsubstrate inhibitors and overlaying three main ligand groups the protein is
hypothesized to recognize: α-amine, α-carboxyl and distal carboxyl group.
Potential differences between the EAAT2 and EAAT3 binding sites could be
elucidated by overlaying an EAAT3 preferring inhibitor (L-β-BA) onto the EAAT2
pharmacophore model and observing points of diversion. It was immediately
obvious that the aromatic regions of L-β-BA and TBOA were in different areas
due to the oxygen in the TBOA β-substituent and/or in the one atom longer arm
of TBOA (Esslinger et. al., 2005). A crystal structure of the EAAT homologue,
Gltph, was recently published, with both aspartate and TBOA bound in the binding
site (Yernool et al., 2004; Boudker et al., 2007). From the crystal structure an
EAAT3 homology model could be constructed by overlaying the EAAT3
sequence onto the crystal structure of Gltph with TBOA bound.

From the
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homology model, the program GOLD could be utilized to optimize the position of
ligands in the active site.
Docking studies performed using the program GOLD revealed distinct
conformations with which L-β-BA and TBOA analogues may bind in the active
sites. These studies suggest that the lipophilic moiety of TBOA analogues reside
in a distinct area from the aromatic moiety of L-β-BA analogues. This different
placement appears to be due to the ability of the ether group of TBOA to
substitute for crucial H-bonding interactions in the active site typically made by
the distal carboxylate of analogues. In contrast, L-β-BA binds in the active site in
a distinct manner due to the absence of alternate atoms (i.e. ether) with which to
form key H-bonding interactions in the active site. This forces the aromatic ring
of L-β-BA into an area of the protein that, as suggested by pharmacological data,
is more available in the EAAT3 protein than in EAAT1 or EAAT2. The docking
studies suggest areas within the EAAT2 and EAAT3 proteins which may be
exploited to design more selective and potent inhibitors.

Both the

pharmacophore model and the conclusions from the docking studies will be
modified as more results become available, increasing the accuracy with which
the models dictate new synthesis.
An important future direction of this work is to characterize the separated
diastereomers: L-β- threo- and erythro-3-F-BA. In light of the results from threoand erythro-BA, we hypothesize that the threo form of L-β-3-F-BA will be the
more potent diastereomer and preliminary data suggests that this is the case.
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More detailed assays of the threo and erythro-diasteromers are currently
underway.
The next generation of EAAT3 inhibitors can be designed from
comparisons of the current EAAT2 and EAAT3 binding site models. An intriguing
approach is to design a compound capable of probing both the lipophilic pocket
that the benzyl group of TBOA resides and the lipophilic pocket that the benzyl
group of L-β-BA probes. An increase in potency would be predicted to occur due
to the enhanced lipophilic interactions of the TBOA like aromatic group.
Selectivity would be maintained by the benzyl aspartate like aromatic group that
probes the lipophilic pocket hypothesized to be unique to EAAT3. Due to the
small size of the proposed lipophilic pocket in EAAT3, smaller substitutions may
be beneficial, such as L-β-3-amine-BA.

Symmetrical substitutions to the

aromatic ring may show an increase in selectivity, L-β-3,5-diamine-BA and L-β3,5-difluoro-BA could be synthesized to test this hypothesis. Larger aromatic
substitutions with more flexibility may be advantageous as they are less rigid and
could possibility avoid steric interactions with the HP2 loop that are predicted to
occur between L-β-naphthyl-BA and the EAAT3 protein. Dibenzyl ring systems
in place of the benzyl ring, such as diphenyl methane, or rings connected by an
ether linkage such as diphenyl ether which is commercially available as the
electrophile; 1-(bromomethyl)-3-phenoxybenzene, may increase the potency and
selectivity of L-β-BA for EAAT3.
In addition to the synthesis of new compounds it is important to test L-βBA and L-β-BA derivatives for cross reactivity.

In particular, it is crucial to
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determine if L-β-BA is interacting with the metabotropic and ionotropic glutamate
receptors. Cross reactivity with the ionotropic EAA receptors is not anticipated
due to the similar template of L-β-BA and TBOA, which did not display cross
reactivity (Shimamoto et al., 2002). To verify this hypothesis receptor binding
assays could be performed.
It is anticipated that this group of L-β-BA derivatives will be useful in
investigating the role that EAAT3 plays in glutamate uptake as related to shaping
the postsynaptic signal. Additionally, L-β-BA could be used as a tool to elucidate
the role of EAAT3 in various physiological roles, such as learning and memory,
as well as in pathophysiological states such as those observed in ischemia and
schizophrenia.
Preceding the syntheses of EAAT selective inhibitors, both EAAT knockout and EAAT antisense animals were utilized to study the physiological role of
the EAATs. EAAT3 knock-out mice present significantly reduced spontaneous
locomotor activity at 12 months as measured in an open-field monitoring
chamber.

The EAAT3 knock-out mice do not show neuronal loss or motor

incoordination in rotorod testing, and learning appears unimpaired in water maze
testing.

A major dysfunction of EAAT3 knock-out animals is the onset of

dicarboxylic aminoaciduria due to the loss of uptake from the renal tubules by
EAAT3 (Peghini et al., 1997). The reason for the mild CNS deficits of knock-out
mice may be due to compensation by other glutamate transporters during
development.

This is supported by behavioral abnormalities observed in

antisense treated animals including staring-freezing episodes and electrographic
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(EEG) seizures (Sepkuty et al., 2002).

Administration of an EAAT3 specific

inhibitor to adult mice would help clarify the effect of decreased EAAT3 on
learning and coordination as well as on the potential to induce seizures, neuronal
damage or dicarboxylic aminoaciduria. These results are particularly important
when considering the use of EAAT3 inhibitors as potential therapies.

The

consequences of EAAT3 inhibition, particularly over long periods, are not clear
and need to be evaluated before therapeutic applications can be seriously
considered.
Due to the availability of EAAT2 specific inhibitors, more is known about
the role of EAAT2 in glutamate uptake than any other EAAT. From these studies
we can conclude that EAAT2 uptake plays a role in shaping the postsynaptic
signal when the synapse is tightly ensheathed by glial cells and the volume of the
synapse is restricted. The EAAT2 preferring inhibitors, DHK and WAY-855, have
been utilized to assess the role of EAAT2 in clearing glutamate from the synaptic
cleft. When DHK was used to selectively inhibit EAAT2, a threefold increase in
the amplitude of mGluR1 mediated EPSCs from oriens-lacunosum molecular
interneurons in hippocampal slices was observed. In contrast, when TBOA was
used to block the EAATs a greater than 15 fold increase in the EPSCs was
observed suggesting a prominent role for EAAT1 and/or EAAT3 (Huang et al.,
2004).

In agreement with the results gained from DHK, the more potent,

selective EAAT2 inhibitor WAY-855 did not cause excitotoxicity in rat
hipppocampal slices, but when TBOA was applied significant neuronal death was
observed (Selkirk et al., 2005).
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Due to the lack of EAAT3 selective inhibitors, the role of EAAT3 in shaping
the excitatory post synaptic response among excitatory circuits in varying parts of
the brain is not as clearly defined as for EAAT2. In the past the role of EAAT3
was determined by studying the role of EAAT2 and comparing this to the effects
of blocking all of the EAATs then ascribing the difference to EAAT1 and/or
EAAT3. This was further followed up by experiments done in knock out EAAT1
and EAAT3 animals (Huang et al., 2004; Selkirk et al., 2005). Now that EAAT3
selective inhibitors are available, the contribution of EAAT3 to variables such as
the duration, amplitude and decay of the post synaptic response could be directly
examined using electrophysiological techniques.

Glutamate uptake by the

EAATs is the main mechanism by which glutamate is cleared from the synaptic
cleft in brain regions that are tightly ensheathed by glial cells. Hence, one would
be expect the time course of the postsynaptic response to be prolonged by
EAAT3 transport inhibition (Overstreet et al., 1999). In contrast, brain regions
where glutamate clearance is mainly attributed to diffusion, uptake blockers
would not be expected to show significant changes in the duration of the
postsynaptic responses (Isaacson and Nicoll, 1993). In addition, it would be of
interest to determine if EAAT3 contributes to the presynaptic neuronal pool of
glutamate.

If EAAT3 did contribute to this pool, blocking EAAT3 might be

expected to change the probability of release as measured by paired pulse
ratios.
Glutamate that escapes the synaptic cleft has been shown to affect
neighboring synapses. This phenomenon is termed spillover (Scanziani et al.,
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1997; Kullman and Asztely, 1998). The perisynaptic localization of EAAT3 on
neurons implicates EAAT3 in controlling the extent of spillover, and thus the
extent to which glutamate stimulates receptors outside of the synaptic cleft.
Spillover of glutamate from excitatory mossy fibers has been shown to inhibit
GABA release by activating presynapic mGluRs on inhibitory interneuron axons
within the cerebellar glomerulus and the hippocampus. This may be a way of
sharpening the output of select cells by inhibiting neighboring boutons. (Vogt and
Nicoll, 1998; Mitchell and Silver, 2000).

Blocking EAAT3 may increase the

inhibition of GABA release by allowing more glutamate to stimulate the
presynaptic mGluRs. This could be measured directly with the use of an EAAT3
selective inhibitor.
The localization of EAAT3 to presynaptic GABA neurons led to the
hypothesis that EAAT3 played a role in GABA synthesis. In order to test the role
of EAAT3 in GABA synthesis, rats were administered EAAC1 antisense
oligonucleotides which resulted in a 60% decrease in EAAC1 expression.
Behavioral abnormalities, including staring-freezing episodes and electrographic
seizures, were observed along with a decrease in miniature inhibitory post
synaptic currents (mIPSCs) in whole cell patch clamp recordings of CA1
pyramidal neurons and a 50% loss of hippocampal GABA levels (Sepkuty et al.,
2002). These results suggest that EAAT3 plays a significant role in controlling
the amount of GABA in the hippocampus. An EAAT3 blocker offers a direct
method with which to examine the role of EAAT3 in GABA synthesis and release.
In addition, an EAAT3 blocker could directly and reversibly block EAAT3 to
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determine the time course with which blocking EAAT3 decreases GABA
synthesis as well the time course to recover full GABA activity after the EAAT3
blocker is removed.
Long term potentiation (LTP) is the cellular basis for learning and memory
(Larkman and Jack, 1995; Bennett, 2000).

LTP works by strengthening

synapses either presynaptically, by increasing the probability of release or
postsynaptically, by altering the sensitivity of the cell to glutamate (Kawamura et
al., 2004). Contextual fear conditioning is a form of learning in which fear is
associated with a neutral stimulus and learning can be measured by the ability of
the neutral stimulus to elicit fear. LTP and contextual fear conditioning increase
the uptake of glutamate from the synaptic cleft and increase the membrane
expression of EAAT3. These results suggest that the uptake of glutamate by
EAAT3 may be a component of plasticity at glutamatergic synapses (Levenson et
al., 2002).

This hypothesis could be tested in vivo with animal models

administered an EAAT3 selective inhibitor and submitted to fear conditioning.
Fear conditioning could be accomplished by administering electrical shocks
associated with a neutral stimulus and measuring freezing behavior 24 hours
later when the neutral stimulus was administered.

An EAAT3 blocker

administered before fear conditioning would be predicted to decrease freezing
behavior, which would suggest a learning impairment. In vitro experiments may
help elucidate the mechanism responsible for the learning impairment. Levenson
induced LTP by high frequency stimulation (HFS) of the Schaffer-collateral
pathway in the hippocampus and observed an increase in the uptake of
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glutamate and in the membrane expression of EAAT3 as measured by western
blots. He predicted that decreasing diffusion to inhibitory presynaptic mGluRs,
and/or to limiting NMDA activation to prevent toxicity may be the reason for the
increase in transport activity (Levenson et al., 2002). Our development of an
EAAT3 blocker provides a strategy to determine if LTP is affected by blocking
EAAT3.
One area where EAAT3 inhibitors may be therapeutically useful is in
alleviating damage during brain ischemia.

Brain ischemia is an important

therapeutic target as it is the third cause of death in industrialized countries.
Glutamate release contributes to neuronal damage observed during ischemia
and is hypothesized to be due, in part, to the reversal of the EAATs, particularly
EAAT3 (Rossi et al., 2000). The reversal of the EAATs has been observed
under conditions of ATP depletion or elevated extracellular potassium levels
(Anderson et al., 2001). The cytosolic concentration of glutamate in neurons is
approximately 10mM, much higher than the 3mM observed in glial cells. This
suggests that EAAT3 is more likely to release glutamate than a glial transporter
(Camacho and Massieu, 2006). Of the glial transporters EAAT1 is a more likely
candidate than EAAT2. EAAT2 does not appear to run in reverse, as supported
by the EAAT2 knock down rats which undergo transient middle cerebral artery
occlusion (MCAO) and display more damage. These results suggest that EAAT2
aids in clearing glutamate from the synaptic cleft during ischemia. Administration
of an EAAT3 inhibitor post transient MCAO and examination of the damage as
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marked by infarct volume, brain edema and mortality would answer many
important questions about the role of EAAT3 in ischemia.
EAAT3 inhibitors are emerging as potential pharmaceuticals in the
development of novel antipsychotics. The glutamate hypofunction model states
that the positive, negative and cognitive symptoms of schizophrenia are
associated with reduced stimulation of NMDA.

This is supported by the

application of NMDA antagonists, which produce schizophrenia like symptoms
and are used as a model of schizophrenia. From these observations it can be
hypothesized that Increasing stimulation of NMDA may alleviate symptoms of
schizophrenia. If EAAT3 controls the amount of glutamate available to stimulate
NMDA receptors this indicates it as a potential drug target. Consistent with this
is altered EAAT3 levels in persons with schizophrenia as well as in rats and
persons treated by antipsychotic medications (McCullumsmith and MeadorWoodruff, 2002; Schmitt et al., 2003). The EAAT3 inhibitor, NBI-59159, displays
an approximate 5 and 40 fold selectivity over EAAT2 and EAAT1.

This

compound was shown to decrease amphetamine-stimulated locomotor activity in
mice (Dunlop and Marquis, 2006). Further support of the role of EAAT3 inhibition
in decreasing amphetamine-stimulated locomotor activity is the application of a
selective EAAT2 inhibitor WAY-855 which did not influence amphetaminestimulated locomotion (Dunlop and Marquis, 2006).
selectivity reported for NBI-59159

Because the 5 fold

over EAAT2 is less than the selectivity

observed for L-β-threo-BA and derivatives of L-β-BA, it would advantageous to
compare the results from Dunlop and Marquis with results obtained from
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administration of L-β-threo-BA and/or L-β-threo-3-F-BA to amphetamine
stimulated mice.
In summary, the excitatory amino acid transporters (EAATs) play a central
role in regulating extracellular glutamate levels in the Central Nervous System
(CNS). These uptake systems are capable of influencing the amount and/or time
course with which L-glutamate is in contact with the EAA receptors. Among five
identified isoforms, EAAT3 is the most abundant subtype present on neurons and
is widely expressed throughout the forebrain and cerebellum. The synthesis of
selective inhibitors and the creation of a binding site model will aid in elucidating
the roles of EAAT3 in CNS function. EAAT3 has been implicated in a variety of
both physiological and pathophysiological processes including long term
potentiation, schizophrenia, neurodegeneration and ischemia. Its roles however,
remain undefined, due to the lack of reagents with which to selectively modulate
its activity.

Specifically, work in our laboratories has led to the first EAAT3

preferring inhibitor and the first family of EAAT3 preferring inhibitors. We suggest
that these analogues will serve as excellent tools with which to study the
specialized roles of EAAT3 in the CNS.
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Appendix A:
History of 1,2-asymmetric induction

The synthesis of unnatural amino acids has assumed an important role in
a variety of pharmacological systems. This has created a demand for stereocontrolled methodologies based on amino acids. 1,2-asymmetric induction in the
alkylation of aspartic acid ester enolates is one area that has received
considerable attention.
In 1990 Dunn et al., studied the regioselective β-benzylation of Nphenylfluorenyl 2,3 diester (α-tert-butyl, β-methyl) at the β-carbon with KHMDS
and benzyl bromide at -78°C. This reaction yielded 2S,3S : 2S,3R (S,S:S,R) in a
2:1 ratio. The ratio of diastereomers can be affected by a number of factors.
One way to increase the diasteromeric yield is to increase the reactivity of the
electrophile. Consistent with this observation the ratio of S,S:S,R increased to
7:1 when the electrophile was switched from benzyl bromide to benzyl iodide.
Dener et al., 1993, also used the N-phenylfluorenyl protecting group (2,3 diesterα-methyl, β-methyl) aspartate, alkylation at the β-carbon with ethyl triflate and got
a 2:1 SS:SR ratio. After optimizing the mole percents of base and ethyl triflate
the ratio increased to 18:1, displaying the importance of the stoichiometry of the
base and electrophile to substrate (Dener et al., 1993).
β-addition of N-phenylfluorenyl 2,3 diester (α-methyl, β-methyl) was used
for hydroxylation using MoOPH with KHMDS at -78 - -65 °C and got SS:SR in a
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3:1 ratio.

LHMDS reversed this ratio to 1:8 and adding DMPU and HMPU

reversed this to 8:1 and 11:1 respectively. (Fernandez-Megia, 1994)
Altering the N-protecting group to replace both amine hydrogen atoms by
adding an N-benzyl group to the amine in addition to the N-phenylfluorenyl group
increased the stereoselectivity to 30:1 at -23 °C. Complications arose with this
scheme as the methyl ester could not be hydrolyzed without epimerization at C-3
(Dunn et al., 1990).
In order to correct this the β-methyl ester was replaced with a β-benzyl
ester and diasteromeric ratios at -23°C decreased to 12:1 and 25:1 using benzyl
bromide and benzyl iodide respectively. In contrast alkylation of dibenzyl amine
gave almost no diastereoselectivity (Dunn et al., 1990).
Substituting methyl for t-butyl as the α-ester protecting group dramatically
affected the diasteromeric outcome. N-phenylfluorenyl 2,3 diester (α-methyl, βbenzyl) aspartate gave ratios of 1:1.5 S,S to S,R at -23°C with either benzyl
bromide or benzyl iodide, interestingly the preference for S,R was reversed when
the temperature was decreased to -78°C to 2.5:1 (Denner et al., 1993).
A paper by Humphrey et al., 1994 describes the diastereoselective β-alkylation of
the D-isomer, N-benzyl phenylfluorenyl, 2-3 diester (α-methyl, β-methyl)
aspartate. Enolate formation with KHMDS at -23 °C favored formation of the R,R
diastereomer in excess of 50:1.

Interestingly, Humphrey also observed that

switching the base to LiHMDS reverses this selectivity to 1:50 (R,R:R,S).
The N-protecting group, carbobenzyloxy with LiHMDS as a base at -78°C
gave diasteromeric ratios of 3:1, S,S:S,R (Parr et. al. 1996). Interestingly with
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N-Pro.
Group
PhF

Base

E+

SR:SS
ratio
1:2

Temp

Paper

BnBr

Ester protecting
Groups
α -t Bu β-CH3

KHMDS

-78

Dunn, 1990

PhF

KHMDS

BnI

α -t Bu β-CH3

1:7

-78

Dunn, 1990

BnPhF

KHMDS (2)

BnBr (2)

α -t Bu β-CH3

1:30

-20

Dunn, 1990

BnPhF

KHMDS

BnBr

α -t Bu β-Bn

1:12

-23

Dunn, 1990

BnPhF

KHMDS

BnI

α -t Bu β-Bn

1:25

-23

Dunn, 1990

BnPhF

KHMDS

BnBr/bnI

α - Bn β-Bn

1:1.6

-23

Dunn, 1990

BnPhF

KHMDS

BnBr/BnI

α - CH3 β-Bn

1.5:1

-23

Dunn, 1990

BnPhF

KHMDS

BnI

α - CH3 β-Bn

1:2.5

-78

Dunn, 1990

BnPhF

KHMDS

BnBr

α - CH3 β-CH3

1:50

-23

BnPhF

LiHMDS

BnBr

α - CH3 β-CH3

50:1

CBZ

Cycloheyn α - CH3 β-CH3
yl Bromide

75:25

Cycloheyn α–TMSE β-CH3
yl Bromide

99:1

-78

Hanessian
1998

CBZ
PhF

LiHMDS
+DMPU\HM
PA
LiHMDS
+DMPU
\HMPA
LiHMDS
KHMDS

-23
-78
-78

Humphrey,
1994
Humphrey,
1994
Hanessian,
1998

α -t Bu β-CH3
α - CH3 β- CH3

1:3
1:18

-78
-75-0

Parr, 1996
Dener 1992

PhF

KHMSD

MeI
Ethyl
triflate
MoOPH

α - CH3 β- CH3

1:3

PhF

LiHMDS

MoOPH

α - CH3 β- CH3

8:1

PhF

LDA

MoOPH

α - CH3 β- CH3

1:2

PhF

LiHMDS
DMPU
NBuLi/LHMD
S
NBuLi/LiHMD
S +HMPA

MoOPH

α - CH3 β-CH3

1:8

MoOPH

α - CH3 β-CH3

20:1

-78 –
-65
-78 –
-65
-78 –
-65
-78 –
-65
-78 –
-65

FernandezMegia, 1994
FernandezMegia, 1994
FernandezMegia, 1994
FernandezMegia, 1994
FernandezMegia, 1994

MoOPH

α - CH3 β-CH3

1:2

-78 –
-65

FernandezMegia, 1994

CBZ

PhF

PhF

Table 1. Diasteromeric control of 1,2 asymmetric induction as reported in the
literature.
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DMPU or HMPA as a co-solvent/additive S,R formation was favored over S,S,
75:25 to 99:1, S,R;S,S (Hanessian, 1998).
Attempts to improve these results were also performed using various
solvents (ethyl ether, toluene) as well as additives (HMPA or DMPU), which
modify the enolate aggregation state.

Another important factor is the

temperature, maintaining the reaction at a temperature below -50°C has been
shown to improve 1,2-asymmetric induction. An interesting issue stemming from
reaction temperature is the way in which the reaction is quenched. Parr et al.,
1999, found that a mixture of diasteromeric products resulted from quenching
their 1,2 asymmetric induction reaction by pouring an aqueous acid solution into
the reaction at a low temperature followed by warming.

Conversely, If they

poured the cold reaction into an aqueous acid solution they obtained a single
diastereomer.
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Appendix B:
Synthetic Schemes of β-substituted Aspartates:

This appendix describes the synthesis used to prepare the β-substituted
analogues. In particular the details not covered in chapter two of this dissertation
are covered including failed schemes, abandoned
synthetic routes as well as the reasoning behind the
routes chosen.

Protecting groups:
Figure 2.

Trityl:

Triphenylmethyl
The N-triphenylmethyl protecting group was

protecting group.

initially chosen for the ease of which large amounts of
starting material can be prepared as well as for its large size which was
hypothesized to protect from alpha racemization (for
preparation see chapter 2 methods). This protection
from alpha racemization is observed at temperatures
N

below 0°C, as reactions carried out at temperatures
exceeding 0°C yield racemic products.
Benzyl phenyl fluorenyl:
For preparation of N-benzyl phenyl fluorenyl
dimethyl ester aspartate see Humphrey et al., 1994.

Figure 3. Benzyl
phenyl fluorenyl
protecting group
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Carbobenzyloxy:
The CBZ-Carbobenzyloxy protecting group
was also used.

N-CBZ-L-aspartate dimethyl ester

O C
O

was prepared by dissolving aspartate in 3M sodium
hydroxide, adding toluene then 1.5 equivalents
benzyl chloroformate drop wise. The reaction was

Figure 4.
Carbobenzyloxy
protecting group.

stirred for 24 hours at a pH greater than 10, the pH
was adjusted with NaOH when necessary. The reaction was then acidified with
6N HCl to a pH of about 1, extracted into ethyl acetate, washed with brine, dried
with magnesium sulfoxide, filtered and rotovaped. Esterification is achieved by
adding 1.4 equivalents thionyl chloride drop wise to the starting material in
methanol and allowing the reaction to proceed for 48 hours. The product does
not crystallize so concentration by rotary evaporation followed by chasing with
methanol, methylene chloride, toluene and hexane is sufficient to remove excess
solvents and water.
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CBZ sm: 1H NMR (400 MHz, CDCl3) δ: 7.38-7.28 (m, 5H), 5.81-5.78 (m, 1H),
4.65-4.60 (m, 1H), 3.72 (s, 3H), 3.64 (s, 3H), 3.02-2.97 (m, 1H), 2.84-2.80 (m,
1H).

13

C (100 MHz CDCl3) δ: 171.17, 171.05, 155.82, 136.00, 128.42, 128.10,

128.01, 67.00, 52.71, 51.95, 50.22, 36.34.

Alkylation of N-CBZ-dimethyl ester with 3-cloro benzyl bromide, LiHMDS +
DMPU :
In an oven dried round bottom flask with stir bar 3.6 equivalents of
LiHMDS and 3ml DMPU were cooled to -55°C under argon. .513g N-CBZdimethyl ester was added in 12 ml THF slowly by a syringe. About 2 hours later
3 equivalents of 3-cloro-benzyl bromide was slowly added and the reaction
proceeded for 21 hours when it was quenched with 10 ml of 10% HCl, the
reaction rose to room temperature and was extracted into ethyl acetate and
concentrated for separation on a silica column (.2mg, 27%)
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1

H NMR (400 MHz, CDCl3) δ: 7.38-7.16 (m, 9H), 5.19-5.08 (m, 2H), 4.49-4.46

(m, 1H), 3.69 (s, 3H), 3.63 (s, 3H), 3.39-3.34 (m, 1H), 3.08-3.03 (m, 1H), 2.802.75 (m, 1H).

Deprotection of N-CBZ-dimethyl ester β-3-cloro-benzyl-aspartate
Hydrogenation of starting material (.2g) in ethanol with acetic acid (.25ml)
and Palladium on Carbon (.15g) under 50 psi for 25 hours did not remove the
CBZ protecting group. The NMR was messy and hard to define.

Alkylation of N-CBZ-dimethyl ester with 4-bromo-benzyl bromide
The alkylation was carried out in the presence of DMPU, 2.1 equivalents
of LiHMDS and 3 equivalents of 4-benzyl bromide in the manner described for
alkylation of N-CBZ-dimethyl ester with 3-cloro-benzyl bromide (58%)
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Deprotection of N-CBZ-dimethyl ester β-4-bromo-benzyl-aspartate
Deprotection under the conditions given for N-CBZ 3-cloro-benyl aspartate
did not go to completion. The resultant material from the hydrogenation was
taken on and deprotected with 6N HCl for 24 hours.

The water layer was

extracted with ethyl acetate and product was precipitated out of water. NMR was
too messy to assign peaks to.

Benzyl Phenyl fluorenyl: N-BPF-dimethyl ester-3-F-Benzyl-Aspartate
In a dry round bottom flask, .5g of N-BPfl-dimethyl aspartate was
dissolved in 5 ml THF. 2M KHMDS was added drop wise at -23°C. 20 minutes
later 3-floro-benzyl bromide was added drop wise and the reaction proceeded for
53 hours at which time it was quenched with 8ml saturated NH4Cl. The product
was extracted into ether. Organic layers were combined washed with brine and
subsequently concentrated. The product was isolated on a silica column to give
a 16% yield.
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Deprotection of N-BPF-dimethyl ester-3-F-Benzyl-Aspartate
To

N-BPF-dimethyl

ester-3-F-Benzyl-Aspartate

(.1g,

.166mm)

in

methylene chloride (2ml) and ethyl acetate (2ml) concentrated HCl and methanol
(15ml) were added with 10% palladium on carbon (.1g). Hydrogenation under 52
psi for 24 hours followed by filter through celite and heated to 65°C for 24 hours
followed by washing with ethyl acetate and concentration of the aqueous layer
yielded an absolute mess, yellow gooey layer that was incomprehensible by
NMR.

Deprotection of N-trityl-L-β-substituted aspartate dimethyl ester
The most commonly used deprotection scheme was to heat the alkylated
intermediate in 6N HCl for 24 hours at about 80°C. The aqueous layer was then
washed with ether to remove trityl chloride and concentrated to give the chloride
salt of the product. Next an anion exchange resin was used in the ratio of 1:10
product:resin, weight:weight and eluted with varying fractions of acetic acid from
.1N to 5N with product coming off from 1N to 5N. This method resulted in yields
from 8% to 73%.
Another deprotection scheme was to de-tritylate with 1N HCl in ethanol,
heat 1-2 minutes in a water bath, evaporate ethanol and triturate with ether. With
N-trityl diester p-nitro benzyl aspartate to diester p-nitro benzyl aspartate the
yield was 37% with this method. Next the alkylated product can be added to a
2N solution of LiOH or KOH in ethanol, stirring at room temperature for 30
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minutes.

As the product is de-methylated it crashes out of solution.

The

problem we encountered with this method is that both methyl groups are often
not saponified and the yields are very low, less than10%.
The easiest deprotection scheme is to deprotect in 6N acid at 80°C and
concentrate down the sample, rotovap off excess HCl by 2-3 water rinses and
dried on the high vac.

Next the product is precipitated out of ethyl acetate

(sample must be very dry and free of excess Cl-) followed by precipitation from
water.

With this method yields are consistently higher, 75%, though some

product is lost due to incomplete removal of methyl peaks even at reaction times
greater than 30 hours.

Aromatic ring transformations
3-Nitro Benzyl Bromide: aldehyde to bromide
3nitro benzaldehyde was transformed to 3 nitro benzyl alcohol using 1
equivalent sodium borohydride in ethanol.

The reaction was stirred at room

temperature until starting material spot disappeared by TLC (30/70 Ethyl
acetate/Hexanes). The reaction was quenched by adding ammonium chloride
(saturated), extracted with ethyl acetate and dried over magnesium sulfate. 3nitro benzyl alcohol was transformed to 3-nitro benzyl bromide under argon by
adding dry ether and drop wise addition of 1 equivalent phosphorous tribromide
(PBr3). The reaction was monitored by TLC (50/50 ethyl acetate/hexane). Cold
water was added drop wise to quench the reaction. The product was extracted
into ether and washed with brine then filtered through a silica plug.
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3-methoxy Benzyl Bromide
3 methoxy benzyl alcohol was transformed to 3 methoxy benzyl bromide
using the same procedure as for 3 nitro benzyl alcohol.

2-benzyl fluorenyl
Attempts to synthesize 2-benzyl fluorenyl from 2-fluorenyl aldehyde
started with the successful transformation of 2-fluorenyl aldehyde to 2 fluorenyl
alcohol.

This was acheived by a standard reduction in ethanol and addition of

sodium borohydride and quenching with water. The reaction was worked up by
extracting product into ethyl acetate layer, yield 90%.
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H NMR (400 MHz, CDCl3) δ: 7.32-7.25 (m, 1H), 7.79-7.73 (m, 2H), 7.55-7.50

(m, 2H), 7.40-7.22 (m, 3H), 4.74 (m, 2H), 3.86 (m, 2H), 1.74 (m, 1H).
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Attempts to convert the alcohol moiety to bromine were achieved using
phosphorous tribromine in methylene chloride at -10°C under argon.

The

reaction appeared to proceed as indicated by the disappearance of the alcohol
proton at 1.74.
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H NMR (400 MHz, CDCl3) δ: 7.80-7.75 (m, 2H), 7.59-7.55 (m, 2H), 7.43-7.31

(m, 3H), 4.62 (s, 2H), 3.92 (s, 2H).

Alkylations of N-Trityl dimethyl ester aspartate with LiHMDS base
Alkylation with 3-methoxy benzyl bromide
Alkylation with 3-methoxy benzyl bromide proved to be extremely difficult.
The reaction was allowed to proceed for 2 hours with 2 and 1.5 equivalents of
base and electophile respectively. There appeared to be a product spot above
the starting material on TLC using 30/70 ethyl acetate/hexanes, but upon work
up this spot could not be positively identified as product.
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3-methoxy benzyl bromide was converted to 3-methoxy benzyl iodide by
the addition of 10 equivalents of sodium iodide to 3-methoxy benzyl iodide in
acetone.

The reaction was allowed to reach room temperature and stir

overnight. This method showed very light staining under the starting material
spot via TLC that may have been product. After deprotection and ion exchange
no product was isolated.
Another method used to attempt alkylation was to tosylate the three
methoxy benzyl alcohol using tosyl chloride. This method was also unsuccessful
though it could have been due to the age of tosyl chloride and the storage
conditions; outside of a desiccator.
In addition to tosylate the mesolate was made from 3-methoxy benzyl
alcohol and chloromesolate. This was performed in a dry round bottom flask in
1M dry methylene chloride, 2 equivalents pyridine were added and 1.5
equivalents of chloromesolate. The reaction was diluted with ether, washed with
1N HCL, dried with magnesium sulfate and roto-vaped with ether.

When

alkylation was attempted no appreciable product was discerned.

Alkylation with cinnamyl chloride
Alkylation with cinnamyl chloride began by the conversion of the chloride
to iodide via sodium iodide and acetone. The alkylation reaction did not proceed
below 0°C, and above it yielded racemic product.
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Alkylation with phenyl ethyl bromide
The alkylation ran for 5 hours at 0°C with 3 equivalents base and 2.5
equivalents electrophile gave no product. The starting material was converted
from phenyl ethyl bromide to phenyl ethyl iodide employing the same reaction
conditions as described for 3-methoxy benzyl bromide, this yielded a faint spot
above starting material by TLC that was not taken on.
The mesolate was then made from benzyl ethyl alcohol and chloromesolate. This was performed in a dry round bottom flask in 1M dry methylene
chloride.

2 equivalents of pryidine were added and 1.5 equivalents of

chloromesolate. The reaction was diluted with ether, washed with 1N HCL, dried
with magnesium sulfate and rotovaped with ether.

When alkylation was

attempted no appreciable product was discerned.
Finally triflouoro methyl sulfonic acid was reacted with phenethylalcohol to
form trifluoromethyl sulfonic leaving group.

This was achieved by adding a

solution of trifluoromethylsulfonic (1.4eq) acid in dry chloroform (3 eq) to a
solution of pyridine and phenethylalcohol (.8eq) on ice under argon. The transfer
was difficult due to using a needle and getting it jammed, perhaps from moisture,
I may have only transferred about 70% of the solution. A cannula may have
been easier. A precipitate was formed upon addition and the clear supernant
was concentrated with argon and taken up in dry THF for the next (alkylation)
step. The alkylation was carried out with 3.5 equivalents of LiHMDS and 2.5
equivalents

of

phenethyltrifluoromethylsulfonic

acid.

The

phenethyltrifluoromethylsulfonic acid was difficult to transfer due to extreme
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insolubility in THF, sonication did not solubilize it so I had to crush it up and
transfer it to the reaction via a needle. Reaction proceeded for 4 hours. By TLC,
reaction appears to have gone but upon separation by silica column no product
could be discerned.

2-Nitro Benzyl Bromide
Reaction carried out with 2.5 equivalents of base and 3.5 equivalents of 2nitro Benzyl bromide. The reaction went for 4.5 hours at what time no alkylation
appeared to occur.

Propargyl Bromide
Reaction carried out with 3 equivalents LiHMDS and 2.5 equivalents of
propargyl bromide. At 4.5 hours at 0°C no reaction could be observed by TLC.
Propargly bromide was old and may have been wet explaining the lack of
product.

2-benzyl fluorenyl
Unfortunately attempts to alkylate N-trityl-diester aspartate with 2-benzyl
fluorenyl were unsuccessful.

Additives to Alkylation
Manganese bromide (MnBr2) 1.4 equivalents added to starting material in
THF, 3 equivalents LiHMDS and 2.5 equivalents BnBr.

Reaction proceeded
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about 60% in 5 hours at -30°C. Unfortunately at this time additives were only
used with the aim of increasing yields not for effects on diasteromeric control.

DMPU
DMPU was added to alkylations with CBZ (Appendix A; Hanessian, 1998;
Fernandez-Megia, 1994) and trityl. Alkylation of N-trityl-dimethyl ester aspartate
with 3-benzyl bromide gave yields of 74% post silica column in a 1:3 ratio of
threo:erythro (Mavencamp et al., 2008).

Though DMPU does affect

diasteromeric control and often increases ratios, it is very difficult to remove,
causing problems during deprotection and requiring an ion exchange column for
a clean final sample.

Diasteromeric Enrichment Procedure
Diasteromeric enrichment can be achieved by heating the mixture in a
small amount of water (compound will not be dissolved) much as you would
approach a crystallization procedure. Heat for about 20 minutes until no more
material dissolves. The material is then hot-filtered and dried. This gives an
approximate 11:1 enrichment of threo:erythro or S,S:S,R even when starting with
a mixture of mostly erythro.

2,3 diester N-trityl asparatate conversion to 2, ester 3 amino, N-trityl
aspartate
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Conversion from the distal carboxyl group to the amine was achieved by
heating the starting material (.130g) in 3.3 ml methanol and 1 ml concentrated
NH4OH to about 80°C in a pressure tube for 3 days. Product is extracted into
ethyl acetate and concentrated then taken up in 6N HCl for deprotection.
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H NMR (400 MHz, CDCl3) δ: 7.51-7.30 (m, 5H), 7.29-7.16 (m, 10H), 3.63-3.66

(m, 1H), 3.26 (s, 3H), 2.60-2.55 (m, .5H), 2.34-2.31 (m, .5H), 1.95-1.93 (m, 1H).
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H NMR (400 MHz, D20) δ: 7.20-7.17 (m, .8H), 6.94-6.85 (m, 2H), 3.62 (s, 1H),

3.09-3.05 (m, .6H), 2.90-2.78 (m, 1.4H).
There may be residual trityl in the final product or another impurity may be a
small amount of starting material in with the amide.
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Appendix C. NMR Spectra of Synthesized Compounds.
4.1. N-tritylamino dimethyl ester aspartate (2)
1.0

MeO2C

0.9
CO2Me

TrHN

Normalized Intensity

0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1

12

1.0

11

10

9

8

7

6

5
4
3
2
Chemical Shift (ppm)

1

0

-1

-2

MeO2C

0.9
TrHN

0.8

CO2Me

Normalized Intensity

0.7
0.6
0.5
0.4
0.3
0.2
0.1

220

200

180

160

140

120

100
80
60
Chemical Shift (ppm)

40

20

0

-20

178

4.3. N-tritylamino dimethyl ester β-benzyl aspartate (3a)
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4.4. N-tritylamino dimethyl ester β-2-napthyl methyl aspartate (3b)
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4.5. N-tritylamino dimethyl ester β-3,5 dimethyl-benzyl aspartate (3c)
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4.6. N-tritylamino dimethyl ester β-3 methyl-benzyl aspartate (3d)
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4.7. N-tritylamino dimethyl ester β-2,6 dicloro-benzyl aspartate (3e)
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4.8. N-tritylamino dimethyl ester β-3 bromo-benzyl aspartate (3f)
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4.9. N-tritylamino dimethyl ester β-3 fluoro-benzyl aspartate (3g)
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4.10. N-tritylamino dimethyl ester β-3 fluoro-benzylaspartate (3g, S,S)
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4.11. N-tritylamino dimethyl ester β-3 fluoro-benzylaspartate (3g. S,R)
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4.12 N-tritylamino dimethyl ester β-4-fluoro-benzyl aspartate (3h)
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4.13. N-tritylamino dimethyl ester β-3-nitro-benzyl aspartate (3i)
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4.14. N-tritylamino dimethyl ester β-3-nitro-benzylaspartate (3i, S,S)
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4.15. N-tritylamino dimethyl ester β-P-nitro benzyl aspartate (3j)
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4.16. N-tritylamino dimethyl ester β-3-chloro benzylaspartate
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4.18. β-Benzyl aspartate (4A)
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4.19. S,S L-β-Benzylaspartate (4A)
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4.75

4.20. β-2-Napthyl methyl aspartate (4B)
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4.21. β-3,5 Dimethyl-benzyl aspartate (4C)
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4.22. β-3 Methyl-benzyl aspartate (4D)
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4.23. β-2,6 Dicloro-benzyl aspartate (4E)
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4.24. β-3 Bromo-benzyl aspartate (4F)
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4.25. β-3 Fluoro-Benzyl aspartate (4G)
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4.26. β-3 Fluoro-Benzylaspartate (4G, S,S)
Spectra a from synthesis with KHMDS, spectra b from HPLC (spectra b.
reported).
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Carbon data from HPLC, spectra reported.
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4.27. β-3 Fluoro-Benzylaspartate (4G, S,R)
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4.28. β-4-Fluoro-benzyl aspartate (4H)
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4.29. β-3-Nitro-benzyl aspartate (4I)
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4.30. β-3 Nitro-benzylaspartate (4I, S,S)
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4.31. β-para-nitro-benzyl aspartate (4J)
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4.32. β-3 Chloro-benzylaspartate S,R
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